EBM　血液疾患の治療　2023-2024

出版社： 中外医学社
著者：
発行日： 2022-10-20
分野： 臨床医学：内科  >  血液
ISBN： 9784498225404
電子書籍版： 2022-10-20 （1版1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：4～8営業日

14,300 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

14,300 円(税込)

購入する

商品紹介

血液疾患における諸問題をいかに解決し，対応すべきか，最新のエビデンスをもとに解説したレファランス．治療に必須の知見を「序論，指針，エビデンス，根拠となった臨床研究の問題点と限界，患者に適応する際の注意点，コメント」の順に紹介し，今日の時点における最新の治療法，考え方だけでなく，現場で判断に迷うような事柄・問題点に指針を与えるものとなっている．さらにはCOVID-19や最新研究の話題までフォローしており，血液疾患診療を網羅的に学ぶために最適な一冊である．

目次

  • I．話題
    　　1．新型コロナウイルス感染症流行下における造血器腫瘍の治療
    　　Topics 1　血液疾患患者への新型コロナワクチン接種の現状と課題
    　　Topics 2　COVID-19と血栓症

    II．赤血球系疾患
    　　1．再生不良性貧血とHLA
    　　2．再生不良性貧血に対するTPO-RA
    　　3．重症再生不良性貧血に対するHLA半合致移植・臍帯血移植
    　　4．赤芽球癆の治療
    　　5．MDSの分子病態解明の進歩
    　　6．MDSに対する予後予測
    　　7．低リスクMDSの治療
    　　8．高リスクMDSの治療
    　　9．遺伝性骨髄不全症候群に対する診断と治療
    　　Topics 1　血液疾患とゲノム編集治療
    　　10．温式自己免疫溶血性貧血（wAIHA）の治療
    　　11．寒冷凝集素症の治療
    　　12．PNHに対する治療
    　　Topics 2　PNHに対する開発中の新規治療薬
    　　13．腎性貧血に対するHIF-PH阻害薬
    　　Topics 3　加齢とクローン性造血

    III．白血病

    A．急性骨髄性白血病（AML）
    　　1．初発AMLの治療
    　　2．再発・難治性AMLの治療
    　　3．高齢者AMLの治療
    　　4．小児AMLの治療
    　　5．CBF白血病の治療
    　　6．AMLに対する分子標的治療の現状
    　　7．AMLに対する造血幹細胞移植の現状と課題
    　　Topics 1　AMLの分子病態解析研究の進歩
    　　Topics 2　AML幹細胞

    B．急性前骨髄球性白血病（APL）
    　　1．初発APLの治療
    　　2．再発・難治APLの治療

    C．急性リンパ性白血病（ALL）
    　　1．成人Ph陽性ALLの治療
    　　2．成人Ph陰性ALLの治療
    　　3．再発・難治ALLの治療
    　　4．AYA世代ALLの治療
    　　5．高齢者ALLの治療

    D．慢性骨髄性白血病（CML）
    　　1．初発CML-CPにおける治療選択
    　　2．進行期（AP／BP）CMLの治療
    　　3．チロシンキナーゼ阻害薬による有害事象のマネジメント
    　　4．TFRを目指したCML治療の現状と課題
    　　Topics　慢性骨髄性白血病におけるTKI耐性機序とその克服

    E．骨髄増殖性腫瘍（MPN）
    　　1．真性多血症（PV）の治療
    　　2．本態性血小板血症の治療
    　　3．原発性骨髄線維症（PMF）の治療
    　　4．慢性好中球性白血病の病態と診断・治療
    　　5．好酸球増加症の診断と治療
    　　Topics　MPN分子病態研究の進歩
    　　　　　　「成人発症MPNのドライバー変異は胎児期や小児期に生じている」

    IV．リンパ系腫瘍

    A．慢性リンパ性白血病（CLL）
    　　1．初発CLLの治療方針
    　　2．再発・難治性CLLの治療方針
    　　3．CLLで検索すべき遺伝子異常

    B．Indolent B細胞リンパ腫
    　　1．進行期低腫瘍量濾胞性リンパ腫の治療方針
    　　2．進行期高腫瘍量濾胞性リンパ腫の治療方針
    　　3．再発・再燃濾胞性リンパ腫の治療方針
    　　4．辺縁帯リンパ腫・リンパ形質細胞リンパ腫の治療方針

    C．マントル細胞リンパ腫
    　　1．若年者マントル細胞リンパ腫（MCL）の治療方針
    　　2．高齢者マントル細胞リンパ腫（MCL）の治療方針

    D．Aggressive B細胞リンパ腫
    　　1．限局期びまん性大細胞型B細胞リンパ腫の初回治療方針
    　　2．若年進行期びまん性大細胞型B細胞リンパ腫の初回治療方針
    　　3．高齢者びまん性大細胞型B細胞リンパ腫の治療方針
    　　4．再発・再燃びまん性大細胞型B細胞リンパ腫の治療方針
    　　5．中枢神経原発リンパ腫の治療

    E．T／NK細胞リンパ腫
    　　1．末梢性T細胞リンパ腫の初回治療方針
    　　2．再発・難治末梢性T細胞リンパ腫の治療方針
    　　3．節外性NK／T細胞リンパ腫の治療方針
    　　4．アグレッシブNK細胞白血病の治療方針

    F．成人T細胞白血病／リンパ腫（ATLL）
    　　1．ATLLの治療方針
    　　2．ATLに対する造血幹細胞移植

    G．ホジキンリンパ腫
    　　1．限局期ホジキンリンパ腫の治療方針
    　　2．進行期ホジキンリンパ腫の治療
    　　3．再発・難治ホジキンリンパ腫の治療方針

    H．総合・その他
    　　1．AYA世代リンパ腫の特徴と治療方針
    　　2．リンパ系腫瘍に対して今後期待される新薬
    　　3．次期WHO分類（第5版）リンパ系腫瘍における方針
    　　Topics　リンパ腫病型とゲノム異常

    V．多発性骨髄腫と関連疾患
    　　1．MGUS／くすぶり型多発性骨髄腫（SMM）の治療方針
    　　2．移植適応初発多発性骨髄腫（MM）の治療
    　　3．移植非適応初発多発性骨髄腫（MM）の治療方針
    　　4．再発・難治性多発性骨髄腫（MM）の治療
    　　5．多発性骨髄腫（MM）における維持療法の意義
    　　6．多発性骨髄腫（MM）に対する免疫療法の現状と課題
    　　7．Frailty評価と高齢者多発性骨髄腫（MM）の治療
    　　8．原発性ALアミロイドーシスの治療戦略
    　　9．原発性マクログロブリン血症の治療
    　　10．POEMS症候群に対する治療戦略
    　　11．Castleman病の診断と治療
    　　12．原発性形質細胞性白血病の治療
    　　Topics 1　多発性骨髄腫の病態解明研究の進歩
    　　Topics 2　多発性骨髄腫に対する新薬開発の動向

    VI．出血・血栓性疾患
    　　1．特発性血小板減少性紫斑病（ITP）の診断・治療
    　　2．後天性血栓性血小板減少性紫斑病（aTTP）治療の新展開
    　　3．血友病診療の新しい考え方
    　　4．新しいVWD診療ガイドライン
    　　5．後天性凝固因子インヒビターに対する診断・治療の進歩
    　　6．最近の抗血栓療法の考え方
    　　7．DICの診断と治療
    　　Topics 1　がん関連血栓塞栓症の病態生理
    　　Topics 2　遺伝性血栓性素因に対する妊娠管理

    VII．支持療法・輸血
    　　1．輸血のトリガー値
    　　2．TRALIとTACOの予防と治療
    　　3．発熱性好中球減少症（FN）の予防と治療
    　　4．アゾール系抗真菌薬と新規抗がん剤の相互作用
    　　5．造血器腫瘍女性患者の妊娠後の経過

    VIII．造血幹細胞移植
    　　1．急性GVHDの新規治療
    　　2．慢性GVHDの新規治療
    　　3．特発性肺炎症候群（IPS）の治療
    　　4．造血幹細胞移植後のクローン性ドナー造血の影響
    　　5．造血幹細胞移植前後における免疫チェックポイント阻害薬使用が与える影響
    　　6．同種造血幹細胞移植後のメチル化阻害薬維持療法
    　　7．造血幹細胞移植後のB型肝炎ウイルス対策

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I. 話題

P.5 掲載の参考文献
1) Buske C, Dreyling M, Alvarez-Larran A, et al. Managing hematological cancer patients during the COVID-19 pandemic : an ESMO-EHA Interdisciplinary Expert Consensus. ESMO Open. 2022 ; 7 : 100403.
PubMed
2) Calderon-Parra J, Munez-Rubio E, Fernandez-Cruz A, et al. Incidence, clinical presentation, relapses and outcome of SARS-CoV-2 infection in patients treated with anti-CD20 monoclonal antibodies. Clin Infect Dis. 2021.
 
3) Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19 : a systematic review and meta-analysis of 3377 patients. Blood. 2020 ; 136 : 2881-92.
PubMed
4) Sharma A, Bhatt NS, St Martin A, et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients : an observational cohort study. Lancet Haematol. 2021 ; 8 : e185-93.
PubMed
5) Okamoto A, Fujigaki H, Iriyama C, et al. CD19-positive lymphocyte count is critical for acquisition of anti-SARS-CoV-2 IgG after vaccination in B-cell lymphoma. Blood Adv. 2022 ; 6 : 3230-33.
 
6) Shree T, Shankar V, Lohmeyer JJK, et al. CD20-targeted therapy ablates de novo antibody response to vaccination but spares preestablished immunity. Blood Cancer Discov. 2022 ; 3 : 95-102.
PubMed
7) Ollila TA, Masel RH, Reagan JL, et al. Seroconversion and outcomes after initial and booster COVID-19 vaccination in adults with hematologic malignancies. Cancer. 2022.
PubMed
8) Mittelman M, Magen O, Barda N, et al. Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting. Blood. 2022 ; 139 : 1439-51.
 
9) Magen O, Waxman JG, Makov-Assif M, et al. Fourth dose of BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med. 2022 ; 386 : 1603-14.
 
10) Riise J, Meyer S, Blaas I, et al. Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination. Br J Haematol. 2022 ; 197 : 697-708.
PubMed
11) Lim SH, Stuart B, Joseph-Pietras D, et al. Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies : UK PROSECO study. Nat Cancer. 2022 ; 3 : 552-64.
 
P.10 掲載の参考文献
1) Seneviratne SL, Yasawardene P, Wijerathne W, et al. COVID-19 vaccination in cancer patients : a narrative review. J Int Med Res. 2022 ; 50 : 3000605221086155.
PubMed
2) Addeo A, Shah PK, Bordry N, et al. Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell. 2021 ; 39 : 1091-8.e2.
 
3) Monin L, Laing AG, Munoz-Ruiz M, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer : interim analysis of a prospective observational study. Lancet Oncol. 2021 ; 22 : 765-78.
PubMed
4) Guven DC, Sahin TK, Akin S, et al. Impact of therapy in patients with hematologic malignancies on seroconversion rates after SARS-CoV-2 vaccination. Oncologist. 2022 ; 27 : e357-61.
PubMed
5) Herzog Tzarfati K, Gutwein O, Apel A, et al. BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies. Am J Hematol. 2021 ; 96 : 1195-203.
PubMed
6) Lim SH, Stuart B, Joseph-Pietras D, et al. Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies : UK PROSECO study. Nat Cancer. 2022. doi : 10.1038/s43018-022-00364-3.
 
7) Nooka AK, Shanmugasundaram U, Cheedarla N, et al. Determinants of neutralizing antibody response after SARS CoV-2 vaccination in patients with myeloma. J Clin Oncol. 2022 ; 1-9.
 
8) Terao T, Yamashita T, Fukumoto A, et al. Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma. Int J Hematol. 2022. doi : 10.1007/s12185-022-03300-4.
 
9) Van Oekelen O, Gleason CR, Agte S, et al. Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. Cancer Cell. 2021 ; 39 : 1028-30.
PubMed
10) Riccardi N, Falcone M, Yahav D. Vaccination for SARS-CoV-2 in hematological patients. Acta Haematol. 2022 ; 2. doi : 10.1159/000523753.
 
11) Ikeda D, Terao T, Miura D, et al. Impaired antibody response following the second dose of the BNT162b2 vaccine in patients with myeloproliferative neoplasms receiving ruxolitinib. Front Med. 2022 ; 9 : 1-6.
 
12) Einarsdottir S, Martner A, Waldenstrom J, et al. Deficiency of SARS-CoV-2 T-cell responses after vaccination in long-term allo-HSCT survivors translates into abated humoral immunity. Blood Adv. 2022. doi : 10.1182/bloodadvances.2021006937.
 
13) Song Q, Bates B, Shao YR, et al. Risk and outcome of breakthrough COVID-19 infections in vaccinated patients with cancer : real-world evidence from the National COVID Cohort Collaborative. J Clin Oncol. 2022 ; JCO.21.02419.
 
14) Lee EJ, Cines DB, Gernsheimer T, et al. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol. 2021 ; 96 : 534-7.
PubMed
15) Kuter DJ. Exacerbation of immune thrombocytopenia following COVID-19 vaccination. Br J Haematol. 2021 ; 195 : 365-70.
PubMed
16) Gerber GF, Yuan X, Yu J, et al. COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria. Blood. 2021 ; 137 : 3670-73.
 
17) Kamura Y, Sakamoto T, Yokoyama Y, et al. Hemolysis induced by SARS-CoV-2 mRNA vaccination in patients with paroxysmal nocturnal hemoglobinuria. Int J Hematol. 2022 ; 116 : 55-9.
PubMed
P.13 掲載の参考文献
1) Spyropoulos AC, Levy JH, Ageno W, et al. Subcommittee on perioperative, critical care thrombosis, haemostasis of the scientific, standardization committee of the international society on thrombosis and haemostasis. scientific and standardization committee communication : Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020 ; 18 : 1859-65.
PubMed
2) Piazza G, Campia U, Hurwitz S, et al. Registry of arterial and venous thromboembolic complications in patients with COVID-19. J Am Coll Cardiol. 2020 ; 76 : 2060-72.
PubMed
3) Horiuchi H, Morishita E, Urano T, et al. COVID-19-related thrombosis in Japan : Final report of a Questionnaire-based survey in 2020. J Atheroscler Thromb. 2021 ; 28 : 406-16.
PubMed
4) Katsoularis I, Fonseca-Rodriguez O, Farrington P, et al. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19 : nationwide self-controlled cases series and matched cohort study. BMJ. 2022 ; 377 : e069590.
PubMed
5) Datta PK, Liu F, Fischer T, et al. SARS-CoV-2 pandemic and research gaps : understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. Theranostics. 2020 ; 10 : 7448-64.
PubMed
6) Zheng Y, Zhao J, Li J, et al. SARS-CoV-2 spike protein causes blood coagulation and thrombosis by competitive binding to heparan sulfate. Int J Biol Macromol. 2021 ; 193 : 1124-9.
 
7) Scully M, Singh D, Lown R, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 Vaccination. N Engl J Med. 2021 ; 384 : 2202-11.
PubMed
8) Klein NP, Lewis N, Goddard K, et al. Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA. 2021 ; 326 : 1390-9.
PubMed

II. 赤血球系疾患

P.19 掲載の参考文献
1) Young NS. Aplastic Anemia. N Engl J Med. 2018 ; 379 : 1643-56.
PubMed
2) Katagiri T, Sato-Otsubo A, Kashiwase K, et al. Frequent loss of HLA alleles associated with copy number-neutral 6pLOH in acquired aplastic anemia. Blood. 2011 ; 118 : 6601-9.
PubMed
3) Zaimoku Y, Takamatsu H, Hosomichi K, et al. Identification of an HLA class I allele closely involved in the autoantigen presentation in acquired aplastic anemia. Blood. 2017 ; 129 : 2908-16.
 
4) Mizumaki H, Hosomichi K, Hosokawa K, et al. A frequent nonsense mutation in exon 1 across certain HLA-A and-B alleles in leukocytes of patients with acquired aplastic anemia. Haematologica. 2021 ; 106 : 1581-90.
 
5) Zaimoku Y, Patel BA, Adams SD, et al. HLA associations, somatic loss of HLA expression, and clinical outcomes in immune aplastic anemia. Blood. 2021 ; 138 : 2799-809.
PubMed
6) Savage SA, Viard M, O'hUigin C, et al. Genome-wide association study identifies HLA-DPB1 as a significant risk factor for severe aplastic anemia. Am J Hum Genet. 2020 ; 106 : 264-71.
 
7) Pagliuca S, Gurnari C, Awada H, et al. The similarity of class II HLA genotypes defines patterns of autoreactivity in idiopathic bone marrow failure disorders. Blood. 2021 ; 138 : 2781-98.
PubMed
P.24 掲載の参考文献
1) Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012 ; 367 : 11-9.
PubMed
2) Desmond R, Townsley DM, Dumitriu B, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014 ; 123 : 1818-25.
PubMed
3) Winkler T, Fan X, Cooper J, et al. Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag. Blood. 2019 ; 133 : 2575-85.
PubMed
4) Yamazaki H, Ohta K, Iida H, et al. Hematologic recovery induced by eltrombopag in Japanese patients with aplastic anemia refractory or intolerant to immunosuppressive therapy. Int J Hematol. 2019 ; 110 : 187-96.
PubMed
5) Jang JH, Tomiyama Y, Miyazaki K, et al. Efficacy and safety of romiplostim in refractory aplastic anaemia : a Phase II/III, multicentre, open-label study. Br J Haematol. 2021 ; 192 : 190-9.
PubMed
6) Ise M, Iizuka H, Kamoda Y, et al. Romiplostim is effective for eltrombopag-refractory aplastic anemia : results of a retrospective study. Int J Hematol. 2020 ; 112 : 787-94.
PubMed
7) Hosokawa K, Yamazaki H, Tanabe M, et al. High-dose romiplostim accelerates hematologic recovery in patients with aplastic anemia refractory to eltrombopag. Leukemia. 2021 ; 35 : 906-9.
PubMed
8) Peffault de Latour R, Kulasekararaj A, Iacobelli S, et al. Eltrombopag added to immunosuppression in severe aplastic anemia. N Engl J Med. 2022 ; 386 : 11-23.
PubMed
9) Patel BA, Groarke EM, Lotter J, et al. Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag : a phase 2 study. Blood. 2022 ; 139 : 34-43.
PubMed
10) Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017 ; 376 : 1540-50.
PubMed
11) Goronkova O, Novichkova G, Salimova T, et al. Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemia. Blood Adv. 2022 Apr 21. Online ahead of print.
PubMed
12) Zaimoku Y, Patel BA, Shalhoub R, et al. Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag. Haematologica. 2022 ; 107 : 126-33.
PubMed
P.29 掲載の参考文献
1) Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood. 2012 ; 120 : 1185-96.
 
2) Bacigalupo A. How I treat acquired aplastic anemia. Blood. 2017 ; 129 : 1428-36.
 
3) Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016 ; 172 : 187-207.
PubMed
4) Yamamoto H, Kato D, Uchida N, et al. Successful sustained engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with severe aplastic anemia. Blood. 2011 ; 117 : 3240-2.
PubMed
5) Peffault de Latour R, Chevret S, Jubert C, et al. Unrelated cord blood transplantation in patients with idiopathic refractory severe aplastic anemia : a nationwide phase 2 study. Blood. 2018 ; 132 : 750-4.
PubMed
6) Ochi T, Onishi Y, Nasu K, et al. Umbilical cord blood transplantation using reduced-intensity conditioning without antithymocyte globulin in adult patients with severe aplastic anemia. Biol Blood Marrow Transplant. 2019 ; 25 : e55-9.
PubMed
7) DeZern AE, Zahurak M, Symons H, et al. Alternative donor transplantation with high-dose post-transplantation cyclophosphamide for refractory severe aplastic anemia. Biol Blood Marrow Transplant. 2017 ; 23 : 498-504.
PubMed
8) Prata PH, Eikema DJ, Afansyev B, et al. Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients : a report from the EBMT Severe Aplastic Anemia Working Party. Bone Marrow Transplant. 2020 ; 55 : 1050-8.
PubMed
9) DeZern AE, Zahurak ML, Symons HJ, et al. Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide. Blood Adv. 2020 ; 4 : 1770-9.
PubMed
10) Yoshimi A, Kojima S, Taniguchi S, et al. Unrelated cord blood transplantation for severe aplastic anemia. Biol Blood Marrow Transplant. 2008 ; 14 : 1057-63.
PubMed
11) Hiramoto N, Yamazaki H, Nakamura Y, et al. Total body irradiation-containing conditioning regimens without antithymocyte globulin in adults with aplastic anemia undergoing umbilical cord blood transplantation. Ann Hematol. 2022 ; 101 : 165-75.
PubMed
12) Kuwatsuka Y, Kanda J, Yamazaki H, et al. A comparison of outcomes for cord blood transplantation and unrelated bone marrow transplantation in adult aplastic anemia. Biol Blood Marrow Transplant. 2016 ; 22 : 1836-43.
PubMed
13) Onishi Y, Mori T, Kako S, et al. Outcome of second transplantation using umbilical cord blood for graft failure after allogeneic hematopoietic stem cell transplantation for aplastic anemia. Biol Blood Marrow Transplant. 2017 ; 23 : 2137-42.
PubMed
P.33 掲載の参考文献
1) Means RT Jr. Pure red cell aplasia. Blood. 2016 ; 128 : 2504-9.
PubMed
2) Gurnari C, Maciejewski JP. How I manage acquired pure red cell aplasia in adults. Blood. 2021 ; 137 : 2001-9.
 
3) 廣川誠, 藤島直仁, 澤田賢一, 他. 赤芽球癆診療の参照ガイド 令和1年改訂版 (第6版) 2020. [Available from : http://zoketsushogaihan.umin.jp/file/2020/03.pdf]
 
4) Sawada K, Hirokawa M, Fujishima N, et al. Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine A. A nationwide cohort study in Japan for the PRCA collaborative study group. Haematologica. 2007 ; 92 : 1021-8.
 
5) Hirokawa M, Sawada K, Fujishima N, et al. Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia : a nationwide cohort study in Japan by the PRCA collaborative study group. Haematologica. 2008 ; 93 : 27-33.
 
6) Hirokawa M, Sawada K, Fujishima N, et al. Long-term outcome of patients with acquired chronic pure red cell aplasia (PRCA) following immunosuppressive therapy : a final report of the nationwide cohort study in 2004/2006 by the Japan PRCA collaborative study group. Br J Haematol. 2015 ; 169 : 879-86.
 
7) Halkes C, de Wreede LC, Knol C, et al. Allogeneic stem cell transplantation for acquired pure red cell aplasia. Am J Hematol. 2019 ; 94 : E294-6.
PubMed
8) Balasubramanian SK, Sadaps M, Thota S, et al. Rational management approach to pure red cell aplasia. Haematologica. 2018 ; 103 : 221-30.
PubMed
P.40 掲載の参考文献
1) Sanada M, Suzuki T, Shih LY, et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature. 2009 ; 460 : 904-8.
PubMed
2) Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011 ; 365 : 1384-95.
PubMed
3) Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011 ; 478 : 64-9.
PubMed
4) Meggendorfer M, Roller A, Haferlach T, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood. 2012 ; 120 : 3080-8.
PubMed
5) Makishima H, Visconte V, Sakaguchi H, et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood. 2012 ; 119 : 3203-10.
PubMed
6) Beck DB, Ferrada MA, Sikora KA, et al. Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med. 2020 ; 383 : 2628-38.
PubMed
7) Makishima H, Maciejewski JP. Pathogenesis and consequences of uniparental disomy in cancer. Clin Cancer Res. 2011 ; 17 : 3913-23.
PubMed
8) Shiozawa Y, Malcovati L, Galli A, et al. Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia. Nat Commun. 2018 ; 9 : 3649.
PubMed
9) Malcovati L, Karimi M, Papaemmanuil E, et al. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood. 2015 ; 126 : 233-41.
PubMed
10) Malcovati L, Papaemmanuil E, Bowen DT, et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood. 2011 ; 118 : 6239-46.
PubMed
11) Malcovati L, Hellstrom-Lindberg E, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults : recommendations from the European LeukemiaNet. Blood. 2013 ; 122 : 2943-64.
PubMed
12) Heiblig M, Patel, BA, Groarke EM, et al. Toward a pathophysiology inspired treatment of VEXAS syndrome. Semin Hematol. 2021 ; 58 : 239-46.
 
13) Lindsley RC, Saber W, Mar BG, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med. 2017 ; 376 : 536-47.
PubMed
14) Yoshizato T, Nannya Y, Atsuta Y, et al. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia : impact on outcome of stem cell transplantation. Blood. 2017 ; 129 : 2347-58.
PubMed
15) Bernard E, Nannya Y, Hasserjian RP, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020 ; 26 : 1549-56.
PubMed
16) Balasubramanian SK, Aly M, Nagata Y, et al. Distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasms. Leukemia. 2018 ; 32 : 550-3.
PubMed
17) Awada H, Nagata Y, Goyal A, et al. Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia. Blood Adv. 2019 ; 3 : 339-49.
PubMed
18) Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010 ; 363 : 2424-33.
PubMed
19) Jankowska AM, Makishima H, Tiu RV, et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation : UTX, EZH2, and DNMT3A. Blood. 2011 ; 118 : 3932-41.
PubMed
20) Saiki R, Momozawa Y, Nannya Y, et al. Combined landscape of single-nucleotide variants and copy number alterations in clonal hematopoiesis. Nat Med. 2021 ; 27 : 1239-49.
PubMed
21) Yoshizato T, Dumitriu B, Hosokawa K, et al. Somatic mutations and clonal hematopoiesis in aplastic anemia. N Engl J Med. 2015 ; 373 : 35-47.
PubMed
22) Shen W, Clemente MJ, Hosono N, et al. Deep sequencing reveals stepwise mutation acquisition in paroxysmal nocturnal hemoglobinuria. J Clin Invest. 2014 ; 124 : 4529-38.
PubMed
23) Negoro E, Nagata Y, Clemente MJ, et al. Origins of myelodysplastic syndromes after aplastic anemia. Blood. 2017 ; 130 : 1953-7.
PubMed
24) Abelson S, Collord G, Ng SWK, et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature. 2018 ; 559 : 400-4.
PubMed
25) Malcovati L, Galli A, Travaglino E, et al. Clinical significance of somatic mutation in unexplained blood cytopenia. Blood. 2017 ; 129 : 3371-8.
PubMed
26) Nagata Y, Zhao R, Awada H, et al. Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes. Blood. 2020 ; 136 : 2249-62.
PubMed
27) Mori J, Kaji S, Kawai H, et al. Assessment of dysplasia in bone marrow smear with convolutional neural network. Sci Rep. 2020 ; 10 : 14734.
PubMed
28) Nazha A, Sekeres MA, Bejar R, et al. Genomic biomarkers to predict resistance to hypomethylating agents in patients with myelodysplastic syndromes using artificial intelligence. JCO Precis Oncol. 2019 ; 3 : PO.19.00119.
 
29) Ko BS, Wang YF, Li JL, et al. Clinically validated machine learning algorithm for detecting residual diseases with multicolor flow cytometry analysis in acute myeloid leukemia and myelodysplastic syndrome. EBioMedicine. 2018 ; 37 : 91-100.
PubMed
30) Naqvi K, Jabbour E, Bueso-Ramos C, et al. Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood. 2011 ; 118 : 4690-3.
PubMed
P.46 掲載の参考文献
1) Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012 ; 120 : 2454-65.
PubMed
2) Nazha A, Komrokji R, Meggendorfer M, et al. Personalized prediction model to risk stratify patients with myelodysplastic syndromes. J Clin Oncol. 2021 ; 39 : 3737-46.
PubMed
3) Bernard E, Tuechler H, Greenberg PL, et al. Molecular International Prognostic Scoring System for Myelodysplastic syndromes. NEJM Evid. 2022 ; 1 (7). doi : https://doi.org/10.1056/EVIDoa2200008
 
4) Scheid C, de Wreede L, van Biezen A, et al. Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation : a retrospective analysis of the EBMT chronic malignancies working party. Bone Marrow Transplant. 2017 ; 52 : 1519-25.
PubMed
5) Kuendgen A, Nomdedeu M, Tuechler H, et al. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS. Leukemia. 2021 ; 35 : 835-49.
 
6) Pfeilstocker M, Tuechler H, Sanz G, et al. Time-dependent changes in mortality and transformation risk in MDS. Blood. 2016 ; 128 : 902-10.
PubMed
P.55 掲載の参考文献
1) 日本血液学会. 造血器腫瘍診療ガイドライン 第2版補訂版. (造血器腫瘍診療ガイドライン 2018年版補訂版. 日本血液学会 (jshem.or.jp) ; 2020)
 
2) 日本血液学会. 造血器腫瘍ゲノム検査ガイドライン (2021年度一部改訂版). (造血器腫瘍ゲノム検査ガイドライン. 日本血液学会 (jshem.or.jp) ; 2021)
 
3) Network NCC. NCCN clinical practice guidelines in oncology, myelodysplastic syndromes, version 3. 2022. mds. pdf (nccn.org). 2022.
 
4) Fenaux P, Haase D, Santini V, et al. Myelodysplastic syndromes : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021 ; 32 : 142-56.
PubMed
5) Killick SB, Ingram W, Culligan D, et al. British Society for Haematology guidelines for the management of adult myelodysplastic syndromes. Br J Haematol. 2021 ; 194 : 267-81.
PubMed
6) Platzbecker U, Symeonidis A, Oliva EN, et al. A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes. Leukemia. 2017 ; 31 : 1944-50.
PubMed
7) Fenaux P, Santini V, Spiriti MAA, et al. A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS. Leukemia. 2018 ; 32 : 2648-58.
 
8) Toma A, Kosmider O, Chevret S, et al. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion. Leukemia. 2016 ; 30 : 897-905.
 
9) List AF, Sun Z, Verma A, et al. Lenalidomide-epoetin alfa versus lenalidomide monotherapy in myelodysplastic syndromes refractory to recombinant erythropoietin. J Clin Oncol. 2021 ; 39 : 1001-9.
PubMed
10) Stahl M, Bewersdorf JP, Giri S, et al. Use of immunosuppressive therapy for management of myelodysplastic syndromes : a systematic review and meta-analysis. Haematologica. 2020 ; 105 : 102-11.
PubMed
11) Angelucci E, Li J, Greenberg P, et al. Iron chelation in transfusion-dependent patients with low- to intermediate-1-risk myelodysplastic syndromes : a randomized trial. Ann Intern Med. 2020 ; 172 : 513-22.
PubMed
12) Hoeks M, Yu G, Langemeijer S, et al. Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry. Haematologica. 2020 ; 105 : 640-51.
PubMed
13) Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med. 2020 ; 382 : 140-51.
PubMed
14) Henry DH, Glaspy J, Harrup R, et al. Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome : open-label, dose-selection, lead-in stage of a phase 3 study. Am J Hematol. 2022 ; 97 : 174-84.
PubMed
15) Garcia-Manero G, Santini V, Almeida A, et al. Phase III, randomized, placebo-controlled trial of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2021 ; 39 : 1426-36.
PubMed
16) Steensma DP, Fenaux P, Van Eygen K, et al. Imetelstat achieves meaningful and durable transfusion independence in high transfusion-burden patients with lower-risk myelodysplastic syndromes in a phase II study. J Clin Oncol. 2021 ; 39 : 48-56.
 
17) Greenberg PL, Sun Z, Miller KB, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor : results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood. 2009 ; 114 : 2393-400.
PubMed
18) Jabbour E, Short NJ, Montalban-Bravo G, et al. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood. 2017 ; 130 : 1514-22.
PubMed
19) Park S, Hamel JF, Toma A, et al. Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents. J Clin Oncol. 2017 ; 35 : 1591-97.
PubMed
20) Bernard E Tuechler H, Greenberg PL, et al. Molecular international prognosis scoring system for myelodysplastic syndromes. ASH annual meeting ; 2021.
 
P.61 掲載の参考文献
1) Heidenreich S, Ziagkos D, de Wreede LC, et al. Allogeneic stem cell transplantation for patients age > 70 years with myelodysplastic syndrome : A retrospective study of the MDS subcommittee of the chronic malignancies working party of the EBMT. Biol Blood Marrow Transplant. 2017 ; 23 : 44-52.
 
2) Nakaya A, Mori T, Tanaka M, et al. Does the hematopoietic cell transplantation specific comorbidity index (HCT-CI) predict transplantation outcomes? A prospective multicenter validation study of the Kanto Study Group for Cell Therapy. Biol Blood Marrow Transplant. 2014 ; 20 : 1553-9.
 
3) Della Porta MG, Jackson CH, Alessandrino EP, et al. Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. Leukemia. 2017 ; 31 : 2449-57.
 
4) Kroger N, Iacobelli S, Franke GN, et al. Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome : A prospective randomized phase III study of the EBMT (RICMAC Trial). J Clin Oncol. 2017 ; 35 : 2157-64.
 
5) Lindsley RC, Saber W, Mar BG, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med. 2017 ; 376 : 536-47.
PubMed
6) Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes : a randomised, open-label, phase III study. Lancet Oncol. 2009 ; 10 : 223-32.
PubMed
7) Itzykson R, Thepot S, Quesnel B, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood. 2011 ; 117 : 403-11.
PubMed
8) Nazha A. The MDS genomics-prognosis symbiosis. Am Soc Hematol Educ Program. 2018 ; 2018 : 270-6.
PubMed
9) Voso MT, Leone G, Piciocchi A, et al. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia : results of the BMT-AZA prospective study. Ann Oncol. 2017 ; 28 : 1547-53.
PubMed
10) Oran B, de Lima M, Garcia-Manero G, et al. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Adv. 2020 ; 4 : 5580-8.
PubMed
11) Ades L, Boehrer S, Prebet T, et al. Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion : results of a phase 2 study. Blood. 2009 ; 113 : 3947-52.
PubMed
12) Morita Y, Kanamaru A, Miyazaki Y, et al. Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group. Int J Hematol. 2010 ; 91 : 97-103.
 
13) Prebet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011 ; 29 : 3322-7.
PubMed
14) Damaj G, Duhamel A, Robin M, et al. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes : a study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies. J Clin Oncol. 2012 ; 30 : 4533-40.
PubMed
15) Nakamura R, Saber W, Martens MJ, et al. Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50-75 years of age with advanced myelodysplastic syndrome. J Clin Oncol. 2021 ; 39 : 3328-39.
PubMed
16) Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens : working definitions. Biol Blood Marrow Transplant. 2009 ; 15 : 1628-33.
PubMed
17) Grunwald MR, Zhang MJ, Elmariah H, et al. Alternative donor transplantation for myelodysplastic syndromes : haploidentical relative and matched unrelated donors. Blood Adv. 2021 ; 5 : 975-83.
PubMed
18) Ossenkoppele GJ, Breems DA, Stuessi G, et al. Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS. Leukemia. 2020 ; 34 : 1751-9.
PubMed
19) Makishima H, Yoshizato T, Yoshida K, et al. Dynamics of clonal evolution in myelodysplastic syndromes. Nat Genet. 2017 ; 49 : 204-12.
PubMed
20) Nazha A, Hu ZH, Wang T, et al. A personalized prediction model for outcomes after allogeneic hematopoietic cell transplant in patients with myelodysplastic syndromes. Biol Blood Marrow Transplant. 2020 ; 26 : 2139-46.
 
21) Drug Approval Package : INQOVI [multi-discipline review]. Available from : https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212576Orig1s000MultidisciplineR.pdf
 
22) Garcia-Manero G, Gore SD, Cogle C, et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol. 2011 ; 29 : 2521-7.
PubMed
23) Garcia-Manero G, Roboz G, Walsh K, et al. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes : phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. Lancet Haematol. 2019 ; 6 : e317-27.
PubMed
24) Jones CL, Stevens BM, D'Alessandro A, et al. Inhibition of amino acid metabolism selectively targets human leukemia stem cells. Cancer Cell. 2018 ; 34 : 724-40.e4.
 
25) Cluzeau T, Sebert M, Rahme R, et al. Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia : A phase II study by the Groupe Francophone des Myelodysplasies (GFM). J Clin Oncol. 2021 ; 39 : 1575-83.
PubMed
26) Sekeres MA, Watts J, Radinoff A, et al. Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML. Leukemia. 2021 ; 35 : 2119-24.
 
27) Welch JS, Petti AA, Miller CA, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med. 2016 ; 375 : 2023-36.
PubMed
P.67 掲載の参考文献
1) Hirschhorn R, Yang DR, Israni A, et al. Somatic mosaicism for a newly identified splice-site mutation in a patient with adenosine deaminase-deficient immunodeficiency and spontaneous clinical recovery. Am J Hum Genet. 1994 ; 55 : 59-68.
 
2) Revy P, Kannengiesser C, Fischer A. Somatic genetic rescue in Mendelian haematopoietic diseases. Nat Rev Genet. 2019 ; 20 : 582-98.
PubMed
3) Pollard JA, Furutani E, Liu S, et al. Metformin for treatment of cytopenias in children and young adults with Fanconi anemia. Blood Adv. 2022 ; 6 : 3803-11.
 
4) Tan S, Kermasson L, Hilcenko C, et al. Somatic genetic rescue of a germline ribosome assembly defect. Nat Commun. 2021 ; 12 : 5044.
PubMed
P.71 掲載の参考文献
1) Adli M. The CRISPR tool kit for genome editing and beyond. Nat Commun. 2018 ; 9 : 1911.
PubMed
2) Frangoul H, Altshuler D, Cappellini MD, et al. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med. 2021 ; 384 : 252-60.
 
3) Qasim W, Zhan H, Samarasinghe S, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med. 2017 ; 9 : eaaj2013.
 
4) Gillmore JD, Gane E, Taubel J, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021 ; 385 : 493-502.
PubMed
P.75 掲載の参考文献
1) Jager U, Barcellini W, Broome CM, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults : Recommendations from the first consensus meeting. Blood Reviews. 2020 ; 41 : 100648.
PubMed
2) Barcellini W, Fattizzo B, Zaninoni A, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia : a GIMEMA study of 308 patients. Blood. 2014 ; 124 : 2930-6.
PubMed
3) 上田恭典. 自己免疫性溶血性貧血に対する輸血療法. 臨床血液. 2018 ; 59 : 2354-61.
 
4) Salama A, Berghofer H, Mueller-Eckhardt C. Red blood cell transfusion in warm-type autoimmune haemolytic anaemia. Lancet. 1992 ; 340 : 1515-7.
PubMed
5) Park SH, Choe W-H, Kwon S-W. Red blood cell transfusion in patients with autoantibodies : Is it effective and safe without increasing hemolysis risk? Ann Lab Med. 2015 ; 35 : 436-44.
PubMed
6) Chen C, Wang L, Han B, et al. Autoimmune hemolytic anemia in hospitalized patients 450 patients and their red blood cell transfusions. Medicine (Baltimore). 2020 ; 99 : e18739.
 
7) Pirofsky B. Immune haemolytic disease : the autoimmune haemolytic anaemias. Clin Haematol. 1975 ; 4 : 167-80.
PubMed
8) Petz LD, Garratty G. Immune Hemolytic Anemias. 2nd ed. Philadelphia : Churchill Livingstone ; 2004.
 
9) Voulgaridou A, Kalfa TA. Autoimmune hemolytic anemia in the pediatric setting. J Clin Med. 2021 ; 10 : 216.
PubMed
10) Murphy S, LoBuglio AF. Drug therapy of autoimmune hemolytic anemia. Semin Hematol. 1976 ; 13 : 323-34.
PubMed
11) Lechner K, Jager U. How I treat autoimmune hemolytic anemias in adults. Blood. 2010 ; 116 : 1831-8.
 
12) Dussadee K, Taka O, Thedsawad A, et al. Incidence and risk factors of relapses in idiopathic autoimmune hemolytic anemia. J Med Assoc Thai. 2010 ; 93 (Suppl. 1) : S165-70.
 
13) Roumier M, Loustau V, Guillaud C, et al. Characteristics and outcome of warm antibody autoimmune hemolytic anemia in adults : new insights based on single-center experience with 60 patients. Am J Hematol. 2014 ; 89 : E150-5.
PubMed
14) Birgens H, Frederiksen H, Hasselbalch HC, et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br J Haematol. 2013 ; 163 : 393-9.
PubMed
15) Nakasone H, Kako S, Endo H, et al. Diabetes mellitus is associated with high early-mortality and poor prognosis in patients with autoimmune hemolytic anemia. Hematology. 2009 ; 14 : 361-5.
PubMed
16) 和田秀穂. 難治性自己免疫性溶血性貧血 (AIHA) の治療. In : 金倉譲, 監修. EBM血液疾患の治療 2021-2022. 東京 : 中外医学社 ; 2018. p.66-73.
 
17) Branch DR, Petz LD. Detecting alloantibodies in patients with autoantibodies. Transfusion. 1999 ; 39 : 6-10.
PubMed
18) Barcellini W, Zaninoni A, Alessandro J, et al. New insights in autoimmune hemolytic anemia : from pathogenesis to therapy. J Clin Med. 2020 ; 9 : 3859.
 
19) Ness PM. How do I encourage clinicians to transfuse mismatched blood to patients with autoimmune hemolytic anemia in urgent situations? Transfusion. 2006 ; 46 : 1859-62.
PubMed
20) Reardon JE, Marques MB. Laboratory evaluation and transfusion support of patients with autoimmune hemolytic anemia. Am J Clin Pathol. 2006 ; 125 Suppl : S71-7.
 
21) King KE, Ness PM. Treatment of autoimmune hemolytic anemia. Semin Hematol. 2005 ; 42 : 131-6.
PubMed
22) Petz LD. "Least incompatible" units for transfusion in autoimmune hemolytic anemia : Should we liminatethis meaningless term? A commentary for clinicians and transfusion medicine professionals. Transfusion. 2003 ; 43 : 1503-7.
PubMed
23) 廣瀬匡, 徳永博俊, 清水里紗, 他. クームス陽性自己免疫性溶血性貧血と悪性腫瘍に関する後方視的検討. 臨床血液. 2019 ; 60 : 1418-24.
 
24) 小峰光博, 梶井英治, 亀崎豊実, 他. 自己免疫性溶血性貧血診療の参照ガイド. 臨床血液. 2006 ; 47 : 116-36.
 
25) Kawamoto S, Kamesaki T, Masutani R, et al. Ectopic expression of band 3 anion transport protein in colorectal cancer revealed in an autoimmune hemolytic anemia patient. Hum Pathol. 2019 ; 83 : 193-8.
 
26) Kitao A, Kawamoto S, Kurata K, et al. Band 3 ectopic expression in colorectal cancer induces an increase in erythrocyte membrane-bound IgG and may cause immune-related anemia. Int J Hematol. 2020 ; 111 : 657-66.
PubMed
27) Matsuyama Y, Hosoi H, Horitani R, et al. Management of warm autoimmune hemolytic anemia related to band 3-positive colon carcinoma. Ann Hematol. 2022 ; 101 : 1343-4.
PubMed
28) Takahashi N, Kameoka J, Takahashi N, et al. Causes of macrocytic anemia among 628 patients : mean corpuscular volumes of 114 and 130 fL as critical markers for categorization. Int J Hematol. 2016 ; 104 : 344-57.
PubMed
P.80 掲載の参考文献
1) Berentsen S, Barcellini W, D'Sa S, et al. Cold agglutinin disease revisited : a multinational, observational study of 232 patients. Blood. 2020 ; 136 : 480-8.
PubMed
2) 張替秀郎, 西村純一, 植田康敬, 他. 自己免疫性溶血性貧血 診療の参照ガイド 令和1年改訂版.
 
3) Berentsen S, Ulvestad E, Langholm R, et al. Primary chronic cold agglutinin disease : a population based clinical study of 86 patients. Haematologica. 2006 ; 91 : 460-6.
PubMed
4) Lahav M, Rosenberg I, Wysenbeek AJ. Steroid-responsive idiopathic cold agglutinin disease : a case report. Acta Haematol. 1989 ; 81 : 166-8.
PubMed
5) Berentsen S, Ulvestad E, Gjertsen BT, et al. Rituximab for primary chronic cold agglutinin disease : a prospective study of 37 courses of therapy in 27 patients. Blood. 2004 ; 103 : 2925-8.
PubMed
6) Roth A, Barcellini W, D'Sa S, et al. Sutimlimab in cold agglutinin disease. N Engl J Med. 2021 ; 384 : 1323-34.
 
7) Roeth A, Berentsen S, Barcellini W, et al. Inhibition of complement C1s by sutimlimab in patients with cold agglutinin disease (CAD) : Efficacy and safety results from the randomized, placebo-controlled phase 3 CADENZA study. Blood. 2021 ; 138 (Supplement 1) : 349-51.
 
8) Roth A, Bommer M, Huttmann A, et al. Eculizumab in cold agglutinin disease (DECADE) : an open-label, prospective, bicentric, nonrandomized phase 2 trial. Blood Adv. 2018 ; 2 : 2543-9.
PubMed
9) Berentsen S. How I treat cold agglutinin disease. Blood. 2021 ; 137 : 1295-303.
 
P.84 掲載の参考文献
1) Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal 5 ; 106 : 3699-709.
 
2) Risitano AM, Notaro R, Marando L, et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood. 2009 ; 113 : 4094-100.
PubMed
3) Hill A, Rother RP, Arnold L, et al. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization. Haematologica. 2010 ; 95 : 567-73.
PubMed
4) 三谷絹子. 発作性夜間ヘモグロビン尿症診療の参照ガイド 令和1年改訂版. 厚生労働科学研究費補助金 難治性疾患克服研究事業 特発性造血障害に関する調査研究班. 2020.
 
5) Kulasekararaj AG, Griffin M, Langemeijer S, et al. Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria : 2-year results from two pivotal phase 3 studies. Eur J Haematol. 2022.
PubMed
6) Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors : the 301 study. Blood. 2019 ; 133 : 530-9.
PubMed
7) Kulasekararaj AG, Hill A, Rottinghaus ST, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH : the 302 study. Blood. 2019 ; 133 : 540-9.
PubMed
8) Roth A, Nishimura JI, Nagy Z, et al. The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. Blood. 2020 ; 135 : 912-20.
PubMed
9) Kulasekararaj AG, Risitano AM, Maciejewski JP, et al. Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab. Blood. 2021 ; 138 : 1928-38.
PubMed
10) Jang JH, Wong Lee Lee L, Ko BS, et al. Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria : a 2-cohort open-label proof-of-concept study. Blood Adv. 2022.
 
11) Hillmen P, Szer J, Weitz I, et al. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2021 ; 384 : 1028-37.
PubMed
12) 三谷絹子. PNH 妊娠の参照ガイド (付記) 令和1年改訂版. 厚生労働科学研究費補助金 難治性疾患等政策研究事業 特発性造血障害に関する調査研究班. 2020.
 
13) Ueda Y, Takamori H, Nishimura JI. Pegcetacoplan versus eculizumab in PNH. N Engl J Med. 2021 ; 385 : 1723-4.
PubMed
P.87 掲載の参考文献
1) Nishimura J, Yamamoto M, Hayashi S, et al. Genetic variants in C5 and poor response to eculizumab. N Engl J Med. 2014 ; 370 : 632-9.
PubMed
2) Risitano AM, Notaro R, Marando L, et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood. 2009 ; 113 : 4094-100.
PubMed
3) Risitano AM, Marotta S. Therapeutic complement inhibition in complement-mediated hemolytic anemias : Past, present and future. Semin Immunol. 2016 ; 28 : 223-40.
PubMed
4) Nishimura JI, Usuki K, Ramos J, et al. Crovalimab for treatment of patients with paroxysmal nocturnal haemoglobinuria and complement C5 polymorphism : Subanalysis of the phase 1/2 COMPOSER study. Br J Haematol. 2022 ; 198 : e46-e50.
PubMed
5) Hillmen P, Szer J, Weitz I, et al. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2021 ; 384 : 1028-37.
PubMed
6) Ueda Y, Takamori H, Nishimura JI. Pegcetacoplan versus eculizumab in PNH. N Engl J Med. 2021 ; 385 : 1723-4.
PubMed
7) Kulasekararaj AG, Risitano AM, Maciejewski JP, et al. Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab. Blood. 2021 ; 138 : 1928-38.
PubMed
8) Jang JH, Wong Lee Lee L, Ko BS, et al. Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria : a 2-cohort open-label proof-of-concept study. Blood Adv. 2022 ; 6 : 4450-60.
 
9) Risitano AM, Peffault de Latour R. How we ('ll) treat paroxysmal nocturnal haemoglobinuria : diving into the future. Br J Haematol. 2022 ; 196 : 288-303.
PubMed
10) Brodsky RA, Lee JW, Nishimura JI, et al. Lactate dehydrogenase versus haemoglobin : which one is the better marker in paroxysmal nocturnal haemoglobinuria? Br J Haematol. 2022 ; 196 : 264-5.
PubMed
P.93 掲載の参考文献
1) Sugahara M, Tanaka T, Nangaku M. Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease. Kidney Int. 2017 ; 92 : 306-12.
PubMed
2) 内田啓子, 南学正臣, 阿部雅紀, 他. HIF-PH阻害薬適正使用に関するrecommendation. 日本腎臓学会誌. 2020 ; 62 : 711-6.
 
3) Yap DYH, McMahon LP, Hao CM, et al. Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF-PH inhibitors. Nephrology. 2021 ; 26 : 105-18.
PubMed
4) Chertow GM, Pergola PE, Farag YMK, et al. Vadadustat in patients with anemia and non-dialysis-dependent CKD. N Engl J Med. 2021 ; 384 : 1589-600.
PubMed
5) Eckardt KU, Agarwal R, Aswad A, et al. Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. N Engl J Med. 2021 ; 384 : 1601-12.
PubMed
6) Provenzano R, Szczech L, Leong R, et al. Efficacy and cardiovascular safety of roxadustat for treatment of anemia in patients with non-dialysis-dependent CKD pooled results of three randomized clinical trials. Clin J Am Soc Nephrol. 2021 ; 16 : 1190-200.
PubMed
7) Barratt J, Sulowicz W, Schomig M, et al. Efficacy and cardiovascular safety of roxadustat in dialysis-dependent chronic kidney disease : pooled analysis of four phase 3 studies. Adv Ther. 2021 ; 38 : 5345-60.
PubMed
8) Singh AK, Carroll K, McMurray JJV, et al. Daprodustat for the treatment of anemia in patients not undergoing dialysis. N Engl J Med. 2021 ; 385 : 2313-24.
 
9) Singh AK, Carroll K, Perkovic V, et al. Daprodustat for the treatment of anemia in patients undergoing dialysis. N Engl J Med. 2021 ; 385 : 2325-35.
PubMed
10) Csiky B, Schomig M, Esposito C, et al. Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis : a European phase 3, randomized, open-label, active-controlled study (PYRENEES). Adv Ther. 2021 ; 38 : 5361-80.
PubMed
P.96 掲載の参考文献
1) Gondek LP. CHIP : is clonal hematopoiesis a surrogate for aging and other disease? Hematology. 2021 ; 2021 : 384-9.
PubMed
2) Genovese G, Kahler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014 ; 371 : 2477-87.
PubMed
3) Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014 ; 371 : 2488-98.
PubMed
4) Xie M, Lu C, Wang J, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014 ; 20 : 1472-8.
PubMed
5) Challen GA, Goodell MA : Clonal hematopoiesis : mechanisms driving dominance of stem cell clones. Blood. 2020 ; 136 : 1590-8.
PubMed
6) Yoshizato T, Dumitriu B, Hosokawa K, et al. Somatic mutations and clonal hematopoiesis in aplastic anemia. N Engl J Med. 2015 ; 373 : 35-47.
PubMed
7) Coombs CC, Zehir A, Devlin SM, et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell. 2017 ; 21 : 374-82.e4.
 
8) King KY, Huang Y, Nakada D, et al. Environmental influences on clonal hematopoiesis. Exp Hematol. 2020 ; 83 : 66-73.
PubMed
9) Silver AJ, Bick AG, Savona MR. Germline risk of clonal haematopoiesis. Nat Rev Genet. 2021 ; 22 : 603-17.
PubMed
10) Saiki R, Momozawa Y, Nannya Y, et al. Combined landscape of single-nucleotide variants and copy number alterations in clonal hematopoiesis. Nat Med. 2021 ; 27 : 1239-49.
PubMed
11) Abelson S, Collord G, Ng SWK, et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature. 2018 ; 559 : 400-4.
PubMed
12) Desai P, Mencia-Trinchant N, Savenkov O, et al. Somatic mutations precede acute myeloid leukemia years before diagnosis. Nat Med. 2018 ; 24 : 1015-23.
PubMed
13) Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015 ; 126 : 9-16.
PubMed
14) Malcovati L, Galli A, Travaglino E, et al. Clinical significance of somatic mutation in unexplained blood cytopenia. Blood. 2017 ; 129 : 3371-8.
PubMed
15) Niroula A, Sekar A, Murakami MA, et al. Distinction of lymphoid and myeloid clonal hematopoiesis. Nat Med. 2021 ; 27 : 1921-7.
PubMed
16) Frick M, Chan W, Arends CM, et al. Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2019 ; 37 : 375-85.
PubMed
17) Jaiswal S. Clonal hematopoiesis and nonhematologic disorders. Blood. 2020 ; 136 : 1606-14.
PubMed
18) Asada S, Kitamura T. Clonal hematopoiesis and associated diseases : A review of recent findings. Cancer Sci. 2021 ; 112 : 3962-71.
 
19) Kakiuchi N, Ogawa S. Clonal expansion in non-cancer tissues. Nat Rev Cancer. 2021 ; 21 : 239-56.
PubMed

III. 白血病

P.104 掲載の参考文献
1) 日本血液学会, 編. 造血器腫瘍診療ガイドライン 2018年版. 東京 : 金原出版 ; 2018. p.8-37.
 
2) National Comprehensive Cancer Network, Inc. The NCCN GuidelinesR for Myelodysplastic Syndromes V.1.2022.2022. (https://www.nccn.org.)
 
3) Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults : 2017 ELN recommendations from an international expert panel. Blood. 2017 ; 129 : 424-47.
 
4) DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020 ; 383 : 617-29.
PubMed
5) Cherry EM, Abbott D, Amaya M, et al. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv. 2021 ; 5 : 5565-73.
PubMed
6) Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018 ; 36 : 2684-92.
PubMed
7) Montesinos P, Recher C, Vives S, et al. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med. 2022 ; 386 : 1519-31.
PubMed
8) Wei AH, Dohner H, Pocock C, et al. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med. 2020 ; 383 : 2526-37.
PubMed
P.109 掲載の参考文献
1) DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020 ; 383 : 617-29.
PubMed
2) Breems DA, Putten W, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. 2005 ; 23 : 1969-78.
PubMed
3) Chevallier P, Labopin M, Turlure P, et al. A new leukemia prognostic scoring system for refractory/relapsed adult acute myelogeneous leukaemia patients : a GOELAMS study. Leukemia. 2011 ; 25 : 939-44.
PubMed
4) Giles F, Verstovsek S, Garcia-Manero G, et al. Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse. Br J Haematol. 2006 ; 134 : 58-60.
PubMed
5) Schlenk RF, Frech P, Weber D, et al. Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia. Leukemia. 2017 ; 31 : 1217-20.
PubMed
6) DeWolf S, Tallman MS. How I treat relapsed or refractory AML. Blood. 2020 ; 136 : 1023-32.
PubMed
7) Herzig RH, Lazarus HM, Wolff SN, et al. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. J Clin Oncol. 1985 ; 3 : 992-7.
PubMed
8) Karanes C, Kopecky KJ, Head DR, et al. A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study. Leukemia Research. 1999 ; 23 : 787-94.
PubMed
9) Parker JE, Pagliuca A, Mijovic A, et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol. 1997 ; 99 : 939-44.
PubMed
10) Hatsumi N, Miyawaki S, Yamauchi T, et al. Phase II study of FLAGM (fludarabine+high-dose cytarabine+granulocyte colony-stimulating factor+mitoxantrone) for relapsed or refractory acute myeloid leukemia. Int J Hematol. 2019 ; 109 : 418-25.
PubMed
11) Amadori S, Arcese W, Isacchi G, et al. Mitoxantrone, etoposide, and intermediate-dose cytarabine : an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J Clin Oncol. 1991 ; 9 : 1210-4.
PubMed
12) Yamamoto C, Ito S, Mashima K, et al. Dose-reduced combination of mitoxantrone, etoposide, and cytarabine (miniMEC) for relapsed and refractory acute leukemia. Leuk Lymphoma. 2016 ; 57 : 2541-7.
PubMed
13) Cortes JE, Khaled S, Martinelli G, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R) : a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019 ; 20 : 984-97.
 
14) Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med. 2019 ; 381 : 1728-40.
 
15) Thol F, Heuser M. Treatment for relapsed/refractory acute myeloid leukemia. Hemasphere. 2021 ; 5 : e572.
PubMed
16) Aldoss I, Yang D, Aribi A, et al. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Haematologica. 2018 ; 103 : e404-7.
PubMed
17) Morsia E, McCullough K, Joshi M, et al. Venetoclax and hypomethylating agents in acute myeloid leukemia : Mayo Clinic series on 86 patients. Am J Hematol. 2020 ; 95 : 1511-21.
 
18) Stahl M, Menghrajani K, Derkach A, et al. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Blood Advances. 2021 ; 5 : 1552-64.
PubMed
19) Kharfan-Dabaja MA, Labopin M, Polge E, et al. Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse. JAMA Oncol. 2018 ; 4 : 1245-53.
PubMed
20) Walter RB, Buckley SA, Pagel JM, et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood. 2013 ; 122 : 1813-21.
PubMed
P.115 掲載の参考文献
1) Burnett AK, Hills RK, Russell N. Twenty five years of UK trials in acute myeloid leukaemia : what have we learned? Br J Haematol. 2020 ; 188 : 86-100.
PubMed
2) Sasaki K, Ravandi F, Kadia TM, et al. De novo acute myeloid leukemia : A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. Cancer. 2021 ; 127 : 2049-61.
PubMed
3) Sekeres MA, Elson P, Kalaycio ME, et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood. 2009 ; 113 : 28-36.
 
4) Bertoli S, Berard E, Huguet F, et al. Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. Blood. 2013 ; 121 : 2618-26.
 
5) Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia : real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009 ; 113 : 4179-87.
PubMed
6) DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020 ; 383 : 617-29.
PubMed
7) Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy : a phase 3 randomized placebo-controlled trial. Blood. 2020 ; 135 : 2137-45.
PubMed
8) Itzykson R, Fournier E, Berthon C, et al. Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. Blood. 2021 ; 138 : 507-19.
PubMed
9) Pollyea DA, Winters A, McMahon C, et al. Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60. Bone Marrow Transplant. 2022 ; 57 : 160-6.
PubMed
10) Min GJ, Cho BS, Park SS, et al. Geriatric assessment predicts non-fatal toxicities and survival for intensively treated older adults with AML. Blood. 2022 ; 139 : 1646-58.
 
11) DiNardo CD, Tiong IS, Quaglieri A, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020 ; 135 : 791-803.
PubMed
P.120 掲載の参考文献
1) Conneely SE, Stevens AM. Acute myeloid leukemia in children : emerging paradigms in genetics Oncology Reports. 2021 ; 23 : 16.
 
2) 急性骨髄性白血病. In : 日本小児血液・がん学会, 編. 小児白血病・リンパ腫診療ガイドライン 2016年版, 第3版. 東京 : 金原出版 ; 2016. p.37-54.
 
3) Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults : 2017 ELN recommendations from an international expert panel. Blood. 2017 ; 129 : 424-47.
 
4) Gamis AS, Alonzo TA, Meshinchi S, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk : results from the randomized phase III Children's Oncology Group Trial AAML0531. J Clin Oncol. 2014 ; 32 : 3021-32.
 
5) Taga T, Tanaka S, Hasegawa D, et al. Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome. Leukemia. 2021 ; 35 : 2508-16.
PubMed
6) Takahashi H, Watanabe T, Kinoshita A, et al. High event-free survival rate with minimum-dose-anthracycline treatment in childhood acute promyelocytic leukaemia : a nationwide prospective study by the Japanese Paediatric Leukaemia/Lymphoma Study Group. Br J Haematol. 2016 ; 174 : 437-43.
 
7) Yamamoto S, Tomizawa D, Kudo K, et al. Hematopoietic stem cell transplantation for pediatric acute promyelocytic leukemia in Japan. Pediatr Blood Cancer. 2020 ; 67 : e28181.
PubMed
8) Inaba H, Coustan-Smith E, Cao X, et al. Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. J Clin Oncol. 2012 ; 30 : 3625-32.
PubMed
9) Tierens A, Bjorklund E, Siitonen S, et al. Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia ; results of the NOPHO-AML 2004 study. Br J Haematol. 2016 ; 174 : 600-9.
PubMed
10) Keino D, Kinoshita A, Tomizawa D, et al. Residual disease detected by multidimensional flow cytometry shows prognostic significance in childhood acute myeloid leukemia with intermediate cytogenetics and negative FLT3-ITD : a report from the Tokyo Children's Cancer Study Group. Int J Hematol. 2016 ; 103 : 416-22.
 
11) Segerink WH, de Haas V, Kaspers GJL. Measurable residual disease in pediatric acute myeloid leukemia : a systematic review. Expert Rev Anticancer Ther. 2021 ; 21 : 451-9.
PubMed
12) Pollard JA, Guest E, Alonzo TA, et al. Gemtuzumab ozogamicin improves event-free survival and reduces relapse in pediatric KMT2A-rearranged AML : Results from the phase III children's oncology group trial AAML0531. J Clin Oncol. 2021 ; 39 : 3149-60.
 
13) McCall D, Roth M, Mahadeo KM, et al. Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia. Blood Advances. 2021 ; 5 : 5215-9.
PubMed
14) Karol SE, Alexander TB, Budhraja A, et al. Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia : a phase 1, dose-escalation study. Lancet Oncol. 2020 ; 21 : 551-60.
 
P.126 掲載の参考文献
1) Goyama S, Mulloy JC. Molecular pathogenesis of core binding factor leukemia : current knowledge and future prospects. Int J Hematol. 2011 ; 94 : 126-33.
PubMed
2) Opatz S, Bamopoulos SA, Metzeler KH, et al. The clinical mutatome of core binding factor leukemia. Leukemia. 2020 ; 34 : 1553-62.
PubMed
3) Miyawaki S, Ohtake S, Fujisawa S, et al. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults : the JALSG AML201 Study. Blood. 2011 ; 117 : 2366-72.
PubMed
4) Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia : a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014 ; 15 : 986-96.
PubMed
5) Marcucci G, Geyer S, Laumann K, et al. Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia : CALGB 10801. Blood Adv. 2020 ; 4 : 696-705.
PubMed
6) Arslan S, Zhang J, Dhakal P, et al. Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia. Am J Hematol. 2021 ; 96 : E59-63.
PubMed
7) Ragon BK, Daver N, Garcia-Manero G, et al. Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. Am J Hematol. 2017 ; 92 : 845-50.
PubMed
8) Jongen-Lavrencic M, Grob T, Hanekamp D, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018 ; 378 : 1189-99.
PubMed
P.132 掲載の参考文献
1) DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020 ; 383 : 617-29.
PubMed
2) Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy : phase 3 randomized placebo-controlled trial. Blood. 2020 ; 135 : 2137-45.
 
3) Burchert A, Bug G, Fritz LV, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN). J Clin Oncol. 2020 ; 38 : 2993-3002.
PubMed
4) Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia : a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014 ; 15 : 986-96.
PubMed
5) Perl AE, Larson RA, Podoltsev NA, et al. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood. 2022 ; 139 : 3366-75.
 
6) Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019 ; 381 : 1728-40.
 
7) Cortes JE, Khaled S, Martinelli G, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R) : a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019 ; 20 : 984-97.
 
8) Aldoss I, Yang D, Aribi A, et al. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Haematologica. 2018 ; 103 : e404-7.
PubMed
9) Kobayashi Y, Tobinai K, Takeshita A, et al. Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia : final results of Japanese multicenter cooperative study. Int J Hematol. 2009 ; 89 : 460-9.
PubMed
10) Pei S, Pollyea DA, Gustafson A, et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 2020 ; 10 : 536-51.
PubMed
11) Hosono N, Yokoyama H, Aotsuka N, et al. Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia. Int J Clin Oncol. 2021 ; 26 : 2131-41.
PubMed
P.137 掲載の参考文献
1) Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission : systematic review and meta-analysis of prospective clinical trials. JAMA. 2009 ; 301 : 2349-61.
PubMed
2) Salvatore D, Labopin M, Ruggeri A, et al. Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics : a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2018 ; 103 : 1317-28.
PubMed
3) Konuma T, Kanda J, Yamasaki S, et al. Single cord blood transplantation versus unmanipulated haploidentical transplantation for adults with acute myeloid leukemia in complete remission. Transplant Cell Ther. 2021 ; 27 : 334.e1-334.e11.
 
4) Cho BS, Min GJ, Park S, et al. Haploidentical vs matched unrelated donor transplantation for acute myeloid leukemia in remission : A prospective comparative study. Am J Hematol. 2021 ; 96 : 98-109.
PubMed
5) Jimenez Jimenez AM, De Lima M, et al. An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. Bone Marrow Transplant. 2021 ; 56 : 3068-77.
PubMed
6) Aoki J, Kanamori H, Tanaka M, et al. Impact of age on outcomes of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in elderly patients with acute myeloid leukemia. Am J Hematol. 2016 ; 91 : 302-7.
PubMed
7) Fuchs EJ, O'Donnell PV, Eapen M, et al. Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation : the BMT CTN 1101 trial. Blood. 2021 ; 137 : 420-8.
PubMed
8) Battipaglia G, Galimard JE, Labopin M, et al. Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia : a study from the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant. 2022 ; 57 : 562-71.
PubMed
P.139 掲載の参考文献
1) Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 ; 127 : 2391-405.
 
2) Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016 ; 374 : 2209-21.
PubMed
3) Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults : 2017 ELN recommendations from an international expert panel. Blood. 2017 ; 129 : 424-47.
 
4) Miles LA, Bowman RL, Merlinsky TR, et al. Single-cell mutation analysis of clonal evolution in myeloid malignancies. Nature. 2020 ; 587 : 477-82.
PubMed
5) Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014 ; 371 : 2488-98.
PubMed
6) Shlush LI, Zandi S, Mitchell A, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014 ; 506 : 328-33.
PubMed
7) Burd A, Levine RL, Ruppert AS, et al. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling : feasibility and preliminary efficacy of the Beat AML Master Trial. Nat Med. 2020 ; 26 : 1852-8.
PubMed
8) Duncavage EJ, Schroeder MC, O'Laughlin M, et al. Genome sequencing as an alternative to cytogenetic analysis in myeloid cancers. N Engl J Med. 2021 ; 384 : 924-35.
PubMed
9) Yasuda T, Sanada M, Nishijima D, et al. Clinical utility of target capture-based panel sequencing in hematological malignancies : A multicenter feasibility study. Cancer Sci. 2020 ; 111 : 3367-78.
PubMed
P.143 掲載の参考文献
1) Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994 ; 367 : 645-8.
PubMed
2) Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997 ; 3 : 730-7.
PubMed
3) Goyama S, Wunderlich M, Mulloy JC. Xenograft models for normal and malignant stem cells. Blood. 2015 ; 125 : 2630-40.
PubMed
4) Thomas D, Majeti R. Biology and relevance of human acute myeloid leukemia stem cells. Blood. 2017 ; 129 : 1577-85.
PubMed
5) Pollyea DA, Jordan CT. Therapeutic targeting of acute myeloid leukemia stem cells. Blood. 2017 ; 129 : 1627-35.
PubMed
6) Villatoro A, Konieczny J, Cuminetti V, et al. Leukemia stem cell release from the stem cell niche to treat acute myeloid leukemia. Front Cell Dev Biol. 2020 ; 8 : 607.
PubMed
7) Long NA, Golla U, Sharma A, et al. Acute myeloid leukemia stem cells : origin, characteristics, and clinical implications. Stem Cell Rev Rep. 2022.
PubMed
8) Naoe T, Kiyoi H. Gene mutations of acute myeloid leukemia in the genome era. Int J Hematol. 2013 ; 97 : 165-74.
PubMed
9) Raffel S, Falcone M, Kneisel N, et al. BCAT1 restricts α-KG levels in AML stem cells leading to IDHmut-like DNA hypermethylation. Nature. 2017 ; 551 : 384-8.
 
10) Pollyea DA, Stevens BM, Jones CL, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med. 2018 ; 24 : 1859-66.
PubMed
11) Ye H, Adane B, Khan N, et al. Leukemic stem cells evade chemotherapy by metabolic adaptation to an adipose tissue niche. Cell Stem Cell. 2016 ; 19 : 23-37.
 
12) Jones CL, Stevens BM, D'Alessandro A, et al. Inhibition of amino acid metabolism selectively targets human leukemia stem cells. Cancer Cell. 2018 ; 34 : 724-40.e724.
 
13) Jones CL, Stevens BM, Pollyea DA, et al. Nicotinamide metabolism mediates resistance to venetoclax in relapsed acute myeloid leukemia stem cells. Cell Stem Cell. 2020 ; 27 : 748-64.e744.
 
14) Subedi A, Liu Q, Ayyathan DM, et al. Nicotinamide phosphoribosyltransferase inhibitors selectively induce apoptosis of AML stem cells by disrupting lipid homeostasis. Cell Stem Cell. 2021 ; 28 : 1851-67.e1858.
 
15) Pei S, Minhajuddin M, Adane B, et al. AMPK/FIS1-mediated mitophagy is required for self-renewal of human AML stem cells. Cell Stem Cell. 2018 ; 23 : 86-100.e106.
 
16) Singh RP, Jeyaraju DV, Voisin V, et al. Disrupting mitochondrial copper distribution inhibits leukemic stem cell self-renewal. Cell Stem Cell. 2020 ; 26 : 926-37.e910.
 
17) Eagle K, Jiang Y, Shi X, et al. An oncogenic enhancer encodes selective selenium dependency in AML. Cell Stem Cell. 2022 ; 29 : 386-99.e7.
 
18) Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting : integrating immunity's roles in cancer suppression and promotion. Science. 2011 ; 331 : 1565-70.
PubMed
19) Vago L, Gojo I. Immune escape and immunotherapy of acute myeloid leukemia. J Clin Invest. 2020 ; 130 : 1552-64.
PubMed
20) Paczulla AM, Rothfelder K, Raffel S, et al. Publisher Correction : Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. Nature. 2019 ; 572 : E19.
PubMed
21) Hayashi Y, Goyama S, Liu X, et al. Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia. Nat Commun. 2019 ; 10 : 4869.
PubMed
22) Flieswasser T, Van den Eynde A, Van Audenaerde J, et al. The CD70-CD27 axis in oncology : the new kids on the block. J Exp Clin Cancer Res. 2022 ; 41 : 12.
 
23) Riether C, Schurch CM, Buhrer ED, et al. CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia. J Exp Med. 2017 ; 214 : 359-80.
PubMed
24) Riether C, Pabst T, Hopner S, et al. Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nat Med. 2020 ; 26 : 1459-67.
PubMed
25) Kikushige Y, Miyamoto T, Yuda J, et al. A TIM-3/Gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression. Cell Stem Cell. 2015 ; 17 : 341-52.
PubMed
26) Harcourt EM, Kietrys AM, Kool ET. Chemical and structural effects of base modifications in messenger RNA. Nature. 2017 ; 541 : 339-46.
PubMed
27) Jiang Q, Crews LA, Holm F, et al. RNA editing-dependent epitranscriptome diversity in cancer stem cells. Nat Rev Cancer. 2017 ; 17 : 381-92.
PubMed
28) Roundtree IA, Evans ME, Pan T, et al. Dynamic RNA modifications in gene expression regulation. Cell. 2017 ; 169 : 1187-200.
PubMed
29) Li Z, Weng H, Su R, et al. FTO plays an oncogenic role in acute myeloid leukemia as a N6-methyladenosine RNA demethylase. Cancer Cell. 2017 ; 31 : 127-41.
PubMed
30) Shen C, Sheng Y, Zhu AC, et al. RNA Demethylase ALKBH5 selectively promotes tumorigenesis and cancer stem cell self-renewal in acute myeloid leukemia. Cell Stem Cell. 2020 ; 27 : 64-80.e69.
 
31) Wang J, Li Y, Wang P, et al. Leukemogenic chromatin alterations promote AML leukemia stem cells via a KDM4C-ALKBH5-AXL signaling axis. Cell Stem Cell. 2020 ; 27 : 81-97.e88.
 
32) Su R, Dong L, Li Y, et al. Targeting FTO suppresses cancer stem cell maintenance and immune evasion. Cancer Cell. 2020 ; 38 : 79-96.e11.
 
33) Huang Y, Su R, Sheng Y, et al. Small-molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia. Cancer Cell. 2019 ; 35 : 677-91.e610.
 
34) Paris J, Morgan M, Campos J, et al. Targeting the RNA m6A Reader YTHDF2 selectively compromises cancer stem cells in acute myeloid leukemia. Cell Stem Cell. 2019 ; 25 : 137-48.e136.
 
35) Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005 ; 434 : 843-50.
PubMed
36) Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017 ; 23 : 1124-34.
PubMed
37) Salik B, Yi H, Hassan N, et al. Targeting RSPO3-LGR4 signaling for leukemia stem cell eradication in acute myeloid leukemia. Cancer Cell. 2020 ; 38 : 263-78.e266.
 
38) Sheng Y, Yu C, Liu Y, et al. FOXM1 regulates leukemia stem cell quiescence and survival in MLL-rearranged AML. Nat Commun. 2020 ; 11 : 928.
 
39) Jamieson C, Martinelli G, Papayannidis C, et al. Hedgehog pathway inhibitors : a new therapeutic class for the treatment of acute myeloid leukemia. Blood Cancer Discov. 2020 ; 1 : 134-45.
PubMed
P.148 掲載の参考文献
1) Sanz MA, Lo Coco F, Martin G, et al. Definition of relapse risk and role of nonanthracycline drags for consolidation in patients with acute promyelocytic leukemia : A joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000 ; 96 : 1247-53.
 
2) Sanz MA, Fenaux P, Tallman MS, et al. Management of acute promyelocytic leukemia : updated recommendations from an expert panel of the European LeukemiaNet. Blood [Internet]. 2019 ; 133 : blood-2019-01-894980. Available from : http://www.bloodjournal.org/lookup/doi/10.1182/blood-2019-01-894980
 
3) Yokoyama H, Takahashi N, Katsuoka Y, et al. Evaluation of the safety and efficacy of recombinant soluble thrombomodulin for patients with disseminated intravascular coagulation associated with acute leukemia : multicenter prospective study by the Tohoku Hematology Forum. Int J Hematol. 2017 ; 105 : 606-13.
PubMed
4) Stahl M, Tallman MS. Differentiation syndrome in acute promyelocytic leukaemia. Br J Haematol. 2019 ; 187 : 157-62.
PubMed
5) Platzbecker U, Avvisati G, Cicconi L, et al. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia : Final results of the randomized Italian-German APL0406 trial. J Clin Oncol. 2017 ; 35 : 605-12.
 
6) Burnett AK, Russell NH, Hills RK, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17) : results of a randomised, controlled, phase 3 trial. Lancet Oncol [Internet]. 2015 ; 16 : 1295-305. Available from : http://dx.doi.org/10.1016/S1470-2045(15)00193-X
 
7) Iland HJ, Collins M, Bradstock K, et al. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study : A non-randomised phase 2 trial. Lancet Haematol. 2015 ; 2 : e357-66.
PubMed
8) Takeshita A, Asou N, Atsuta Y, et al. Tamibarotene maintenance improved relapse-free survival of acute promyelocytic leukemia : a final result of prospective, randomized, JALSG-APL204 study. Leukemia [Internet]. 2019 ; 33 : 358-70. Available from : http://dx.doi.org/10.1038/s41375-018-0233-7
 
9) Ades L, Guerci A, Raffoux E, et al. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy : The European APL Group experience. Blood. 2010 ; 115 : 1690-6.
PubMed
10) Osterroos A, Maia T, Eriksson A, et al. A real-world based score to predict early death in acute promyelocytic leukemia. Haematologica. 2022.
PubMed
P.153 掲載の参考文献
1) Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocyticleukemia. Blood. 1988 ; 72 : 567-72.
 
2) Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL) : II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997 ; 89 : 3354-60.
PubMed
3) Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood. 1997 ; 90 : 1014-21.
PubMed
4) Asou N, Kishimoto Y, Kiyoi H, et al. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy : the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood. 2007 ; 110 : 59-66.
 
5) Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013 ; 369 : 111-21.
PubMed
6) Platzbecker U, Avvisati G, Cicconi L, et al. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia : final results of the randomized Italian-German APL0406 trial. J Clin Oncol. 2017 ; 35 : 605-12.
 
7) Yanada M, Tsuzuki M, Fujita H, et al. Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. Blood. 2013 ; 121 : 3095-102.
PubMed
8) Lengfelder E, Lo-Coco F, Ades L, et al. Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia : registry results from the European LeukemiaNet. Leukemia. 2015 ; 29 : 1084-91.
PubMed
9) Russell N, Burnett A, Hills R, et al. Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL : long-term follow-up of the AML17 trial. Blood. 2018 ; 132 : 1452-4.
PubMed
10) Fouzia NA, Sharma V, Ganesan S, et al. Management of relapse in acute promyelocytic leukaemia treated with up-front arsenic trioxide-based regimens. Br J Haematol. 2021 ; 192 : 292-9.
PubMed
11) Lo-Coco F, Cimino G, Breccia M, et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood. 2004 ; 104 : 1995-9.
PubMed
12) Sanford D, Lo-Coco F, Sanz MA, et al. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. Br J Haematol. 2015 ; 171 : 471-7.
PubMed
13) de Botton S, Sanz MA, Chevret S, et al. Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia. 2006 ; 20 : 35-41.
PubMed
14) Tomita A, Kiyoi H, Naoe T. Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia. Int J Hematol. 2013 ; 97 : 717-25.
PubMed
15) Iaccarino L, Ottone T, Alfonso V, et al. Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse. Am J Hematol. 2019 ; 94 : 1091-7.
PubMed
P.159 掲載の参考文献
1) Foa R, Vitale A, Vignetti M, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011 ; 118 : 6521-28.
PubMed
2) Sugiura I, Doki N, Hata T, et al. Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Adv. 2022 ; 6 : 624-36.
PubMed
3) Nishiwaki S, Akahoshi Y, Mizuta S, et al. Measurable residual disease affects allogeneic hematopoietic stem cell transplantation in Ph+ALL during both CR1 and CR2. Blood Adv. 2021 ; 5 : 584-92.
PubMed
4) Sasaki K, Kantarjian HM, Short NJ. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer. 2021 ; 127 : 2648-56.
PubMed
5) Foa R, Bassan R, Vitale A, et al. Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med. 2020 ; 383 ; 1613-23.
PubMed
6) Pfeifer H, Raum K, Markovic S, et al. Genomic CDKN2A/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantation. Blood. 2018 ; 131 : 1464-75.
PubMed
7) Arber DA, Orazi A, Hasserjian R.et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 ; 127 : 2391-405.
 
8) Roberts KG, Morin RD, Zhang J, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell. 2012 ; 22 : 153-66.
PubMed
P.163 掲載の参考文献
1) Dombret H, Cluzeau T, Huguet F, et al. Pediatric-like therapy for adults with ALL. Curr Hematol Malig Rep. 2014 ; 9 : 158-64.
PubMed
2) Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia : analysis of the LALA-94 trial. J Clin Oncol. 2004 ; 22 : 4075-86.
 
3) Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients : final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008 ; 111 : 1827-33.
 
4) Dhedin N, Huynh A, Maury S, et al. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. Blood. 2015 ; 125 : 2486-96.
 
5) Wieduwilt MJ, Stock W, Advani A, et al. Correction : Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission : analysis from CALGB 10403 and the CIBMTR. Leukemia. 2021 ; 35 : 2140.
 
6) Hayakawa F, Sakura T, Yujiri T, et al. Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol : a phase II study by the Japan Adult Leukemia Study Group. Blood Cancer J. 2014 ; 4 : e252.
 
7) Kako S, Hayakawa F, Imai K, et al. Optimal treatment for Philadelphia-negative acute lymphoblastic leukemia in first remission in the era of high-intensity chemotherapy. Int J Hematol. 2021 ; 114 : 608-19.
PubMed
P.168 掲載の参考文献
1) Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004 ; 101 : 2788-801.
 
2) Oriol A, Vives S, Hernandez-Rivas JM, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica. 2010 ; 95 : 589-96.
 
3) Thomas DA, Kantarjian H, Smith TL, et al. Primary refractory and relapsed adult acute lymphoblastic leukemia : characteristics, treatment results, and prognosis with salvage therapy. Cancer. 1999 ; 86 : 1216-30.
PubMed
4) Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL) ; an MRC UKALL12/ECOG 2993 study. Blood. 2007 ; 109 : 944-50.
PubMed
5) Duval M, Klein JP, He W, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010 ; 28 : 3730-8.
PubMed
6) Cassaday RD, Potts Jr DA, Stevenson PA, et al. Evaluation of allogeneic transplantation in first or later minimal residual disease-negative remission following adult-inspired therapy for acute lymphoblastic leukemia. Leuk Lymphoma. 2016 ; 57 : 2109-18.
PubMed
7) Theresa Hahn, Donna Wall, Bruce Camitta, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults : an evidence-based review. Biol Blood Marrow Transplant. 2006 ; 12 : 1-30.
PubMed
8) 日本造血細胞移植学会. 造血細胞移植ガイドライン-急性リンパ性白血病 (成人) 第3版. p.3. https://www.jshct.com/uploads/files/guideline/03_01_all03.pdf
 
9) 日本造血細胞移植学会. 平成30年度全国調査報告書.
 
10) DiJoseph JF, Armellino DC, Boghaert ER, et al. Antibody-targeted chemotherapy with CMC-544 : a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood. 2004 ; 103 : 1807-14.
PubMed
11) Piccaluga PP, Arpinati M, Candoni A, et al. Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia. Leuk Lymphoma. 2011 ; 52 : 325-7.
PubMed
12) Hoffmann P, Hofmeister R, Brischwein K, et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer. 2005 ; 115 : 98-104.
PubMed
13) Raponi S, De Propris MS, Intoppa S, et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia : analysis of 552 cases. Leuk Lymphoma. 2011 ; 52 : 1098-107.
PubMed
14) Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016 ; 375 : 740-53.
PubMed
15) Kantarjian HM, DeAngelo DJ, Advani AS, et al. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia : results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 2017 ; 4 : e387-98.
 
16) Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia : Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019 ; 125 : 2474-87.
 
17) Kantarjian H, Stein A, Gokbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017 ; 376 : 836-47.
PubMed
18) Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018 ; 378 : 439-48.
 
19) Kochenderfer JN, Dudley ME, Carpenter RO, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013 ; 122 : 4129-39.
PubMed
20) Brudno JN, Somerville RP, Shi V, et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol. 2016 ; 34 : 1112-21.
PubMed
21) 日本造血細胞移植学会ホームページ. https://www.jshct.com/modules/news/index.php?content_id=172
 
P.173 掲載の参考文献
1) Toft N, Birgens H, Abrahamsson J, et al. Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. Leukemia. 2018 ; 32 : 606-15.
PubMed
2) Burke MJ, Devidas M, Chen Z, et al. Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia : report from Children's Oncology Group Study AALL0232. Leukemia. 2022 ; 36 : 648-55.
 
3) Greenwood M, Trahair T, Sutton R, et al. An MRD-stratified pediatric protocol is as deliverable in adolescents and young adults as in children with ALL. Blood Adv. 2021 ; 5 : 5574-83.
 
4) Wieduwilt MJ, Stock W, Advani A, et al. Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission : analysis from CALGB 10403 and the CIBMTR. Leukemia. 2021 ; 35 : 2076-85.
 
5) Bhatia S, Landier W, Shangguan M, et al. Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia : a report from the children's oncology group. J Clin Oncol. 2012 ; 30 : 2094-101.
 
P.177 掲載の参考文献
1) National Cancer Institute Surveillance, Epidemiology, and End Results Program. https://seer.cancer.gov/statfacts/html/alyl.html
 
2) Moorman AV, Chilton L, Wilkinson J, et al. A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood. 2010 ; 115 : 206-14. Erratum in Blood. 2010 ; 116 : 1017.
 
3) Vignetti M, Fazi P, Cimino G, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy : results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood. 2007 ; 109 : 3676-8.
PubMed
4) Rousselot P, Coude MM, Gokbuget N, et al. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood. 2016 ; 128 : 774-82.
PubMed
5) Ottmann O, Pfeifer H, Cayuela JM, et al. Nilotinib (TasignaR) and low intensity chemotherapy for first-line treatment of elderly patients with BCR-ABL1-positive acute lymphoblastic leukemia : final results of a prospective multicenter trial (EWALL-PH02). Blood. 2018 ; 132 (suppl. 1).
 
6) Martinelli G, Papayannidis C, Piciocchi A, et al. INCB84344-201 : Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia. Blood Adv. 2022 ; 6 : 1742-53.
 
7) Sancho JM, Ribera JM, Xicoy B, et al. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. Eur J Haematol. 2007 ; 78 : 102-10.
PubMed
8) O'Brien S, Thomas DA, Ravandi F, et al. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer. 2008 ; 113 : 2097-101.
PubMed
9) Hunault-Berger M, Leguay T, Thomas X, et al. A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia : the GRAALL-SA1 study. Haematologica. 2011 ; 96 : 245-52.
PubMed
10) Sive JI, Buck G, Fielding A, et al. Outcomes in older adults with acute lymphoblastic leukaemia (ALL) : results from the international MRC UKALL XII/ECOG2993 trial. Br J Haematol. 2012 ; 157 : 463-71.
PubMed
11) Martell MP, Atenafu EG, Minden MD, et al. Treatment of elderly patients with acute lympho-blastic leukaemia using a paediatric-based protocol. Br J Haematol. 2013 ; 163 : 458-64.
 
12) Ribera JM, Garcia O, Oriol A, et al. Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia : Results of three prospective parallel trials from the PETHEMA group. Leuk Res. 2016 ; 41 : 12-20.
PubMed
13) Advani AS, Moseley A, O'Dwyer KM, et al. SWOG 1318 : A phase II trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia. J Clin Oncol. 2022 ; 40 : 1574-82.
PubMed
14) Jabbour EJ, Sasaki K, Ravandi F, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia : A propensity score analysis. Cancer. 2019 ; 125 : 2579-86.
PubMed
15) Rosko A, Wang HL, de Lima M, et al. Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia. Am J Hematol. 2017 ; 92 : 42-9.
PubMed
16) Mohty M, Labopin M, Volin L, et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia : a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2010 ; 116 : 4439-43.
 
P.187 掲載の参考文献
1) Bower H, Bjorkholm M, Dickman PW, et al. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016 ; 34 : 2851-7.
PubMed
2) Mughal TI, Radich JP, Deininger MW, et al. Chronic myeloid leukemia : reminiscences and dreams. Haematologica. 2016 ; 101 : 541-58.
PubMed
3) Kizaki M, Takahashi N, Iriyama N, et al. Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period : results from the Japanese registry obtained by the New TARGET system. Int J Hematol. 2019 ; 109 : 426-39.
 
4) Available online : http://www.jshem.or.jp/gui-hemali/table.html
 
5) Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia : 2013. Blood. 2013 ; 122 : 872-84.
PubMed
6) Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 ; 34 : 966-84.
PubMed
7) Hanfstein B, Muller MC, Hehlmann R, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012 ; 26 : 2096-102.
PubMed
8) Hughes TP, Saglio G, Kantarjian HM, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014 ; 123 : 1353-60.
PubMed
9) Hehlmann R, Lauseker M, Sausele S, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia : 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017 ; 31 : 2398-406.
 
10) Hochhaus A, Larson RA, Guilhot F, et al ; IRIS Investigators. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017 ; 376 : 917-27.
PubMed
11) Deininger MW, Shah NP, Altman JK, et al. Chronic myeloid leukemia, version 1.2022, NCCN clinical practice guidelines in oncology [. (accessed on 30 August 2021)]. Available online : https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1427.
 
12) Hehlmann R, Muller MC, Lauseker M, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib : results from the randomized CML-study IV. J Clin Oncol. 2014 ; 32 : 415-23.
 
13) Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010 ; 362 : 2260-70.
PubMed
14) Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia : 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014 ; 123 : 494-500.
 
15) Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION : The dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016 ; 34 : 2333-40.
 
16) Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010 ; 362 : 2251-9.
PubMed
17) Hughes TP, Saglio G, Kantarjian HM, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014 ; 123 : 1353-60.
PubMed
18) Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase : 5-year update of the randomized ENESTnd trial. Leukemia. 2016 ; 30 : 1044-54.
PubMed
19) Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia : results from the randomized BFORE trial. J Clin Oncol. 2018 ; 36 : 231-7.
 
20) Ohnishi K, Nakaseko C, Takeuchi J, et al. Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels : the JALSG CML202 study. Cancer Sci. 2012 ; 103 : 1071-8.
PubMed
21) Cortes J. How to manage CML patients with comorbidities. Hematology Am Soc Hematol Educ Program. 2020 ; 2020 : 237-42.
PubMed
22) Kantarjian HM, Hughes TP, Larson RA, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase : ENESTnd 10-year analysis. Leukemia. 2021 ; 35 : 440-53.
PubMed
P.193 掲載の参考文献
1) How J, Venkataraman V, Hobbs GS. Hematology Am Soc Hematol Educ Program. 2021 ; 2021 : 122-8.
PubMed
2) CQ5 進行期CML (AP およびBP) の治療はTKIが勧められるか. 4 慢性骨髄性白血病/骨髄増殖性腫瘍 (chronic myeloid leukemia/myeloproliferative neoplasms : CML/MPN). 日本血液学会. 造血器腫瘍診療ガイドライン 2018年版改訂版. 東京 : 金原出版 ; 2020. p.111-2.
 
3) Fruehauf S, Topaly J, Buss EC, et al. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer. 2007 ; 109 : 1543-9.
PubMed
4) Yanada M, Takeuchi J, Sugiura I, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia : a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol. 2006 ; 24 : 460-6.
 
5) Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 ; 34 : 966-84.
PubMed
6) Ottmann O, Saglio G, Apperley JF, et al. Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib. Blood Cancer J. 2018 ; 8 : 88.
PubMed
7) Cortes JE, Kim DW, Pinilla-Lbarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia : final 5-year results of the phase 2 PACE trial. Blood. 2018 ; 132 : 393-404.
 
8) Ohanian M, Kantarjian HM, Quintas-Cardama A, et al. Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin Lymphoma Myeloma Leuk. 2014 ; 14 : 155-62.
PubMed
9) Jain P, Kantarjian H, Chorab A, et al. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era : Cohort study of 477 patients. Cancer. 2017 ; 123 : 4391-402.
 
10) Khoury HJ, Kukreja M, Goldman JM, et al. Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era : a CIBMTR analysis. Bone Marrow Transplant. 2012 ; 47 : 810-6.
 
11) Chhabra S, Ahn KW, Hu ZH, et al. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. Blood Adv. 2018 ; 2 : 2922-36.
PubMed
12) DeFilipp Z, Ancheta R, Liu Y et al. Maintenance tyrosine kinase inhibitors following allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia : a center for international blood and marrow transplant research study. Biol Blood Marrow Transplant. 2020 ; 26 : 472-9.
PubMed
P.197 掲載の参考文献
1) Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015 ; 33 : 4210-8.
PubMed
2) Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016 ; 30 : 1648-71.
PubMed
3) Dorer DJ, Knickerbocker RK, Baccarani M, et al. Impact of dose intensity of ponatinib on selected adverse events : Multivariate analyses from a pooled population of clinical trial patients. Leuk Res. 2016 ; 48 : 84-91.
PubMed
4) Fujioka I, Takaku T, Iriyama N, et al. Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors : a retrospective study of the CML Cooperative Study Group database. Ann Hematol. 2018 ; 97 : 2081-8.
 
5) Hughes TP, Mauro MJ, Cortes JE, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019 ; 381 : 2315-26.
PubMed
6) Cortes J, Apperley J, Lomaia E, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia : a randomized, open-label phase 2 clinical trial. Blood. 2021 ; 138 : 2042-50.
PubMed
7) Dahlen T, Edgren G, Lambe M, et al. Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia : a population-based cohort study. Ann Intern Med. 2016 ; 165 : 161-6.
PubMed
8) Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia : final 5-year results of the phase 2 PACE trial. Blood. 2018 ; 132 : 393-404.
PubMed
P.203 掲載の参考文献
1) Sasaki K, Strom S, O'Brien S, et al. Relative survival in patients with chronic-phase chronic myeloid leukemia in the tyrosine-kinase inhibitor era : analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015 ; 2 : e186-93.
 
2) Etienne G, Guilhot J, Rea D, et al. Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017 ; 35 : 298-305.
PubMed
3) Imagawa J, Tanaka H, Okada M, et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial) : a multicentre phase 2 trial. Lancet Haematol. 2015 ; 2 : e528-35.
 
4) Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014 ; 32 : 424-30.
 
5) http://www.jshem.or.jp/gui-hemali/1_4.html
 
6) Deininger MW, et al. Chronic myeloid leukemia Version 3.2020. NCCN clinical practice guideline in oncology. 2020 [cited ; Available from : https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf]
 
7) Radich JP, Hochhaus A, Masszi T, et al. Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia : 5-year update of the ENESTfreedom trial. Leukemia. 2021 ; 35 : 1344-55
 
8) Kimura S, Imagawa J, Murai K, et al. Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial) : a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2020 ; 7 : e218-25.
 
9) Schoenbeck KL, Atallah E, Lin L, et al. Patient-reported functional outcomes in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors. J Natl Cancer Inst. 2022 ; 114 : 160-4.
PubMed
P.207 掲載の参考文献
1) Mughalo TI, Radich JP, Deininger MW, et al. Chronic myeloid leukemia : reminiscences and dreams. Haematologica. 2016 ; 101 : 541-58.
 
2) Hochhaus A, Larson RA, Francois G, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017 ; 376 : 917-27.
 
3) Soverini S, Mancini M, Bavaro L, et al. Chronic myeloid leukemia : the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Mol Cancer. 2018 ; 17 : 49.
PubMed
4) White DL, Radich J, Soverini S, et al. Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib. Haematologica. 2012 ; 97 : 907-14.
PubMed
5) Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005 ; 353 : 172-87.
PubMed
6) Valent P. Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia : implications for the biology, management, and therapy of the disease. Br J Haematol. 2008 ; 142 : 361-78.
PubMed
7) Kim T, Tyndel MS, Kim HJ, et al. Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy. Blood. 2017 ; 129 : 38-47.
PubMed
8) Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004 ; 305 : 399-401.
PubMed
9) Lombardo LJ, Lee FY, Chen P, et al. Discovery of N- (2-chloro-6-methyl-phenyl) -2- (6- (4- (2-hydroxyethyl) -piperazin-1-yl) -2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004 ; 47 : 6658-61.
 
10) Tokarski JS, Newitt JA, Chang CYJ, et al. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 2006 ; 66 : 5790-7.
PubMed
11) Weisberg E, Manley P, Mestan J, et al. AMN107 (nilotinib) : a novel and selective inhibitor of BCR-ABL. Br J Cancer. 2006 ; 94 : 1765-9.
PubMed
12) Rix LLR, Rix U, Colinge J, et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia. 2009 ; 23 : 477-85.
 
13) Golas JM, Arndt K, Etienne C, et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 2003 ; 63 : 375-81.
PubMed
14) Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood. 2003 ; 101 : 690-8.
PubMed
15) Hiwase DK, Saunders V, Hewett D, et al. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells : therapeutic implications. Clin Cancer Res. 2008 ; 14 : 3881-8.
PubMed
16) Davies A, Jordanides NE, Giannoudis A, et al. Nilotinib concentration in cell lines and primary CD34 (+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia. 2009 ; 23 : 1999-2006.
PubMed
17) Zhou T, Commodore L, Huang WS, et al. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534) : lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des. 2011 ; 77 : 1-11.
PubMed
18) Hughes TP, Mauro MJ, Cortes JE, et al. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med. 2019 ; 381 : 2315-26.
PubMed
19) ASH 2020, Late Breaking Abstract (LBA) -4. https://ash.confex.com/ash/2020/webprogram/Paper143816.html
 
20) Rea D, Mauro MJ, Boquimpani C, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021 ; 138 : 2031-41.
PubMed
P.213 掲載の参考文献
1) Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera : an international study. Leukemia. 2013 ; 27 : 1874-81.
 
2) Shirane S, Araki M, Morishita S, et al. JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms. Haematologica. 2015 ; 100 : e46-8.
PubMed
3) Barbui T, Vannucchi AM, Carobbio A, et al. Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis. Am J Hematol. 2015 ; 90 : 434-7.
PubMed
4) Cerquozzi S, Tefferi A. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia : a literature review of incidence and risk factors. Blood Cancer J. 2015 ; 5 : e366.
PubMed
5) Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014 ; 124 : 2507-13.
PubMed
6) Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms : critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011 ; 29 : 761-70.
PubMed
7) 日本血液学会, 編. 造血器腫瘍診療ガイドライン 2018年版 (WEB版) 慢性骨髄性白血病/骨髄増殖性腫瘍 アルゴリズム (http://www.jshem.or.jp/gui-hemali/1_4.html#algo) Accessed 2020 April 30.
 
8) Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013 ; 368 : 22-33.
PubMed
9) Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms : revised management recommendations from European LeukemiaNet. Leukemia. 2018 ; 32 : 1057-69.
PubMed
10) National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Myeloproliferative Neoplasms. Version 2. 2022 (https://www.nccn.org/professionals/physician_gls/pdf/mpn.pdf). Accessed 2022 April 30.
 
11) Landolfi R, Marchioli R, Kutti J, et al ; European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004 ; 350 : 114-24.
PubMed
12) Barbui T, Vannucchi AM, Finazzi G, et al. A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera : A propensity-matched study. Am J Hematol. 2017 ; 92 : 1131-6.
PubMed
13) Alessandro M, Vannucchi AM, Kiladjian JJ, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015 ; 372 : 426-35.
PubMed
14) Passamonti F, Griesshammer M, Palandri F, et al. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2) : a randomised, open-label, phase 3b study. Lancet Oncol. 2017 ; 18 : 88-99.
PubMed
15) Gisslinger H, Klade C, Georgiev P, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV) : a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020 ; 7 : e196-208.
 
16) Mascarenhas J, Kosiorek HE, Prchal JT, et al. A randomized, phase 3, trial of interferon-α versus hydroxyurea in polycythemia vera and essential thrombocythemia. Blood. 2022 ; 139 : 2931-41.
 
17) Barbui T, Vannucchi AM, De Stefano V, et al. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study) : a multicentre, randomised phase 2 trial. Lancet Haematol. 2021 ; 8 : e175-84.
PubMed
18) Barbui T, Vannucchi AM, Carobbio A, et al. The effect of arterial hypertension on thrombosis in low-risk polycythemia vera. Am J Hematol. 2017 ; 92 : E5-6.
PubMed
19) Mancuso S, Santoro M, Accurso V, et al. Cardiovascular risk in polycythemia vera : thrombotic risk and survival : can cytoreductive therapy be useful in patients with low-risk polycythemia vera with cardiovascular risk factors? Oncol Res Treat. 2020 ; 43 : 526-30.
PubMed
P.219 掲載の参考文献
1) Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012 ; 120 : 5128-33.
PubMed
2) Haider M, Gangat N, Lasho T, et al. Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo clinic patients. Am. J. Hematol. 2016 ; 91 : 390-4.
 
3) Edahiro Y, Yasuda H, Gotoh A, et al. Interferon therapy for pregnant patients with essential thrombocythemia in Japan. Int J Hematol. 2021 ; 113 : 106-11.
PubMed
4) Hashimoto Y, Ito T, Gotoh A, et al. Clinical characteristics, prognostic factors, and outcomes of patients with essential thrombocythemia in Japan : the JSH-MPN-R18 study. Int J Hematol. 2022 ; 115 : 208-21.
PubMed
5) Edahiro Y, Araki M, Inano T, et al. Clinical and molecular features of patients with prefibrotic primary myelofibrosis previously diagnosed as having essential thrombocythemia in Japan. EJH. 2019 ; 102 : 516-20.
 
6) Birgegard G, Besses C, Griesshammer M, et al. Treatment of essential thrombocythemia in Europe : a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study. Haematologica. 2018 ; 103 : 51-60.
PubMed
7) Passamonti F, Giorgino T, Mora B, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia. 2017 ; 31 : 2726-31.
 
8) Gagelmann N, Eikema DJ, de Wreede LC, et al. Comparison of dynamic international prognostic scoring system and myelofibrosis secondary to PV and ET prognostic model for prediction of outcome in polycythemia vera and essential thrombocythemia myelofibrosis after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2019 ; 25 : e204-8.
PubMed
9) Barbui T, De Stefano V, Alvarez-Larran A, et al. Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. Blood Cancer J. 2021 ; 11 : 21.
PubMed
10) Kamiunten A, Shide K, Kameda T, et al. Early/prefibrotic primary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia. Int J Hematol. 2018 ; 108 : 411-5.
PubMed
11) Ito T, Hashimoto Y, Tanaka Y, et al. Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naive essential thrombocythemia patients in a real-world setting. Eur J Haematol. 2019 ; 103 : 116-23.
 
12) Tefferi A, Szuber N, Vallapureddy RR, et al. Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide. Am J Hematol. 2019 ; 94 : 5-9.
PubMed
13) Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) : international prospective validation and reliability trial in 402 patients. Blood. 2011 ; 118 : 401-8.
PubMed
14) Murata M, Suzuki R, Nishida T, et al. Allogeneic hematopoietic stem cell transplantation for post-essential thrombocythemia and post-polycythemia vera myelofibrosis. Intern Med. 2020 ; 59 : 1947-56.
PubMed
15) Gisslinger H, Klade C, Georgiev P, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV) : a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020 ; 7 : e196-208.
 
16) Edahiro Y, Ohishi K, Gotoh A, et al. Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera : an open-label, single-arm, phase 2 study. Int J Hematol. 2022 Apr 16. doi : 10.1007/s12185-022-03341-9. Online ahead of print.
 
17) Barbui T, Vannucchi AM, Alvarez-Larran A, et al. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia. 2021 ; 35 : 485-93.
PubMed
P.225 掲載の参考文献
1) Takenaka K, Shimoda K, Uchida N, et al. Clinical features and outcomes of patients with primary myelofibrosis in Japan : report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan. Int J Hematol. 2017 ; 105 : 59-69.
PubMed
2) Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms : revised management recommendations from European LeukemiaNet. Leukemia. 2018 ; 32 : 1057-69.
PubMed
3) 日本血液学会, 編. 造血器腫瘍診療ガイドライン 2018年版補訂版. 東京 : 金原出版 ; 2018.
 
4) Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus : a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011 ; 29 : 392-7.
 
5) Tefferi A, Guglielmelli P, Lasho TL, et al. MIPSS70+ Version 2.0 : Mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis. J Clin Oncol. 2018 ; 36 : 1769-70.
 
6) Kroger NM, Deeg JH, Olavarria E, et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis : a consensus process by an EBMT/ELN international working group. Leukemia. 2015 ; 29 : 2126-33.
 
7) Verstovsek S, Gotlib J, Mesa RA, et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis : COMFORT-I and -II pooled analyses. J Hematol Oncol. 2017 ; 10 : 156.
PubMed
8) Guglielmelli P, Ghirardi A, Carobbio A, et al. Impact of ruxolitinib on survival of patients with myelofibrosis in the real world : update of the ERNEST Study. Blood Adv. 2022 ; 6 : 373-5.
PubMed
9) Gowin K, Ballen K, Ahn KW, et al. Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv. 2020 ; 4 : 1965-73.
PubMed
10) Murata M, Takenaka K, Uchida N, et al. Comparison of outcomes of allogeneic transplantation for primary myelofibrosis among hematopoietic stem cell source groups. Biol Blood Marrow Transplant. 2019 ; 25 : 1536-43.
PubMed
11) McLornan D, Szydlo R, Koster L, et al. Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis : A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019 ; 25 : 2167-71.
PubMed
12) Kroger N, Sbianchi G, Sirait T, et al. Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis : a study of the CMWP of EBMT. Leukemia. 2021 ; 35 : 3551-60.
PubMed
P.229 掲載の参考文献
1) Maxson JE, Gotlib J, Pollyea DA, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med. 2013 ; 368 : 1781-90.
PubMed
2) Arber DA, Orazi A, Hassrjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 ; 127 : 2391-405.
 
3) Szuber N, Finke CM, Lasho TL, et al. CSF3R-mutated chronic neutrophilic leukemia : long-term outcome in 19 consecutive patients and risk model for survival. Blood Cancer J. 2018 ; 8 : 21.
 
4) Dao KT, Gotlib J, Deininger MMN, et al. Efficacy of ruxolitinib in patients with chronic neutrophilic leukemia and atypical chronic myeloid leukemia. J Clin Oncol. 2020 ; 38 ; 1006-18.
PubMed
5) Szuber N, Elliott M, Tefferi A. Chronic neutrophilic leukemia : 2022 update on diagnosis, genomic landscape, prognosis, and management. Am J Hematol. 2022 ; 97 : 491-505.
PubMed
6) Ruan GJ, Smith CJ, Day C, et al. A population-based study of chronic neutrophilic leukemia in the United States. Blood Cancer J. 2020 ; 10 : 68.
 
P.233 掲載の参考文献
1) William R. Hardy MD, Robert E, et al. The Hypereosinophilic syndromes. Ann Intern Med. 1968 ; 68 : 1220-9.
 
2) Chusid MJ, Dale CD, West BC, et al. The hypereosinophilic syndrome : analysis of fourteen cases with review of the literature. Medicine. 1975 ; 54 : 1-27.
 
3) Schmidt B, Roberts RS, Davis P, et al. A Tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003 ; 348 : 1201-14.
 
4) Wang SA, Tam W, Tsai AG, et al. Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. Mod Pathol. 2016 ; 29 : 854-64.
 
5) Shomali W, Gotlib J. World Health Organization-defined eosinophilic disorders : 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022 ; 97 : 129-48.
PubMed
6) Khoury P, Abiodun AO, Holland-Thomas N, et al. Hypereosinophilic syndrome subtype predicts responsiveness to glucocorticoids. J Allergy Clin Immunol Pract [Internet]. 2018 ; 6 : 190-5. Available from : https://doi.org/10.1016/j.jaip.2017.06.006
 
7) Yoon TY, Ahn GB, Chang SH. Complete remission of hypereosinophilic syndrome after interferon-α therapy : Report of a case and literature review. J Dermatol. 2000 ; 27 : 110-5.
 
8) Baccarani M, Cilloni D, Rondoni M, et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRα- positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica. 2007 ; 92 : 1173-9.
 
9) Cheah CY, Burbury K, Apperley JF, et al. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood. 2014 ; 123 : 3574-7.
PubMed
10) Roufosse F, Kahn JE, Rothenberg ME, et al. Efficacy and safety of mepolizumab in hypereosinophilic syndrome : A phase III, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020 ; 146 : 1397-405.
 
11) Kuang FL, Legrand F, Makiya M, et al. Benralizumab for PDGFRA-negative hypereosinophilic syndrome. N Engl J Med. 2019 ; 380 : 1336-46.
PubMed
P.236 掲載の参考文献
1) Williams N, Lee J, Mitchell E, et al. Life histories of myeloproliferative neoplasms inferred from phylogenies. Nature. 2022 ; 602 : 162-8.
PubMed
2) Sousos N, Ni Leathlobhair M, Simoglou Karali C, et al. In utero origin of myelofibrosis presenting in adult monozygotic twins. Nature Medicine. 2022 ; 28 : 1207-11.
PubMed
3) Mitchell E, Spencer Chapman M, Williams N, et al. Clonal dynamics of haematopoiesis across the human lifespan. Nature. 2022 ; 606 : 343-50.
PubMed

IV. リンパ系腫瘍

P.241 掲載の参考文献
1) Burger JA. Treatment of Chronic Lymphocytic Leukemia. N Engl J Med. 2020 ; 383 : 460-73.
PubMed
2) Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018 ; 131 : 2745-60.
PubMed
3) Herling CD, Cymbalista F, Gros-Ophoff-Muller C, et al. Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL) : a randomized phase 3 trial. Leukemia 2020 ; 34 : 2038-50.
 
4) Dighiero G, Maloum K, Desablens B, et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med. 1998 ; 338 : 1506-14.
 
5) Langerbeins P, Zhang C, Robrecht S, et al. The CLL12 trial : ibrutinib vs placebo in treatment-naive, early-stage chronic lymphocytic leukemia. Blood. 2022 ; 139 : 177-87.
PubMed
6) Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib-Rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019 ; 381 : 432-43.
 
7) Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018 ; 379 : 2517-28.
PubMed
8) Ahn IE, Tian X, Ipe D, et al. Prediction of outcome in patients with chronic lymphocytic leukemia treated with Ibrutinib : development and validation of a four-factor prognostic model. J Clin Oncol. 2021 ; 39 : 576-85.
 
9) International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI) : a meta-analysis of individual patient data. Lancet Oncol. 2016 ; 17 : 779-90.
 
10) Ruppert AS, Booth AM, Ding W, et al. Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens : Alliance A041202. Leukemia. 2021 ; 35 : 2854-61.
PubMed
P.246 掲載の参考文献
1) Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018 ; 379 : 2517-28.
PubMed
2) Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019 ; 381 : 432-43.
 
3) Al-Sawaf O, Zhang C, Tandon M, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14) : follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020 ; 21 : 1188-200.
PubMed
4) Munir T, Brown JR, O'Brien S, et al. Final analysis from RESONATE : Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019 ; 94 : 1353-63.
PubMed
5) Ghia P, Pluta A, Wach M, et al. ASCEND : phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020 ; 38 : 2849-61.
 
6) Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018 ; 378 : 1107-20.
 
7) Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018 ; 131 : 2745-60.
PubMed
8) Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia : Results of the first randomized phase III trial. J Clin Oncol. 2021 ; 39 : 3441-52.
PubMed
9) Kater AP, Wu JQ, Kipps T, et al. Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia : 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study. J Clin Oncol. 2020 ; 38 : 4042-54.
PubMed
10) Awan FT, Schuh A, Brown JR, et al. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv. 2019 ; 3 : 1553-62.
PubMed
P.251 掲載の参考文献
1) 青木定夫. CLL の形態観察における乾燥法の違いについて. 日本検査血液学会雑誌 2014 ; 15 : 396-403.
 
2) 鈴宮淳司. 慢性リンパ性白血病とその類縁疾患のWHO分類と診断アルゴリズム. 日本臨牀. 2021 ; 79 : 1705-13.
Medical*Online
3) Stilgenbauer S, Schnaiter A, Paschka P, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia : results from the CLL8 trial. Blood. 2014 ; 123 : 3247-54.
PubMed
4) Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018 ; 379 : 2517-28.
PubMed
5) Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019 ; 381 : 432-43.
 
6) Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019 ; 380 : 2225-36.
PubMed
7) Wiestner A, Ghia P, Byrd JC, et al. Rarity of B-cell receptor pathway mutations in progression-free patients with chronic lymphocytic leukemia (CLL) during first-line versus relapsed/refractory (R/R) treatment with Ibrutinib. ASH2020 #2225 (abstract) https://ash.confex.com/ash/2020/webprogram/Paper134386.html
 
8) Yoshino T, Tanaka T, Sato Y. Differential diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma and other indolent lymphomas, including mantle cell lymphoma. J Clin Exp Hematop. 2020 ; 60 : 124-9.
PubMed
9) Thompson PA, Tam CS, O'Brien SM, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016 ; 127 : 303-9.
 
10) Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL : Updated results of the CLL8 trial. Blood. 2016 ; 127 : 208-15.
PubMed
11) Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021 ; 32 : 23-33.
PubMed
12) Ahn IE, Farooqui MZH, Tian X, et al. Depth and durability of response to ibrutinib in CLL : 5-year follow-up of a phase 2 study. Blood. 2018 ; 131 : 2357-66.
PubMed
13) Farooqui MZ, Valdez J, Martyr S, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations : a phase 2, single-arm trial. Lancet Oncol. 2015 ; 16 : 169-76.
PubMed
14) Ahn IE, Tian X, Wiestner A. brutinib for chronic lymphocytic leukemia with TP53 alterations. N Engl J Med. 2020 ; 383 : 498-500.
PubMed
15) Kater AP, Wu JQ, Kipps T, et al. Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia : 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study. J Clin Oncol. 2020 ; 38 : 4042-54.
PubMed
16) Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018 ; 378 : 1107-20.
 
17) Tausch E, Schneider C, Robrecht S, et al. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. Blood. 2020 ; 135 : 2402-12.
PubMed
18) Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019 ; 380 : 2225-36.
PubMed
19) Campo E, Cymbalista F, Ghia P, et al. TP53 aberrations in chronic lymphocytic leukemia : an overview of the clinical implications of improved diagnostics. Haematologica. 2018 ; 103 : 1956-68.
PubMed
P.256 掲載の参考文献
1) Katushima H, Fukuhara N, Ichikawa S, et al. Non-biased and complete case registration of lymphoid leukemia and lymphoma for five years : a first representative index of Japan from an epidemiologically stable Miyagi Prefecture. Leuk Lymphoma. 2017 ; 58 : 80-8.
 
2) Sarkozy C, Maurer MJ, Link BK, et al. Cause of death in follicular lymphoma in the first decade of the rituximab era : a pooled analysis of French and US cohorts. J Clin Oncol. 2019 ; 37 : 144-52.
 
3) Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa : a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1997 ; 15 : 1110-7.
PubMed
4) Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma : a randomised controlled trial. Lancet. 2003 ; 362 : 516-22.
PubMed
5) Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med. 1984 ; 311 : 1471-5.
 
6) Ardeshna KM, Qian W, Smith P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma : an open-label randomised phase 3 trial. Lancet Oncol. 2014 ; 15 : 424-35.
PubMed
7) Kahl BS, Hong F, Williams ME, et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma : Eastern Cooperative Oncology Group Protocol E4402. J Clin Oncol. 2014 ; 32 : 3096-102.
 
8) Kahl BS, Hong F, Peterson C, et al. Long term follow up of the resort study (E4402) : a randomized phase III study comparing two different rituximab dosing strategie for low tumor burden follicular lymphoma. Blood. 2021 ; 138, Supple 1 : 815.
 
P.263 掲載の参考文献
1) Brice P, Bastion Y, Lepage E, et al. Comparsion in low-tumorburden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon a : a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1997 ; 15 : 1110-17.
 
2) Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone : results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005 ; 106 : 3725-32.
 
3) Federico M, Luminari S, Dondi A, et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma : results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol. 2013 ; 31 : 1506-13.
PubMed
4) Luminari S, Ferrari A, Manni M, et al. Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma. J Clin Oncol. 2018 ; 36 : 689-96.
PubMed
5) Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas : an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013 ; 381 : 1203-10.
PubMed
6) Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017 ; 377 : 1331-44.
PubMed
7) Morschhauser F, Fowler NH, Feugier P, et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med. 2018 ; 379 : 934-47.
PubMed
8) Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA) : a phase 3, randomised controlled trial. Lancet. 2011 ; 377 : 42-51.
 
9) Bachy E, Seymour JF, Feugier P, et al. Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma : long-term results of the PRIMA study. J Clin Oncol. 2019 ; 37 : 2815-24.
PubMed
10) Luminari S, Manni M, Galimberti S, et al. Response-adapted postinduction strategy in patients with advanced-stage follicular lymphoma : the FOLL12 study. J Clin Oncol. 2022 ; 40 : 729-39.
PubMed
11) Ohmachi K, Tobinai K, Kinoshita T, et al. Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma : a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial. Int J Hematol. 2018 ; 108 : 499-509.
PubMed
P.269 掲載の参考文献
1) Junlen HR, Peterson S, Kimby E, et al. Follicular lymphoma in Sweden : nationwide improved survival in the rituximab era, particularly in elderly women : a Swedish Lymphoma Registry study. Leukemia. 2015 ; 29 : 668-76.
PubMed
2) Link BK, Maurer MJ, Nowakowski GS, et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era : a report from the University of Iowa/Mayo-Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol. 2013 ; 31 : 3272-8.
 
3) Sarkozy C, Trneny M, Xerri L, et al. Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial. J Clin Oncol. 2016 ; 34 : 2575-82.
 
4) Sehn LH, Chua N, Mayer J, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN) : a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016 ; 17 : 1081-93.
PubMed
5) Cheson BD, Chua N, Mayer J, et al. Overall survival benefit in patients with rituximab-refractory indolent non-hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. J Clin Oncol. 2018 ; 36 : 2259-66.
PubMed
6) Matsumoto K, Takayama N, Aisa Y, et al. A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab : BRB study. Int J Hematol. 2015 ; 101 : 554-62.
PubMed
7) van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma : long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010 ; 28 : 2853-8.
PubMed
8) Leonard JP, Trneny M, Izutsu K, et al. AUGMENT : A phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019 ; 37 : 1188-99.
PubMed
9) Morschhauser F, Tilly H, Chaidos A, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma : an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020 ; 21 : 1433-42.
PubMed
10) Izutsu K, Ando K, Nishikori M, et al. Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan. Cancer Sci. 2021 ; 112 : 3627-35.
PubMed
11) Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002 ; 20 : 2453-63.
 
12) Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol. 2002 ; 20 : 3262-9.
PubMed
13) Maurer MJ, Bachy E, Ghesquieres H, et al. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol. 2016 ; 91 : 1096-101.
PubMed
14) Jurinovic V, Kridel R, Staiger AM, et al. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood. 2016 ; 128 : 1112-20.
PubMed
15) Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death : an analysis from the National LymphoCare Study. J Clin Oncol. 2015 ; 33 : 2516-22.
PubMed
16) Casulo C, Friedberg JW, Ahn KW, et al. Autologous transplantation in follicular lymphoma with early therapy failure : A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. Biol Blood Marrow Transplant. 2018 ; 24 : 1163-71.
PubMed
17) Smith SM, Godfrey J, Ahn KW, et al. Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. Cancer. 2018 ; 124 : 2541-51.
PubMed
18) Okamoto A, Fujigaki H, Iriyama C, et al. CD19-positive lymphocyte count is critical for acquisition of anti-SARS-CoV-2 IgG after vaccination in B-cell lymphoma. Blood Adv. 2022.
 
P.275 掲載の参考文献
1) Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of tumours of haematopoietic and lymphoid tissues, Revised 4th ed. Lyon : IARC Press ; 2017.
 
2) Broccoli A, Zinzani PL. How do we sequence therapy for marginal zone lymphoma. Hematology Am Soc Hematol Educ Program. 2020 ; 2020 : 295-305.
PubMed
3) Thieblemont C, Cascione L, Concon A, et al. A MALT lymphoma prognostic index. Blood. 2017 ; 130 : 1409-17.
 
4) Kastritis E, Morel P, Duhamel A, et al. A revised international prognostic score system for Waldenstrom's macroglobulinemia. Leukemia. 2019 ; 33 : 2654-61.
 
5) Rossi D, Bertoni F, Zucca E. Marginal-Zone lymphomas. N Engl J Med. 2022 ; 386 : 568-81.
PubMed
6) Dimopoulos MA, Kastritis E, Owen RG, et al. Treatment recommendations for patients with Waldenstrom macroglobulinemia (WM) and related disorders : IWWM-7 consensus. Blood. 2014 ; 124 : 1404-11.
PubMed
7) Sekiguchi N, Rai S, Munakata W, et al. A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenstrom's macroglobulinemia. Cancer Science. 2020 ; 111 : 3327-37.
PubMed
8) Sekiguchi N, Rai S, Munakata W, et al. Two-year outcomes of tirabrutinib monotherapy in Waldenstrom's macroglobulinemia. Cancer Sci. 2022 ; 113 : 2085-96.
PubMed
9) Castillo JJ, Itchaki G, Gustine JN, et al. A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenstrom macroglobulinemia. Leuk Lymphoma. 2020 ; 61 : 1388-94.
PubMed
10) Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as_rst-line treatment for patients with indolent and mantle-cell lymphomas : an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013 ; 381 : 1203-10.
 
11) Walewski J, Paszkiewicz-Kozik E, Michalskiet W, et al. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4. Br J Haematol. 2020 ; 188 : 898-906.
 
12) Herold M, Hoster E, Janssens A, et al. Immunochemotherapy and maintenance with obinutuzumab or rituximab in patients with previously untreated marginal zone lymphoma in the randomized GALLIUM trial. Hemasphere. 2022 ; 6 : e699.
PubMed
13) Leonard JP, Trneny M, Izutsu K, et al. AUGMENT : A phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019 ; 37 : 1188-99.
PubMed
14) Paludo J, Abeykoon JP, Shreders A, et al. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstrom macroglobulinemia. Ann Hematol. 2018 ; 97 : 1417-25.
PubMed
15) Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017 ; 377 : 1331-44.
PubMed
16) Castillo JJ, Treon SP. Management of Waldenstrom macroglobulinemia in 2020. Am Soc Hematol Educ Program. 2020 : 372-9.
PubMed
17) Yamasaki S, Chihara D, Yoshida I, et al. Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory marginal zone lymphoma. Ann Hematol. 2019 ; 98 : 1521-3.
PubMed
18) Sakurai M, Mori T, Uchiyama H, et al. Outcome of stem cell transplantation for Waldenstrom's macroglobulinemia : analysis of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) Lymphoma Working Group. Ann. Hematol. 2020 ; 99 : 1635-42.
 
P.281 掲載の参考文献
1) Gerson JN, Handorf E, Villa D, et al. Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era. J Clin Oncol. 2019 : 37 : 471-80.
PubMed
2) Hermine O, Hoster E, Walewski, J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger) : a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016 ; 388 : 565-75.
PubMed
3) Ogura M, Yamamoto K, Morishima Y, et al. R-High-CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma : JCOG0406 STUDY. Cancer Sci. 2018 : 109 : 2830-40.
PubMed
4) Merryman RW, Edwin N, Redd R, et al. Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv. 2020 ; 4 : 858-67.
PubMed
5) Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017 ; 377 : 1250-60.
PubMed
P.287 掲載の参考文献
1) 日本血液学会. 造血器腫瘍診療ガイドライン 2018年版補訂版.
 
2) Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle cell lymphoma (MCL) : long-term follow-up of the randomized European MCL elderly trial. J Clin Oncol. 2020 ; 38 : 248-56.
 
3) Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012 ; 367 : 520-31.
PubMed
4) Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas : an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013 ; 381 : 1203-10.
PubMed
5) Robak T, Jin J, Pylypenko H, et al. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma : final overall survival results of a randomised, open-label, phase 3 study. Lancet Oncol. 2018 ; 19 : 1449-58.
 
6) Robak T, Huang H, Jin J, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015 ; 372 : 944-53.
PubMed
7) Tisi MC, Nassi L, Patti C, et al. Rituximab plus bendamustine and cytarabine (R-BAC) in elderly patients with newly diagnosed mantle cell lymphoma : long term follow-up and mrd results of a phase 2 study from the fondazione Italiana linfomi. Blood. 2021 ; 138 : 384.
 
8) Salles G, Wang M, Kumar A, et al. Role of maintenance rituximab after first-line bendamustine+rituximab or R-CHOP in patients with mantle cell lymphoma from a large US real-world cohort. EHA. 2021 ; abstract EP785.
PubMed
9) Dreyling M, Goy A, Hess G, et al. Long-term outcomes with ibrutinib treatment for patients with relapsed/refractory mantle cell lymphoma : a pooled analysis of 3 clinical trials with nearly 10 years of follow-up. Hemasphere. 2022 ; 6 : e712.
PubMed
10) Wang ML, Jurczak W, Jerkeman M, et al. Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med. 2022 ; 386 : 2482-94.
PubMed
11) Flinn IW, van der Jagt R, Kahl B, et al. First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP : results of the BRIGHT 5-year follow-up study. J Clin Oncol. 2019 ; 37 : 984-91.
 
12) Fung M, Jacobsen E, Freedman A, et al. Increased risk of infectious complications in older patients with indolent non-Hodgkin lymphoma exposed to bendamustine. Clin Infect Dis. 2019 ; 68 : 247-55.
PubMed
P.292 掲載の参考文献
1) Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med. 1998 ; 339 : 21-6.
PubMed
2) Stephens DM, Li H, LeBlanc ML, et al. Continued risk of relapse independent of treatment modality in limited-stage diffuse large B-cell lymphoma : final and long-term analysis of Southwest Oncology Group Study S8736. J Clin Oncol. 2016 ; 34 : 2997-3004.
 
3) Poeschel V, Held G, Ziepert M, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER) : a randomised, phase 3, non-inferiority trial. Lancet. 2019 ; 394 : 2271-81.
 
4) Persky DO, Li H, Stephens DM, et al. Positron emission tomography-directed therapy for patients with limited-stage diffuse large B-cell lymphoma : results of Intergroup National Clinical Trials Network Study S1001. J Clin Oncol. 2020 ; 38 : 3003-11.
PubMed
5) Persky DO, Unger JM, Spier CM, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma : Southwest Oncology Group study 0014. J Clin Oncol. 2008 ; 26 : 2258-63.
 
P.297 掲載の参考文献
1) Wright GW, Huang DW, Phelan JD, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020 ; 37 : 551-68 e14.
 
2) Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma : a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006 ; 7 : 379-91.
PubMed
3) Chiappella A, Martelli M, Angelucci E, et al. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04) : final results of a multicentre, open-label, randomised, controlled, phase 3 study. Lancet Oncol. 2017 ; 18 : 1076-88.
PubMed
4) Bartlett NL, Wilson WH, Jung SH, et al. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma : clinical outcomes of the phase III intergroup trial Alliance/CALGB 50303. J Clin Oncol. 2019 ; 37 : 1790-9.
 
5) Younes A, Sehn LH, Johnson P, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 2019 ; 37 : 1285-95.
PubMed
6) Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022 ; 386 : 351-63.
PubMed
7) Wilson WH, Wright GW, Huang DW, et al. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell. 2021 ; 39 : 1643-53 e3.
 
P.302 掲載の参考文献
1) Muto R, Miyoshi H, Sato K, et al. Epidemiology and secular trends of malignant lymphoma in Japan : Analysis of 9426 cases according to the World Health Organization classification. Cancer Med. 2018 ; 7 : 5843-58.
 
2) Mareschal S, Lanic H, Ruminy P, et al. The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age. Haematologica. 2011 ; 96 : 1888-90.
PubMed
3) Wilson WH, Wright GW, Huang DW, et al. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell. 2021 ; 39 : 1643-53.
 
4) 日本血液学会. 造血器腫瘍診療ガイドライン 2018年版補訂版. 東京 : 金原出版 ; 2020.
 
5) Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the Use of WBC Growth Factors : American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015 ; 33 : 3199-212.
 
6) Delarue R, Tilly H, Mounier N, et al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study) : a randomised phase 3 trial. Lancet Oncol. 2013 ; 14 : 525-33.
PubMed
7) Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma : a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013 ; 381 : 1817-26.
 
8) Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma : a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011 ; 12 : 460-8.
PubMed
9) Oberic L, Peyrade F, Puyade M, et al. Subcutaneous rituximab-miniCHOP compared with subcutaneous rituximab-miniCHOP plus lenalidomide in diffuse large B-cell lymphoma for patients age 80 years or older. J Clin Oncol. 2021 ; 39 : 1203-13.
PubMed
10) Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022 ; 386 : 351-63.
PubMed
11) Miura K, Konishi J, Miyake T, et al. A host-dependent prognostic model for elderly patients with diffuse large B-cell lymphoma. Oncologist. 2017 ; 22 : 554-60.
PubMed
P.308 掲載の参考文献
1) Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma : results from the international SCHOLAR-1 study. Blood. 2017 ; 130 : 1800-8.
PubMed
2) Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995 ; 333 : 1540-5.
PubMed
3) Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010 ; 28 : 4184-90.
 
4) Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011 ; 2011 : 498-505.
PubMed
5) Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019 ; 380 : 45-56.
 
6) Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017 ; 377 : 2531-44.
 
7) Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001) : a multicentre seamless design study. Lancet. 2020 ; 396 : 839-52.
PubMed
8) Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020 ; 38 : 155-65.
 
9) Salles G, Duell J, Gonzalez Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND) : a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020 ; 21 : 978-88.
 
10) Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 2022 ; 386 : 640-54.
 
11) Bishop MR, Dickinson M, Purtill D, et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med. 2022 ; 386 : 629-39.
PubMed
12) Budde LE, Assouline S, Sehn LH. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas : Phase I Dose-Escalation Study. J Clin Oncol. 2022 ; 40 : 481-91.
PubMed
13) Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma : an open-label, phase 1/2 study. Lancet. 2021 ; 398 : 1157-69.
PubMed
14) Hutchings M, Morschhauser F, Iacoboni G. Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma : a phase I trial. J Clin Oncol. 2021 ; 39 : 1959-70.
PubMed
15) Bannerji R, Arnason JE, Advani RH, et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1) : results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 ; 9 : e327-39.
 
16) Caimi PF, Ai W, Alderuccio JP, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2) : a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021 ; 22 : 790-800.
 
P.313 掲載の参考文献
1) Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1) : a phase 3, randomised, non-inferiority trial. Lancet Oncol [Internet]. 2010 ; 11 : 1036-47. Available from : http://dx.doi.org/10.1016/S1470-2045 (10) 70229-1
 
2) Ferreri AJM, Cwynarski K, Pulczynski E, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma : results of the second randomisation of the International Extranodal L. Lancet Haematol. 2017 ; 4 : e510-23.
 
3) Ferreri AJM, Cwynarski K, Pulczynski E, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma : Results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol [Internet]. 2016 May 1 [cited 2020 Jan 7] ; 3 (5) : e217-27. Available from : http://dx.doi.org/10.1016/
 
4) Houillier C, Taillandier L, Dureau S, et al. Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger : Results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study. J Clin Oncol. 2019 ; 37 : 823-33.
 
5) Schorb E, Kasenda B, Ihorst G, et al. High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma : A pilot study. Blood Adv. 2020 ; 4 : 3378-81.
PubMed
6) Herrlinger U, Schafer N, Fimmers R, et al. Early whole brain radiotherapy in primary CNS lymphoma : negative impact on quality of life in the randomized G-PCNSL-SG1 trial. J Cancer Res Clin Oncol. 2017 ; 143 : 1815-21.
 
P.318 掲載の参考文献
1) Shipp MA, Harrington DP. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993 ; 329 : 987-94.
 
2) Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U) : a new prognostic model from a retrospective multicentric clinical study. Blood. 2004 ; 103 : 2474-9.
 
3) Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993 ; 328 : 1002-6.
PubMed
4) Horwitz S, O'Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2) : a global, double-blind, randomised, phase 3 trial. Lancet. 2019 ; 393 : 229-40.
 
5) Horwitz S, O'Connor OA, Pro B, et al. The ECHELON-2 Trial : 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2022 ; 33 : 288-98.
PubMed
6) Bachy E, Camus V, Thieblemont C, et al. Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma : results of the Ro-CHOP Phase III study (conducted by LYSA). J Clin Oncol. 2022 ; 40 : 242-51.
PubMed
7) Savage KJ, Horwitz SM, Advani R, et al. Role of stem cell transplant in CD30-positive PTCL following frontline brentuximab vedotin+CHP or CHOP in ECHELON-2. Blood Adv. 2022.
PubMed
P.322 掲載の参考文献
1) Pileri SA, Weisenburger DD, Sng I, et al. Peripheral T-cell lymphoma, NOS. Swerdlow SH, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon : IARC Press ; 2017. p.403-7.
 
2) 日本血液学会, 編. 末梢性T細胞リンパ腫 (PTCL). 造血器腫瘍診療ガイドライン 2018年版補訂版. 東京 : 金原出版 ; 2020. p.266-72.
 
3) Zain JM, Hanona P. Aggressive T-cell lymphomas : 2021 Updates on diagnosis, risk stratification and management. Am J Hematol. 2021 ; 96 : 1027-46.
PubMed
4) Bellei M, Foss FM, Shustov AR, et al. The outcome of peripheral T-cell lymphoma patients failing first-line therapy : a report from the prospective, International T-Cell Project. Haematologica. 2018 ; 103 : 1191-7.
 
5) Ogura M, Ishida T, Hatake K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014 ; 32 : 1157-63.
PubMed
6) Barta SK, Gong JZ, Porcu P. Brentuximab vedotin in the treatment of CD30+ PTCL. Blood. 2019 ; 134 : 2339-45.
PubMed
7) Ogura M, Tsukasaki K, Nagai H, et al. Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T/natural killer-cell malignancies. Cancer Sci. 2012 ; 103 : 1290-5.
PubMed
8) O'Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma : results from the pivotal PROPEL study. J Clin Oncol. 2011 ; 29 : 1182-9.
PubMed
9) Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012 ; 30 : 631-6.
PubMed
10) Kawai H, Ando K, Maruyama D, et al. Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma. Cancer Sci. 2021 ; 112 : 2426-35.
PubMed
11) Shi Y, Dong M, Hong X, et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015 ; 26 : 1766-71.
PubMed
12) Luminari S, Skrypets T. What's new in peripheral T-cell lymphomas. Hematol Oncol. 2021 ; 39 Suppl 1 : 52-60.
 
13) Horwitz SM, Ansell S, Ai WZ, et al. T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 ; 20 : 285-308.
PubMed
14) d'Amore F, Gaulard P, Trumper L, et al. Peripheral T-cell lymphomas : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 ; 26 (suppl 5) : v108-15.
 
15) Ghione P, Faruque P, Mehta-Shah N, et al. T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma. Blood Adv. 2020 ; 4 : 4640-7.
PubMed
16) Ohmachi K, Ando K, Ogura M, et al. E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma : A phase I study. Cancer Sci. 2018 ; 109 : 794-802.
PubMed
17) Falchi L, Ma H, Klein S, et al. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL : a multicenter phase 2 study. Blood. 2021 ; 137 : 2161-70.
PubMed
18) Marchi E, Zullo KM, Amengual JE, et al. The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma. Br J Haematol. 2015 ; 171 : 215-26.
PubMed
19) O'Connor OA, Falchi L, Lue JK, et al. Oral 5 azacytidine and romidepsin exhibit marked activity in patients with PTCL : a multicenter phase 1 study. Blood. 2019 ; 134 : 1395-405.
PubMed
20) O'Connor OA, Ozcan M, Jacobsen ED, et al. Randomized phase III study of alisertib or investigator's choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma. J Clin Oncol. 2019 ; 37 : 613-23.
 
P.332 掲載の参考文献
1) Chan JKC, Quintanilla-Martinez L, Ferry JA. Extranodal NK/T-cell lymphoma, nasal type. Swerdlow SH, Campo E, Harris NK, et al (.eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. Lyon : IARC ; 2017. p.368-71.
 
2) Yamaguchi M, Oguchi M, Suzuki R. Extranodal NK/T-cell lymphoma : updates in biology and management strategies. Best Pract Res Clin Haematol. 2018 ; 31 : 315-21.
PubMed
3) Xiong J, Cui B-W, Wang N, et al. Genomic and transcriptomic characterization of natural killer T cell lymphoma. Cancer Cell. 2020 ; 37 : 403-19.
PubMed
4) Au W-Y, Weisenburger DD, Inttragumtornchai T, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma : a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood. 2009 ; 113 : 3931-7.
PubMed
5) Kim SJ, Yoon DH, Jaccard A, et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment : a multicentre, retrospective analysis. Lancet Oncol. 2016 ; 17 : 389-400.
PubMed
6) Tao R, Fan L, Song Y, et al. Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma : a multicenter, single-arm, phase 2 tria (l ORIENT-4). Signal Transduct Target Ther. 2021 ; 6 : 365.
 
7) Yamaguchi M, Tobinai K, Oguchi M, et al. Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma : an updated analysis of the Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol. 2012 ; 30 : 4044-6.
 
8) Yamaguchi M, Kwong Y-L, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type : the NK-Cell Tumor Study Group study. J Clin Oncol. 2011 ; 29 : 4410-6.
PubMed
9) Jaccard A, Gachard N, Marin B, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood. 2011 ; 117 : 1834-9.
PubMed
10) Yamaguchi M, Suzuki R, Oguchi M, et al. Treatments and outcomes of patients with extranodal natural killer/T-cell lymphoma diagnosed between 2000 and 2013 : a cooperative study in Japan. J Clin Oncol. 2017 ; 35 : 32-9.
PubMed
11) Li X, Cui Y, Sun Z, et al. DDGP versus SMILE in newly diagnosed advanced natural killer/T-cell lymphoma : a randomized controlled, multicenter, open-label study in China. Clin Cancer Res. 2016 : 22 : 5223-8.
 
12) Song G-Y, Yoon DH, Suh C, et al. Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma. Bone Marrow Transplant. 2021 ; 56 : 1205-8.
PubMed
13) Kanate AS, DiGilio A, Ahn KW, et al. Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type : a CIBMTR analysis. Br J Haematol. 2018 ; 182 : 916-20.
PubMed
P.342 掲載の参考文献
1) Fernandez LA, Pope B, Lee C, et al. Aggressive natural killer cell leukemia in an adult with establishment of an NK cell line. Blood. 1986 ; 67 : 925-30.
 
2) Tang YT, Wang D, Luo H, et al. Aggressive NK-cell leukemia : clinical subtypes, molecular features, and treatment outcomes. Blood Cancer J. 2017 ; 7 : 660.
PubMed
3) Nakashima Y, Tagawa H, Suzuki R, et al. Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma/leukemia : different genomic alteration patterns of aggressive NK-cell leukemia and extranodal Nk/T-cell lymphoma, nasal type. Genes Chromosomes Cancer. 2005 ; 44 : 247-55.
PubMed
4) Dufva O, Kankainen M, Kelkka T, et al. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. Nat Commun. 2018 ; 9 : 1567.
PubMed
5) Chan JKC, Jaffe ES, Ko Y-H. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues/Aggressive NK-cell leukaemia. International Agency for Research on Cancer ; 2017. p.353-4.
 
6) Caligiuri MA. Human natural killer cells. Blood. 2008 ; 112 : 461-9.
PubMed
7) Ishida F, Ko YH, Kim WS, et al. Aggressive natural killer cell leukemia : therapeutic potential of L-asparaginase and allogeneic hematopoietic stem cell transplantation. Cancer Sci. 2012 ; 103 : 1079-83.
PubMed
8) Suzuki R, Suzumiya J, Nakamura S, et al. Aggressive natural killer-cell leukemia revisited : large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia. 2004 ; 18 : 763-70.
PubMed
9) Kimura H, Ito Y, Kawabe S, et al. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts : prospective analysis of 108 cases. Blood. 2012 ; 119 : 673-86.
PubMed
10) Ando M, Sugimoto K, Kitoh T, et al. Selective apoptosis of natural killer-cell tumours by l-asparaginase. Br J Haematol. 2005 ; 130 : 860-8.
PubMed
11) Jung KS, Cho SH, Kim SJ, et al. L-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia. J Hematol Oncol. 2016 ; 9 : 41.
PubMed
12) Takahashi H, Sakai R, Hattori Y, et al. Successful disease control with L-asparaginase monotherapy for aggressive natural killer cell leukemia with severe hepatic failure. Leuk Lymphoma. 2013 ; 54 : 662-4.
 
13) Suzuki R, Suzumiya J, Yamaguchi M, et al. Prognostic factors for mature natural killer (NK) cell neoplasms : aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol. 2010 ; 21 : 1032-40.
PubMed
14) Fujimoto A, Ishida F, Izutsu K, et al. Allogeneic stem cell transplantation for patients with aggressive NK-cell leukemia. Bone Marrow Transplant. 2021 ; 56 : 347-56.
PubMed
15) Fujimoto A, Ishida F, Izutsu K, et al. Allogeneic stem cell transplantation for patients with aggressive NK-cell leukemia. Bone Marrow Transplant. 2021 ; 56 : 347-56.
PubMed
16) Hamadani M, Kanate AS, DiGilio A, et al. Allogeneic hematopoietic cell transplantation for aggressive NK cell leukemia. A Center for International Blood and Marrow Transplant Research Analysis. Biol Blood Marrow Transplant. 2017 ; 23 : 853-6.
PubMed
17) Dufva O, Kankainen M, Kelkka T, et al. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. Nat Commun. 2018 ; 9 : 1567.
PubMed
18) Huang L, Liu D, Wang N, et al. Integrated genomic analysis identifies deregulated JAK/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia. Cell Res. 2018 ; 28 : 172-86.
 
19) El Hussein S, Patel KP, Fang H, et al. Genomic and immunophenotypic landscape of aggressive NK-cell leukemia. Am J Surg Pathol. 2020 ; 44 : 1235-43.
PubMed
P.347 掲載の参考文献
1) Uchiyama T, Yodoi J, Sagawa K, et al. Adult T-cell leukemia : clinical and hematologic features of 16 cases. Blood. 1977 ; 50 : 481-92.
PubMed
2) Poiesz BJ, Ruscetti FW, Mier JW, et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA. 1980 ; 77 : 7415-9.
 
3) Himuma Y, Nagata K, Hanaoka M, et al. Adult T-cell leukemia : antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA. 1981 ; 78 : 6476-80.
 
4) Yoshida M, Seike M, Yamaguchi K, et al. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc Natl Acad Sci USA. 1984 ; 81 : 2534-7.
 
5) Nosaka K, Iwanaga M, Imaizumi Y, et al. Epidemiological and clinical features of adult T-cell leukemia-lymphoma in Japan, 2010-2011 : A nationwide survey. Cancer Sci. 2017 ; 108 : 2478-86.
PubMed
6) Ohshima K, et al. Adult T-cell leukemia/lymphoma. Swerdlow SH, et al.eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon : IARC ; 2017. p.363-7.
 
7) Iwanaga M. Epidemiology of HTLV-1 Infection and ATL in Japan : An Update. Front Microbiol. 2020 ; 11 : 1124.
PubMed
8) Shimoyama M. Diagnostic criteria and classification clinical subtypes of adult T-cell leukemia-lymphoma. Br J Haematol. 1991 ; 79 : 428-37.
PubMed
9) 日本血液学会, 編. 造血器腫瘍診療ガイドライン 2018年版補訂版. 東京 : 金原出版 ; 2020.
 
10) Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma : Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007 ; 25 : 5458-64.
 
11) Ishida T, Jo T, Takemoto S, et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma : a randomized phase II. Br J Haematol. 2015 ; 169 : 672-82.
PubMed
12) Fuji S, Inoue Y, Utsunomia A, et al. Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. J Clin Oncol. 2016 ; 34 : 3426-33.
 
13) Takasaki Y, Iwanaga M, Imaizumi Y, et al. Long-term study of indolent adult T-cell leukemia-lymphoma. Blood. 2010 ; 115 : 4337-43.
PubMed
14) Bazarbachi A, Plumelle Y, Carlos Ramos J, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010 ; 28 : 4177-83.
PubMed
15) Ishida T, Jo T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma : a multicenter phase II study. J Clin Oncol. 2012 ; 30 : 837-42.
 
16) Ishida T, Fujiwara H, Nosaka K, et al. Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia/lymphoma : ATLL-002. J Clin Oncol. 2016 ; 34 : 4086-93.
PubMed
17) Horwitz S, O'Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2) : a global, double-blind, randomized, phase 3 trial. Lancet. 2019 ; 393 : 229-40.
PubMed
18) Utsunomiya A, Izutsu K, Jo T, et al. Oral histone deacetylase inhibitor tucidinostat (HBI-8000) in patients with relapsed or refractory adult T-cell leukemia/lymphoma : Phase IIb results. Cancer Sci. 2022 ; 113 : 2778-87.
PubMed
19) Imaizumi Y, Iwanaga M, Nosaka K, et al. Prognosis of patients with adult T-cell leukemia/lymphoma in Japan : A nationwide hospital-based study. Cancer Sci. 2020 ; 111 : 4567-80.
PubMed
20) Katsuya H, Yamanaka T, Ishitsuka K, et al. Prognostic index for acute- and lymphoma-type adult T-cell leukemia-lymphoma. J Clin Oncol. 2012 ; 30 : 1635-40.
PubMed
21) Fuji S, Yamaguchi T, Inoue Y et al. Development of a modified prognostic index for patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger : possible risk-adapted management strategies including allogeneic transplantation. Haematologica. 2017 ; 102 : 1258-65.
PubMed
22) Kataoka K, Iwanaga M, Yasunaga JI, et al. Prognostic relevance of integrated genetic profiling in adult T-cell leukemia-lymphoma. Blood. 2017 ; 130 : 39-47.
 
P.354 掲載の参考文献
1) 造血細胞移植ガイドライン. 成人T細胞白血病・リンパ腫. 日本造血細胞移植学会 ; 2018.
 
2) Cook LB, Fuji S, Hermine O, et al. Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report. J Clin Oncol. 2019 ; 37 : 677-87.
PubMed
3) 日本血液学会, 編. 造血器腫瘍診療ガイドライン 2018年版補訂版, 成人T細胞白血病・リンパ腫. 東京 : 金原出版 ; 2020.
 
4) Utsunomiya A, Tokunaga M, Nakano N, et al. Long-term follow-up of patients with ATL after autologous stem cell transplantation. Bone Marrow Transplant. 2022 ; 57 : 323-5.
PubMed
5) Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia lymphoma : a multicenter phase II study. J Clin Oncol. 2012 ; 30 : 837-42.
PubMed
6) Ishida T, Fujiwara H, Nosaka K, et al. Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia/lymphoma : ATLL-002. J Clin Oncol. 2016 ; 34 : 4086-93.
PubMed
7) Tsukasaki K, Ikeda S, Murata K, et al. Characteristics of chemotherapy-induced clinical remission in long survivors with aggressive adult T-cell leukemia/lymphoma. Leuk Res. 1993 ; 17 : 157-66.
PubMed
8) Toriyama E, Imaizumi Y, Taniguchi H, et al. EPOCH regimen as salvage therapy for adult T-cell leukemia-lymphoma. Int J Hematol. 2018 ; 108 : 167-75.
PubMed
9) Kato K, Uike N, Wake A, et al. The outcome and characteristics of patients with relapsed adult T cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation. Hematol Oncol. 2019 ; 37 : 54-61.
PubMed
10) Tanaka T, Nakamae H, Ito A, et al. A phase I/II multicenter trial of HLA-haploidentical PBSCT with PTCy for aggressive adult T cell leukemia/lymphoma. Transplant Cell Ther. 2021 ; 27 : 928.
 
11) Ito A, Nakano N, Tanaka T, et al. Improved survival of patients with aggressive ATL by increased use of allo-HCT : a prospective observational study. Blood Adv. 2021 ; 5 : 4156-66.
PubMed
12) Tsukasaki K, Utsunomiya A, Fukuda H, et. al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma : Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007 ; 25 : 5458-64.
 
13) Fujiwara H, Fuji S, Wake A, et al. Dismal outcome of allogeneic hematopoietic stem cell transplantation for relapsed adult T-cell leukemia/lymphoma, a Japanese nation-wide study. Bone Marrow Transplant. 2017 ; 52 : 484-8.
PubMed
14) Itonaga H, Tsushima H, Taguchi J, et al. Treatment of relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation : the Nagasaki Transplant Group experience. Blood. 2013 ; 121 : 219-25.
PubMed
15) Imaizumi Y, Iwanaga M, Nosaka K, et al ; for collaborative Investigators. Prognosis of patients with adult T-cell leukemia/lymphoma in Japan : A nationwide hospital-based study. Cancer Sci. 2020 ; 111 : 4567-80.
PubMed
P.359 掲載の参考文献
1) Ferme C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med. 2007 ; 357 : 1916-27.
PubMed
2) Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010 ; 363 : 640-52.
PubMed
3) Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma : final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010 ; 28 : 4199-206.
 
4) Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2- [18F] fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma : a report from a joint Italian-Danish study. J Clin Oncol. 2007 ; 25 : 3746-52.
PubMed
5) Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med. 2015 ; 372 : 1598-607.
PubMed
6) Andre MPE, Girinsky T, Federico M, et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma : Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. J Clin Oncol. 2017 ; 35 : 1786-94.
 
7) Fuchs M, Goergen H, Kobe C, et al. Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma : Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. J Clin Oncol. 2019 ; 37 : 2835-45.
 
8) von Tresckow B, Plutschow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkin's lymphoma : final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol. 2012 ; 30 : 907-13.
 
9) van Nimwegen FA, Ntentas G, Darby SC, et al. Risk of heart failure in survivors of Hodgkin lymphoma : effects of cardiac exposure to radiation and anthracyclines. Blood. 2017 ; 129 : 2257-65.
PubMed
10) Johnson P, Federico M, Kirkwood A, et al. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. N Engl J Med. 2016 ; 374 : 2419-29.
PubMed
P.364 掲載の参考文献
1) Brice P, de Kerviler E, Friedberg JW. Classical Hodgkin lymphoma. Lancet 2021 ; 398 : 1518-27.
PubMed
2) Connors JM, Jurczak W, Straus DJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. N Engl J Med. 2018 ; 378 : 331-44.
PubMed
3) Stephens DM, Li H, Schoder H, et al. Five-year follow-up of SWOG S0816 : limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood. 2019 ; 134 : 1238-46.
PubMed
4) Gallamini A, Rossi A, Patti C, et al. Consolidation radiotherapy could be safely omitted in advanced Hodgkin lymphoma with large nodal mass in complete metabolic response after ABVD : final analysis of the randomized GITIL/FIL HD0607 Trial. J Clin Oncol. 2020 ; 38 : 3905-13.
 
5) Ansell SM, Radford J, Connors JM, et al. Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma. N Engl J Med. 2022 ; 387 : 310-20.
 
6) Evens AM, Connors JM, Younes A, et al. Older patients (aged >/=60 years) with previously untreated advanced-stage classical Hodgkin lymphoma : a detailed analysis from the phase III ECHELON-1 study. Haematologica. 2022 ; 107 : 1086-94.
PubMed
7) Evens AM, Helenowski I, Ramsdale E, et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma : outcomes and prognostic factors in the modern era. Blood. 2012 ; 119 : 692-5.
PubMed
8) Evens AM, Advani RH, Helenowski IB, et al. Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma. J Clin Oncol. 2018 ; 36 : 3015-3022.
PubMed
9) Friedberg JW, Forero-Torres A, Bordoni RE, et al. Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged >/=60 years with HL. Blood. 2017 ; 130 : 2829-37.
PubMed
10) Cheson BD, Bartlett NL, LaPlant B, et al. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU) : a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2020 ; 7 : e808-e815.
PubMed
P.369 掲載の参考文献
1) Brockelmann PJ, Muller H, Casasnovas O, et al. Risk factors and a prognostic score for survival ansplantation for relapsed or refractory Hodgkin lymphoma. Ann Oncol. 2017 ; 28 : 1352-58.
PubMed
2) Nieto Y, Gruschkus S, Valdez BC, et al. Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy : a 15-year analysis. Haematologica. 2022 ; 107 : 899-908.
PubMed
3) Epperla N, Hamadani M. Double-refractory Hodgkin lymphoma : tackling relapse after brentuximab vedotin and checkpoint inhibitors. Hematology Am Soc Hematol Educ Program. 2021 ; 1 : 247-53.
PubMed
4) Barrington SF, Qian W, Somer EJ, et al. Concordance between four European Centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2010 ; 37 : 1824-33.
PubMed
5) Merryman RW, Redd RA, Nishihori T, et al. Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. Blood Adv. 2021 ; 5 : 1648-59.
PubMed
6) Yhim H-Y, Eshet Y, Metser U, et al. Risk stratification for relapsed/refractory classical Hodgkin lymphoma integrating pretransplant Deauville score and residual metabolic tumor volume. Am J Hematol. 2022 ; 97 : 583-91.
PubMed
7) Moskowitz CH, Walewski J, Nademanee A, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018 ; 132 : 2639-42.
PubMed
8) Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015 ; 385 : 1853-62.
 
9) Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation : extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol. 2018 ; 36 : 1428-39.
 
10) Kuruvilla J, Ramchandren R, Santoro A, et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204) : an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2021 ; 22 : 512-24.
PubMed
11) Merryman RW, Castagna L, Giordano L, et al. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia. 2021 ; 35 : 2672-83.
PubMed
P.374 掲載の参考文献
1) Katanoda K, Shibata A, Matsuda T, et al. Childhood, adolescent and young adult cancer incidence in Japan in 2009-2011. Jpn J Clin Oncol. 2017 : 47 : 762-71.
 
2) Burkhardt B, Oschlies I, Klapper W, et al. Non-Hodgkin's lymphoma in adolescents : experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols. Leukemia. 2011 ; 25 : 153-60.
PubMed
3) Sekimizu M, Hashimoto H, Mori T, et al. Efficacy and safety of administering pediatric treatment to adolescent patients with mature B-cell non-Hodgkin lymphoma within the Japanese Pediatric Leukemia/Lymphoma Study Group clinical trial. Pediatr Blood Cancer. 2018 ; 65 : e27068.
 
4) Gupta S, Alexander S, Pole JD. Superior outcomes with paediatric protocols in adolescents and young adults with aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2022 ; 196 : 743-52.
 
5) Gupta S, Baxter NN, Hodgson D, et al. Treatment patterns and outcomes in adolescents and young adults with Hodgkin lymphoma in pediatric versus adult centers : An IMPACT Cohort Study. Cancer Med. 2020 ; 9 : 6933-45.
 
P.378 掲載の参考文献
1) Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN) : a phase 1/2 study. Lancet. 2021 ; 397 : 892-901.
 
2) Salles G, Duell J, Barca EG, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND) : a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020 ; 21 : 978-88.
PubMed
3) Caimi PF, Ai W, Alderuccio JP, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2) : a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021 ; 22 : 790-800.
 
4) Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020 ; 38 : 155-65.
 
5) Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022 ; 386 : 351-63.
PubMed
6) Budde LE, Assouline S, Sehn LH, et al. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas : phase I dose-escalation study. J Clin Oncol. 2022 ; 40 : 481-91.
PubMed
7) Hutchings M, Morschhauser F, Iacoboni G, et al. Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma : a phase I trial. J Clin Oncol. 2021 ; 39 : 1959-70.
PubMed
8) Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma : an open-label, phase 1/2 study. Lancet. 2021 ; 398 : 1157-69.
PubMed
P.383 掲載の参考文献
1) Swerdlow SH, Campo E, Harris NL, et al (.eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th ed. Lyon : International Agency for Research on Cancer ; 2017.
 
2) Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms : a report from the Clinical Advisory Committee. Blood. 2022. (in press)
 
3) Boyer DF, McKelvie PA, de Leval L, et al. Fibrin-associated EBV-positive large B-cell lymphoma : an indolent neoplasm with features distinct from diffuse large B-cell lymphoma associated with chronic inflammation. Am J Surg Pathol. 2017 ; 41 : 299-312.
 
4) Chan JKC, Aozasa K, Gaulard P. Diffuse large B-cell lymphoma associated with chronic inflammation. Swerdlow SH, Campo E, Harris NL, et al (.eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th ed. Lyon : International Agency for Research on Cancer ; 2017. p.309-11.
 
5) Petitjean B, Jardin F, Joly B, et al. Pyothorax-associated lymphoma : a peculiar clinicopathologic entity derived from B cells at late stage of differentiation and with occasional aberrant dual B- and T-cell phenotype. Am J Surg Pathol. 2002 ; 26 : 724-32.
 
6) Alexanian S, Said J, Lones M, et al. KSHV/HHV8-negative effusion-based lymphoma, a distinct entity associated with fluid overload states. Am J Surg Pathol. 2013 ; 37 : 241-9.
PubMed
7) Nador RG, Cesarman E, Chadburn A, et al. Primary effusion lymphoma : a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood. 1996 ; 88 : 645-56.
PubMed
8) Jeon YK, Kim JH, Sung JY, et al. Epstein-Barr virus-positive nodal T/NK-cell lymphoma : an analysis of 15 cases with distinct clinicopathological features. Hum Pathol. 2015 ; 46 : 981-90.
PubMed
9) Mescam L, Camus V, Schiano JM, et al. EBV+ diffuse large B-cell lymphoma associated with chronic inflammation expands the spectrum of breast implant-related lymphomas. Blood. 2020 ; 135 : 2004-9.
PubMed
10) Asano N, Suzuki R, Kagami Y, et al. Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. Am J Surg Pathol. 2005 ; 29 : 1284-93.
PubMed
P.386 掲載の参考文献
1) Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000 ; 403 : 503-11.
PubMed
2) Wright GW, Huang DW, Phelan JD, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020 ; 37 : 551-68.
PubMed
3) Pastore A, Jurinovic V, Kridel R, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma : a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015 ; 16 : 1111-22.
 
4) Kridel R, Meissner B, Rogic S, et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood. 2012 ; 119 : 1963-71.
PubMed
5) Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011 ; 364 : 2305-15.
PubMed
6) Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. N Engl J Med. 2012 ; 367 : 826-33.
 
7) Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenstrom's macroglobulinemia. N Engl J Med. 2015 ; 372 : 1430-40.
 
8) Kogure Y, Kameda T, Koya J, et al. Whole-genome landscape of adult T-cell leukemia/lymphoma. Blood. 2022 ; 139 : 967-82.
PubMed
9) Kataoka K, Shiraishi Y, Takeda Y, et al. Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers. Nature. 2016 ; 534 : 402-6.
PubMed
10) Fujisawa M, Sakata-Yanagimoto M, Nishizawa S, et al. Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma. Leukemia. 2018 ; 32 : 694-702.
PubMed

V. 多発性骨髄腫と関連疾患

P.393 掲載の参考文献
1) Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007 ; 356 : 2582-90.
PubMed
2) Riccardi A, Mora O, Tinelli C, et al. Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease : a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma. Br J Cancer. 2000 ; 82 : 1254-60.
PubMed
3) Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008 ; 111 : 785-9.
PubMed
4) Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014 ; 15 : e538-48.
 
5) Lakshman A, Rajkumar SV, Buadi FK, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018 ; 8 : 59.
PubMed
6) Mateos MV, Kumar S, Dimopoulos MA, et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020 ; 10 : 102.
 
7) Bustoros M, Sklavenitis-Pistofidis R, Park J, et al. Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression. J Clin Oncol. 2020 ; 38 : 2380-9.
 
8) Mateos MV, Hernandez MT, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013 ; 369 : 438-47.
PubMed
9) Mateos MV, Hernandez MT, Giraldo P, et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex) : long-term follow-up a randomised, controlled, phase 3 trial. Lancet Oncol. 2016 ; 17 : 1127-36.
 
10) Lonial S, Jacobus S, Fonseca R, et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J Clin Oncol. 2020 ; 38 : 1126-37.
PubMed
11) Landgren CO, Chari A, Cohen YC, et al. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma : a randomized, open-label, multicenter, phase 2 study (CENTAURUS). Leukemia. 2020 ; 34 : 1840-52.
PubMed
12) Kazandjian D, Hill E, Dew A, et al. Carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide maintenance for prevention of symptomatic multiple myeloma in patients with high-risk smoldering myeloma : a phase 2 nonrandomized controlled trial. JAMA Oncol. 2021 ; 7 : 1678-85.
PubMed
13) Mateos MV, Martinez-Lopez J, Rodriguez Otero P, et al. Curative strategy (GEM-CESAR) for high-risk smoldering myeloma (SMM) : carfilzomib, lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT, consolidation with KRd and maintenance with Rd. Blood. 2021 ; 138 (Suppl 1) : Abstract#1829.
 
P.398 掲載の参考文献
1) Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017 ; 376 : 1311-20.
PubMed
2) Rosinol L, Oriol A, Rios R, et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Blood. 2019 ; 134 : 1337-45.
PubMed
3) Kumar SK, Jacobus SJ, Cohen AD, et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE) : a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020 ; 21 : 1317-30.
PubMed
4) Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA) : a randomised, open-label, phase 3 study. Lancet. 2019 ; 394 : 29-38.
 
5) Voorhees PM, Kaufman JL, Laubach JP, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma : the GRIFFIN trial. Blood. 2020 ; 136 : 936-45.
 
6) Laubach JP, Kaufman JL, Sborov DW, et al. Daratumumab plus lenalidomide, bortezomib, and dexamethasone in patients with transplant-eligible newly diagnosed multiple myeloma : updated analysis of GRIFFIN after 24 months of maintenance. Blood. 2021 ; 138 : 79.
 
7) Goldschmidt HG, Mai EK, Nievergall E, et al. Addition of isatuximab to lenalidomide, bortezomib and dexamethasone as induction therapy for newly-diagnosed, transplant-eligible multiple myeloma patients : the phase III GMMG-HD7 trial. Blood. 2021 ; 138 : 463.
 
8) Roussel M, Lauwers-Cances V, Marco M, et al. Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma : and IFM randomized phase 3 study. Blood. 2022 ; 139 : 2747-57.
 
9) Sonneveld P, Dimopoulos MA, Beksac M, et al. Consolidation and maintenance in newly diagnosed multiple myeloma. J Clin Oncol. 2021 ; 39 : 3613-22.
PubMed
P.403 掲載の参考文献
1) Giri S, Aryal MR, Yu H, et al. Efficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma : A systematic review and meta-analysis. J Geriatr Oncol. 2020 ; 11 : 1285-92.
PubMed
2) Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018 ; 378 : 518-28.
PubMed
3) Mateos MV, Cavo M, Blade J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE) : a randomised, open-label, phase 3 trial. Lancet. 2020 ; 395 : 132-41.
PubMed
4) Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019 ; 380 : 2104-15.
PubMed
5) Facon T, Kumar SK, Plesner T, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA) : overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021 ; 22 : 1582-96.
PubMed
6) Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777) : a randomised, open-label, phase 3 trial. Lancet. 2017 ; 389 : 519-27.
PubMed
7) Durie BGM, Hoering A, Sexton R, et al. Longer term follow-up of the randomized phase III trial SWOG S0777 : bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020 ; 10 : 53.
PubMed
8) Goicoechea I, Puig N, Cedena MT, et al. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma. Blood. 2021 ; 137 : 49-60.
PubMed
9) Paiva B, Cedena MT, Puig N, et al. Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. Blood. 2016 ; 127 : 3165-74.
PubMed
10) San-Miguel J, Avet-Loiseau H, Paiva B, et al. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood. 2022 ; 139 : 492-501.
PubMed
11) O'Donnell EK, Laubach JP, Yee AJ, et al. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol. 2018 ; 182 : 222-30.
 
12) Larocca A, Dold SM, Zweegman S, et al. Patient-centered practice in elderly myeloma patients : an overview and consensus from the European Myeloma Network (EMN). Leukemia. 2018 ; 32 : 1697-12.
PubMed
P.409 掲載の参考文献
1) Richardson PG, Perrot A, San-Miguel J, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM) : follow-up analysis of a randomised, phase 3 study. Lancet Oncol. 2022 ; 23 : 416-27.
PubMed
2) Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM) : a randomised, multicentre, open-label, phase 3 study. Lancet. 2019 ; 394 : 2096-107.
 
3) Dimopoulos MA, Terpos E, Boccadoro M, et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO) : an open-label, randomised, phase 3 trial. Lancet Oncol. 2021 ; 22 : 801-12.
PubMed
4) Siegel DS, Schiller GJ, Samaras C, et al. Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment. Leukemia. 2020 ; 34 : 3286-97.
PubMed
5) Moreau P, Dimopoulos MA, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA) : a multicentre, open-label, randomised phase 3 trial. Lancet. 2021 ; 397 : 2361-71.
PubMed
6) Dimopoulos M, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR) : results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020 ; 396 : 186-97.
 
7) Usmani SZ, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR) : updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol. 2022 ; 23 : 65-76.
 
8) Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021 ; 384 : 705-16.
PubMed
9) Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1) : a phase 1b/2 open-label study. Lancet. 2021 ; 398 : 314-24.
PubMed
10) Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma : CARTITUDE-1 2-year follow-up. J Clin Oncol. 2022 Jun 4.
PubMed
P.415 掲載の参考文献
1) McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma : a meta-analysis. J Clin Oncol. 2017 ; 35 : 3279-89.
PubMed
2) Goel U, Usmani S, Kumar S. Current approaches to management of newly diagnosed multiple myeloma. Am J Hematol. 2022 ; 97 Suppl 1 : S3-25.
 
3) Caro J, Al Hadidi S, Usmani S, et al. How to treat high-risk myeloma at diagnosis and relapse. Am Soc Clin Oncol Educ Book. 2021 ; 41 : 291-309.
PubMed
4) Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma : a review. JAMA. 2022 ; 327 : 464-77.
PubMed
5) Jackson GH, Davies FE, Pawlyn C, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI) : a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019 ; 20 : 57-73.
 
6) Dimopoulos MA, Spicka I, Quach H, et al. Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation : the phase III TOURMALINE-MM4 trial. J Clin Oncol. 2020 ; 38 : 4030-41.
PubMed
7) Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018 ; 378 : 518-28.
PubMed
8) Mateos MV, Cavo M, Blade J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE) : a randomised, open-label, phase 3 trial. Lancet. 2020 ; 395 : 132-41.
PubMed
9) McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012 ; 366 : 1770-81.
PubMed
10) Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012 ; 366 : 1759-69.
PubMed
11) Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014 ; 371 : 895-905.
PubMed
12) Dimopoulos MA, Gay F, Schjesvold F, et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3) : a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2019 ; 393 : 253-64.
PubMed
13) Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma : results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol. 2012 ; 30 : 2946-55.
 
14) Attal M, Palumbo A, Holstein SA, et al. Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM) : A meta-analysis (MA) of overall survival (OS). J Clin Oncol. 2016 ; 34.15_suppl : 8001.
 
P.420 掲載の参考文献
1) Casneuf T, Adams HC 3rd, van de Donk NWCJ, et al. Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab. Leukemia. 2021 ; 35 : 573-84.
PubMed
2) Avery DT, Kalled SL, Ellyard JI, et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest. 2003 ; 112 : 286-97.
PubMed
3) O'Connor BP, Raman VS, Erickson LD, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 2004 ; 199 : 91-8.
PubMed
4) Cho SF, Anderson KC, Tai YT. Targeting B Cell Maturation Antigen (BCMA) in multiple myeloma : potential uses of BCMA-based immunotherapy. Front Immunol. 2018 ; 9 : 1821.
PubMed
5) Carpenter RO, Evbuomwan MO, Pittaluga S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013 ; 19 : 2048-60.
 
6) Munshi NC, Anderson LD, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021 ; 384 : 705-16.
PubMed
7) Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma : CARTITUDE-1 2-year follow-up. J Clin Oncol. 2022. doi : 10.1200/JCO.22.00842.
 
8) Shah N, Munshi NC, Berdeja JG, et al. Baseline correlates of complete response to idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy in patients with relapsed and refractory multiple myeloma : subanalysis of the KarMMa trial. Blood. 2021 ; 138 (Suppl 1) : 1739.
 
9) Pont MJ, Hill T, Cole GO, et al. γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood. 2019 ; 134 : 1585-97.
 
10) Da Via MC, Dietrich O, Truger M, et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat Med. 2021 ; 27 : 616-9.
 
11) Metelo AM, Jozwik A, Luong LA, et al. Allogeneic anti-BCMA CAR T cells are superior to multiple myeloma-derived CAR T cells in preclinical studies and may be combined with gamma secretase inhibitors. Cancer Res Commun. 2022 : 2 : 159-71.
 
12) Depil S, Duchateau P, Grupp SA, et al'. Off-the-shelf'allogeneic CAR T cells : development and challenges. Nat Rev Drug Discov. 2020 ; 19 : 185-99.
 
13) Hayden PJ, Roddie C, Bader P, et al. Management of adults and children receiving CAR T-cell therapy : 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. 2022 ; 33 : 259-75.
PubMed
14) Martin T, Usmani SZ, Schecter JM, et al. Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Curr Med Res Opin. 2021 ; 37 : 1779-88.
 
15) Topp MS, Duell J, Zugmaier G, et al. Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma. J Clin Oncol. 2020 ; 38 : 775-83.
PubMed
16) Moreau P, Usmani SZ, Garfall AL, et al. Updated results from MajesTEC-1 : phase 1/2 study of teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in relapsed/refractory multiple myeloma. Blood. 2021 ; 138 (Suppl 1) : 896.
 
P.427 掲載の参考文献
1) フレイルに関する日本老年医学会からのステートメント. 日本老年医学会.
 
2) Wildiers H, Heeren P, Puts M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014 ; 32 : 2595-603.
 
3) Palumbo A, Bringhen S, Mateos MV, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients : an International Myeloma Working Group report. Blood. 2015 ; 125 : 2068-74.
 
4) Facon T, Dimopoulos MA, Meuleman N, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia. 2020 ; 34 : 224-33.
PubMed
5) Engelhardt M, Domm AS, Dold SM, et al. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica. 2017 ; 102 : 910-21.
 
6) Stege CAM, Nasserinejad K, van der Spek E, et al. Ixazomib, daratumumab, and low-dose dexamethasone in frail patients with newly diagnosed multiple myeloma : The Hovon 143 Study. J Clin Oncol. 2021 ; 39 : 2758-67.
PubMed
7) Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012 ; 366 : 1759-69.
PubMed
8) Facon T, Cook G, Usmani SZ, et al. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma : frailty subgroup analysis of MAIA. Leukemia. 2022 ; 36 : 1066-77.
PubMed
9) Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019 ; 380 : 2104-15.
PubMed
10) Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018 ; 378 : 518-28.
PubMed
11) Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in transplant-ineligible newly diagnosed multiple myeloma : frailty subgroup analysis of ALCYONE. Clin Lymphoma Myeloma Leuk. 2021 ; 21 : 785-98.
PubMed
12) Older Adult Oncology. In Version 1. 2022 Edition. NCCN Clinical Guidelines in Oncology. 2022.
 
P.431 掲載の参考文献
1) 難病情報センターホームページ. https://www.nanbyou.or.jp/entry/45
 
2) Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL) : a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol. 2005 ; 79 : 319-28.
PubMed
3) Sidiqi MH, Aljama MA, Buadi FK, et al. Stem cell transplantation for light chain amyloidosis : decreased early mortality over time. J Clin Oncol. 2018 ; 36 : 1323-9.
PubMed
4) NCCN Guidelines. https://www.nccn.org/guidelines/guidelines/detail?category=1&id=1467
 
5) Kastritis E, Leleu X, Arnulf B, et al. Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis. J Clin Oncol. 2020 ; 38 : 3252-60.
PubMed
6) Wechalekar AD, Schonland SO, Kastritis E, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013 ; 121 : 3420-7.
PubMed
7) Kastritis E, Palladini G, Minnema MC, et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021 ; 385 : 46-58.
PubMed
8) Afrough A, Saliba RM, Hamdi A, et al. Impact of induction therapy on the outcome of immunoglobulin light chain amyloidosis after autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2018 ; 24 : 2197-203.
PubMed
9) Cornell RF, Fraser R, Costa L, et al. Bortezomib-based induction is associated with superior outcomes in light chain amyloidosis patients treated with autologous hematopoietic cell transplantation regardless of plasma cell burden. Transplant Cell Ther. 2021 ; 27 : 264.e1-264.e7.
 
P.436 掲載の参考文献
1) Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours : lymphoid neoplasms. Leukemia. 2022 ; 36 : 1720-48.
PubMed
2) Ravi G, Kapoor P. Current approach to Waldenstrom macroglobulinemia. Cancer Treat Res Commun. 2022 ; 31 : 100527.
PubMed
3) Sermer D, Sarosiek S, Branagan AR, et al. Targeted therapies and emerging novel treatment approaches for Waldenstrom macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2022 ; 22 : 547-56.
PubMed
4) Varettoni M, Arcaini L, Zibellini S, et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms. Blood. 2013 ; 121 : 2522-8.
PubMed
5) Treon SP, Cao Y, Xu L, et al. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood. 2014 ; 123 : 2791-6.
PubMed
6) Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia : consensus panel recommendations from the second international workshop on Waldenstrom's macroglobulinemia. Semin Oncol. 2003 ; 30 : 116-20.
PubMed
7) Dimopoulos MA, Kastritis E. How I treat Waldenstrom macroglobulinemia. Blood. 2019 ; 134 : 2022-35.
 
8) Pratt G, El-Sharkawi D, Kothari J, et al. Diagnosis and management of Waldenstrom macroglobulinaemia-A British Society for Haematology guideline. Br J Haematol. 2022 ; 197 : 171-87.
PubMed
9) 日本血液学会. 造血器腫瘍診療ガイドライン (2018年度補訂版).
 
10) 日本骨髄腫学会, 編. 多発性骨髄腫の診療指針 第5版. 東京 : 文光堂 ; 2020.
 
11) Zanwar S, Abeykoon JP, Ansell SM, et al. Primary systemic amyloidosis in patients with Waldenstrom macroglobulinemia. Leukemia. 2019 ; 33 : 790-94.
PubMed
12) Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009 ; 113 : 4163-70.
PubMed
13) Kastritis E, Morel P, Duhamel A, et al. A revised international prognostic score system for Waldenstrom's macroglobulinemia. Leukemia. 2019 ; 33 : 2654-61.
 
14) Owen RG, Kyle RA, Stone MJ, et al ; VIth International Workshop on Waldenstrom macroglobulinaemia. Response assessment in Waldenstrom macroglobulinaemia : update from the VIth International Workshop. Br J Haematol. 2013 ; 160 : 171-6.
PubMed
15) Rummel MJ, Niederle N, Maschmeyer G, et al ; Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas : an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013 ; 381 : 1203-10.
 
16) Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol. 2007 ; 25 : 3344-9.
PubMed
17) Kastritis E, Gavriatopoulou M, Kyrtsonis MC, et al. Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia : final analysis of a phase 2 study. Blood. 2015 ; 126 : 1392-4.
PubMed
18) Dimopoulos MA, Garcia-Sanz R, Gavriatopoulou M, et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR) : long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood. 2013 ; 122 : 3276-82.
PubMed
19) Gavriatopoulou M, Garcia-Sanz R, Kastritis E, et al. BDR in newly diagnosed patients with WM : final analysis of a phase 2 study after a minimum follow-up of 6 years. Blood. 2017 ; 129 : 456-9.
PubMed
20) Sekiguchi N, Rai S, Munakata W, et al. A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenstrom's macroglobulinemia. Cancer Sci. 2020 ; 111 : 3327-37.
PubMed
21) Sekiguchi N, Rai S, Munakata W et al. Two-year outcomes of tirabrutinib monotherapy in Waldenstrom's macroglobulinemia. Cancer Sci. 2022 Mar 25. Epub ahead of print.
 
22) Treon SP, Gustine J, Meid K, et al. Ibrutinib monotherapy in symptomatic, treatment-naive patients with Waldenstrom macroglobulinemia. J Clin Oncol. 2018 ; 36 : 2755-61.
PubMed
23) Dimopoulos MA, Tedeschi A, Trotman J, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenstrom's macroglobulinemia. N Engl J Med. 2018 ; 378 : 2399-410.
PubMed
P.442 掲載の参考文献
1) Dispenzieri A. POEMS syndrome : 2021 Update on diagnosis, risk-stratification, and management. Am J Hematol. 2021 ; 96 : 872-88.
PubMed
2) Watanabe O, Arimura K, Kitajima I, et al. Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome. Lancet. 1996 ; 347 : 702.
PubMed
3) Dispenzieri A. POEMS syndrome : 2017 Update on diagnosis, risk stratification, and management. Am J Hematol. 2017 ; 92 : 814-29.
PubMed
4) Misawa S, Sato Y, Katayama K, et al. Safety and efficacy of thalidomide in patients with POEMS syndrome : a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2016 ; 15 : 1129-37.
PubMed
5) Ohwada C, Sakaida E, Kawajiri-Manako C, et al. Long-term evaluation of physical improvement and survival of autologous stem cell transplantation in POEMS syndrome. Blood. 2018 ; 131 : 2173-6.
PubMed
6) Li J, Huang XF, Cai QQ, et al. A prospective phase II study of low dose lenalidomide plus dexamethasone in patients with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome. Am J Hematol. 2018 ; 93 : 803-9.
 
7) Zhao H, Huang XF, Gao XM, et al. What is the best first-line treatment for POEMS syndrome : autologous transplantation, melphalan and dexamethasone, or lenalidomide and dexamethasone? Leukemia. 2019 ; 33 : 1023-9.
PubMed
8) Gao XM, Yu YY, Zhao H, et al. Bortezomib plus dexamethasone as first-line therapy for patients with POEMS syndrome. Ann Hematol. 2021 ; 100 : 2755-61.
PubMed
9) Kawajiri-Manako C, Sakaida E, Ohwada C, et al. Efficacy and long-term outcomes of autologous stem cell transplantation in POEMS syndrome : a nationwide survey in Japan. Biol Blood Marrow Transplant. 2018 ; 24 : 1180-6.
PubMed
10) D'Souza A, Lacy M, Gertz M, et al. Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma) : a single-center experience. Blood. 2012 ; 120 : 56-62.
PubMed
11) Dispenzieri A, Lacy MQ, Hayman SR, et al. Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome. Eur J Haematol. 2008 ; 80 : 397-406.
PubMed
P.448 掲載の参考文献
1) Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer. 1956 ; 9 : 822-30.
PubMed
2) 川端浩, 藤本信乃, 正木康史. TAFRO症候群の診断と治療. In : 木崎昌弘, 他編. EBM血液疾患の治療 2021-2022. 東京 ; 中外医学社 ; 2021. p.451-5.
 
3) 矢野真吾, 青木定夫, 石垣靖人, 他. キャッスルマン病診療ガイドライン (令和2年度初版). 2020. https://castleman.jp/index.html
 
4) Hassman LM, Ellison TJ, Kedes DH. KSHV infects a subset of human tonsillar B cells, driving proliferation and plasmablast differentiation. J Clin Invest. 2011 ; 121 : 752-68.
PubMed
5) 日本血液学会. 造血器腫瘍診療ガイドライン 2018年版. 東京 : 金原出版 ; 2018.
 
6) Dispenzieri A. POEMS Syndrome : 2019 Update on diagnosis, risk-stratification, and management. Am J Hematol. 2019 ; 94 : 812-27.
PubMed
7) Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017 ; 129 : 1646-57.
PubMed
8) 中外製薬. アクテムラ全例調査の中間報告 (キャッスルマン病). 2014. http://www.jshem.or.jp/uploads/files/former/20140909-castleman.pdf
 
9) Bower M, Powles T, Williams S, et al. Brief communication : rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med. 2007 ; 147 : 836-9.
PubMed
10) Gerard L, Berezne A, Galicier L, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease : ANRS 117 CastlemaB Trial. J Clin Oncol. 2007 ; 25 : 3350-6.
 
11) Bower M, Newsom-Davis T, Naresh K, et al. Clinical features and outcome in HIV-associated multicentric Castleman's disease. J Clin Oncol. 2011 ; 29 : 2481-6.
PubMed
12) Lurain K, Yarchoan R and Uldrick TS. Treatment of Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Hematol Oncol Clin North Am. 2018 ; 32 : 75-88.
PubMed
13) van Rhee F, Oksenhendler E, Srkalovic G, et al. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. Blood Adv. 2020 ; 4 : 6039-50.
PubMed
14) van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018 ; 132 : 2115-24.
PubMed
15) Talat N, Belgaumkar AP, Schulte KM. Surgery in Castleman's disease : a systematic review of 404 published cases. Ann Surg. 2012 ; 255 : 677-84.
PubMed
16) Uldrick TS, Polizzotto MN, Aleman K, et al. High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease : a pilot study of virus-activated cytotoxic therapy. Blood. 2011 ; 117 : 6977-86.
PubMed
17) Uldrick TS, Polizzotto MN, Aleman K, et al. Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease. Blood. 2014 ; 124 : 3544-52.
PubMed
18) Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005 ; 106 : 2627-32.
PubMed
19) van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman's disease : a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014 ; 15 : 966-74.
PubMed
20) van Rhee F, Casper C, Voorhees PM, et al. Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease : a prespecified, open-label, extension analysis of two trials. Lancet Haematol. 2020 ; 7 : e209-17.
PubMed
21) Fajgenbaum DC, Langan RA, Japp AS, et al. Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. J Clin Invest. 2019 ; 129 : 4451-63.
PubMed
P.454 掲載の参考文献
1) Fernandez de Larrea C, Kyle R, et al. Primary plasma cell leukemia : consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer J. 2021 ; 11 : 192
 
2) Gonsalves WI, Rajkumar SV, Go RS, et al. Trends in survival of patients with primary plasma cell leukemia : a population-based analysis. Blood. 2014 ; 124 : 907-12.
PubMed
3) Nandakumar B, Kumar SK, Dispenzieri A, et al. Clinical characteristics and outcomes of patients with primary plasma cell leukemia in the era of novel agent therapy. Mayo Clin Proc. 2021 ; 96 : 677-87.
PubMed
4) Van De Donk NWCJ, van der Holt B, Schjesvold FH, et al. Treatment of primary plasma cell leukemia with carfilzomib and lenalidomide-based therapy : results of the first interim analysis of the phase 2 EMN12/HOVON129 Study. Blood. 2019 ; 134 (suppl 1) : 693.
 
5) Gowda L, Shah M, Badar I, et al. Primary plasma cell leukemia : autologous stem cell transplant in an era of novel induction drugs. Bone Marrow Transplant. 2019 ; 54 ; 1089-93.
 
6) Dhakal B, Patel S, Girnius S, et al. Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia. 2020 ; 34 : 3338-47.
PubMed
7) Mina R, Joseph NS, Kaufman JL, et al. Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. Cancer. 2019 ; 125 ; 416-23.
PubMed
8) Lemieux C, Johnston LJ, Lowsky R, et al. Outcomes with autologous or allogeneic stem cell transplantation in patients with plasma cell leukemia in the era of novel agents. Biol Blood Marrow Transplant. 2020 ; 26 : e328-32.
 
9) Parrondo RD, Moustafa MA, Reeder C, et al. Efficacy of daratumumab-based regimens for the treatment of plasma cell leukemia. Clin Lymph Myeloma Leuk. 2021 ; 21 : 355-60.
 
P.456 掲載の参考文献
1) Furukawa Y, Kikuchi J. Molecular basis of clonal evolution in multiple myeloma. Int J Hematol. 2020 ; 111 : 496-511.
PubMed
2) 古川雄祐, 菊池次郎. 多発性骨髄腫 (MM) の分子病態研究の進歩. EBM血液疾患の治療 2021-2022. 東京 : 中外医学社 ; 2020. p.378-85.
 
3) Ledergor G, Weiner A, Zada M, et al. Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. Nat Med. 2018 ; 24 : 1867-76.
PubMed
4) Cohen YC, Zada M, Wang S-Y, et al. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nat Med. 2021 ; 27 : 491-503.
PubMed
5) Frede J, Anand P, Sotudeh N, et al. Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma. Nat Cell Biol. 2021 ; 23 : 1199-211.
PubMed
6) Visram A, Dasari S, Anderson E, et al. Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression. Blood Cancer J. 2021 ; 11 : 45.
PubMed
7) Zavidij O, Haradhvala NJ, Mouhieddine TH, et al. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat Cancer. 2020 ; 1 : 493-506.
PubMed
8) Liu R, Gao Q, Foltz SM, et al. Co-evolution of tumor and immune cells during progression of multiple myeloma. Nat Commun. 2021 ; 12 : 2559.
 
9) Tirier SM, Mallm JP, Steiger S, et al. Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics. Nat Commun. 2021 ; 12 : 6960.
PubMed
10) de Jong MME, Kellermayer Z, Papazian N, et al. The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape. Nat Immunol. 2021 ; 22 : 769-80.
PubMed
P.459 掲載の参考文献
1) Munshi NC, Anderson Jr LD, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021 ; 384 : 705-16.
PubMed
2) Berdeja J, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel. A B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple mieloma (CARTITUDE-1) : a phase 1b/2 open-label study. Lancet. 2021 ; 398 : 314-24.
 
3) Hosen N, Matsunaga Y, Hasegawa K, et al. The activated conformation of integrin β7 is a novel multiple myeloma-specific target for CAR T cell therapy. Nat Med. 2017 ; 23 : 1436-43.
 
4) Usmani SZ, Garfall AL, van de Donk NWC, et al. Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1) : a multicenter, open-label, single-arm, phase 1 study. Lancet. 2021 ; 398 : 665-74.
 
5) Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2) : a two-arm, randomized, open-label, phase 2 study. Lancet Oncol. 2020 ; 21 : 207-21.
 
6) Kumar SK, Harrison SJ, Cavo M, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI) : a randomized, double-blind, multicenter, phase 3 trial. Lancet Oncol. 2020 ; 21 : 1630-42.
 
7) Bjoklund CC, Kang Jm Amatangelo M, et al. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN. Leukemia. 2020 ; 34 : 1197-201.
 

VI. 出血・血栓性疾患

P.465 掲載の参考文献
1) Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children : report from an international working group. Blood. 2009 ; 113 : 2386-93.
 
2) https://www.shouman.jp/disease/details/09_13_023/ (アクセス2022/05/03)
 
3) https://www.nanbyou.or.jp/entry/303 (アクセス2022/05/03)
 
4) Kuwana M, Kurata Y, Fujimura K, et al. Preliminary laboratory based diagnostic criteria for immune thrombocytopenic purpura : evaluation by multi-center prospective study. J Thromb Haemost. 2006 ; 4 : 1936-43.
PubMed
5) Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019 ; 3 : 3829-66.
PubMed
6) Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019 ; 3 : 3780-817.
PubMed
7) 柏木浩和, 桑名正隆, 羽藤高明, 他 ; 厚生労働省難治性疾患政策研究事業 血液凝固異常症等に関する研究班「ITP治療の参照ガイド」作成委員会. 成人特発性血小板減少性紫斑病治療の参照ガイド 2019 改訂版. 臨血. 2019 ; 60 : 877-96.
 
8) Cantoni S, Carpenedo M, Mazzucconi MG, et al. Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients : A retrospective collaborative survey from Italian hematology centers. Am J Hematol. 2018 ; 93 : 58-64.
PubMed
9) Lucchini E, Palandri F, Volpetti S, et al. Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment : results of a phase II, multicentre, prospective study. Br J Haematol. 2021 ; 193 : 386-96.
 
P.469 掲載の参考文献
1) 厚生労働科学研究費補助金 (難治性疾患政策研究事業) 「血液凝固異常症等に関する研究」班. 血栓性血小板減少性紫斑病 (TTP) 診療ガイド 2020.
 
2) Zheng XL, Vesely SK, Cataland SR, et al. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020 ; 18 : 2496-502.
PubMed
3) 宮川義隆. TTP診療の最前線. 臨床血液. 2020 ; 61 : 1331-7.
 
4) Miyakawa Y, Imada K, Ichinohe T, et al. Efficacy and safety of rituximab in Japanese patients with acquired thrombotic thrombocytopenic purpura refractory to conventional therapy. Int J Hematol. 2016 ; 104 : 228-35.
PubMed
5) Scully M, Cataland SR, Peyvandi F, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019 ; 380 : 335-46.
PubMed
6) Coppo P, Bubenheim M, Azoulay E, et al. A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. Blood. 2021 ; 137 : 733-42.
PubMed
P.473 掲載の参考文献
1) 藤井輝久, 天野景裕, 渥美達也, 他. インヒビターのない血友病患者の止血治療ガイドライン : 2013年改訂版. 血栓止血誌. 2013 ; 24 : 619-39.
 
2) 酒井道生, 瀧 正志, 家子正裕, 他. インヒビター保有先天性血友病患者に対する止血治療ガイドライン : 2013年改訂版. 血栓止血誌. 2013 ; 24 : 640-58.
 
3) Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020 ; 26 Suppl 6 : 1-158.
 
4) Shapiro AD, Angchaisuksiri P, Astermark J, et al. Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors : phase 2 trial results. Blood. 2019 28 ; 134 : 1973-82.
 
5) Pasi KJ, Rangarajan S, Georgiev P, et al. Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy. N Engl J Med. 2017 ; 377 : 819-28.
PubMed
6) Warren BB, Thornhill D, Stein J, et al. Young adult outcomes of childhood prophylaxis for severe hemophilia A : results of the Joint Outcome Continuation Study. Blood Adv. 2020 ; 4 : 2451-9.
PubMed
7) Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007 ; 357 : 535-44.
PubMed
8) Oldenburg J, Mahlangu J, Kim B, et al. Emicizumab prophylaxis in hemophilia a with inhibitors. N Engl J Med. 2017 ; 377 : 809-18.
PubMed
9) Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia a without inhibitors. N Engl J Med. 2018 ; 379 : 811-22.
PubMed
10) Carcao MD, Chelle P, Clarke E, et al. Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A : Is there a difference? J Thromb Haemost. 2019 ; 17 : 1085-96.
 
11) Pasi J, Hermans C, Hakimi Z, et al. Improvement in pain-related quality of life in patients with hemophilia A treated with rFVIIIFc individualized prophylaxis : post hoc analysis from the A-LONG study. Ther Adv Hematol. 2022 ; 13 : 1-9.
 
12) Hoefnagels JW, Schrijvers LH, Leebeek FWG, et al. Adherence to prophylaxis and its association with activation of self-management and treatment satisfaction. Haemophilia. 2021 ; 27 : 581-90.
PubMed
P.478 掲載の参考文献
1) Nichols WL, Hultin MB, James AH. von Willebrand disease (VWD) : evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia. 2008 ; 14 : 171-232.
 
2) Sadler JE. Biochemistry and genetics of von Willebrand factor. Ann Rev Biochemistry. 1998 ; 67 : 395-424.
 
3) 日笠聡, 渥美達, 石黒精, 他. von Willebrand 病の診療ガイドライン 2021年版. 日本血栓止血学会誌. 2021 ; 32 : 413-81.
 
4) Federici AB. The use of desmopressin in von Willebrand disease : the experience of the first 30 years (1977-2007). Haemophilia. 2008 ; 14 Suppl 1 : 5-14.
 
5) Favaloro EJ, Pasalic L, Curnow J. Monitoring therapy during treatment of von Willebrand disease. Semin Thromb Hemost. 2017 ; 43 : 338-54.
PubMed
6) Mannucci PM, Franchini M, Castaman G, et al. Evidence-based recommendations on the treatment of von Willebrand disease in Italy. Blood Transfus. 2009 ; 7 : 117-26.
PubMed
7) Castaman G, Goodeve A, Eikenboom J. Principles of care for the diagnosis and treatment of von Willebrand disease. Haematologica. 2013 ; 98 : 667-74.
PubMed
8) Laffan MA, Lester W, O'Donnell JS, et al. The diagnosis and management of von Willebrand disease : a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol. 2014 ; 167 : 453-65.
PubMed
9) James PD, Connell NT, Ameer B, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv. 2021 ; 5 : 280-300.
PubMed
10) Connell NT, Flood VH, Brignardello-Petersen R, et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv. 2021 ; 5 : 301-25.
PubMed
P.483 掲載の参考文献
1) Collins PW, Hirsch S, Baglin TP, et al. Acquired hemophilia A in the United Kingdom : a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood. 2007 ; 109 : 1870-7.
PubMed
2) Knoebl P, Marco P, Baudo F, et al. Demographic and clinical data in acquired hemophilia A : results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost. 2012 ; 10 : 622-31.
PubMed
3) 酒井道生, 天野景裕, 小川孔幸, 他. 後天性血友病A診療ガイドライン 2017年改訂版. 血栓止血誌. 2017 ; 28 : 715-47.
 
4) Bando F, Collins P, Huth-Kuehne A, et al. Management of bleeding in acquired hemophilia A : results from the European Acquired Haemophilia (EACH2) Registry. Blood. 2012 ; 120 : 39-46.
 
5) Collins P, Baudo F, Knoebl P, et al. Immunosuppression for acquired hemophilia A : results from the European Acquired Haemophilia Registry (EACH2). Blood. 2012 ; 120 : 47-55.
PubMed
6) Trossaert M, Graveleau J, Voisin S, et al. The factor VIII : C/VWF : Ag ratio as a useful tool to predict relapse in patients with acquired haemophilia A : A retrospective cohort study. Haemophilia. 2019 ; 25 : 527-34.
PubMed
7) Takeyama M, Sasai K, Matsumoto T, et al. Comprehensive blood coagulation potential in patients with acquired hemophilia A ; retrospective analyses of plasma samples obtained from nationwide centers across Japan. Int J Hematol. 2022 ; 115 : 163-72.
PubMed
8) Kruse-Jarres R, St-Louis J, Greist A, et al. Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia. 2015 ; 21 : 162-70.
PubMed
9) Takeyama M, Furukawa S, Yada K, et al. Ex vivo prediction of comprehensive coagulation potential using simulated blood concentrations of emicizumab in patients with acquired hemophilia A. Thromb Haemost. 2021 ; 121 : 1289-98.
PubMed
10) Zanon E, Pasca S, Santoro C, et al. Activated prothrombin complex concentrate (FEIBA) in acquired haemophilia A : a large multicentre Italian study-the FAIR Registry. Br J Haematol. 2019 ; 184 ; 853-5.
 
11) Tiede A, Klamroth R, Scharf RE, et al. Prognostic factors for remission of and survival in acquired hemophilia A (AHA) : results from the GTH-AH 01/2010 study. Blood. 2015 ; 125 : 1091-7.
PubMed
P.489 掲載の参考文献
1) 朝倉英策. 止血の生理と血栓の病態. In : 朝倉英策, 編 臨床に直結する血栓止血学 改訂2版 東京 : 中外医学社 ; 2018. p.2-11.
 
2) 朝倉英策. 血栓症. しみじみわかる血栓止血 vol. 2 血栓症・抗血栓療法編. 中外医学社 ; 2014. p.2-129.
 
3) Hayashi T, Nakagawa N, Asakura H, et al. Rivaroxaban in a patient with disseminated intravascular coagulation associated with an aortic aneurysm : a case report. Ann Intern Med. 2014 ; 161 : 158-9.
 
4) Kadohira Y, Yamada S, Asakura H, et al. Aortic aneurysm-associated disseminated intravascular coagulation that responded well to a switch from warfarin to rivaroxaban. Intern Med. 2017 ; 56 : 2913-7.
PubMed
5) Yamada S, Asakura H. Management of disseminated intravascular coagulation associated with aortic aneurysm and vascular malformations. Int J Hematol. 2021 ; 113 : 15-23.
PubMed
6) Yamada S, Asakura H. Therapeutic strategies for disseminated intravascular coagulation associated with aortic aneurysm. Int J Mol Sci. 2022 ; 23 : 1296.
PubMed
7) Weitz JI, Strony J, Ageno W, et al. Milvexian for the prevention of venous thromboembolism. N Engl J Med. 2021 ; 385 : 2161-72.
PubMed
8) Verhamme P, Yi BA, Segers A, et al. Abelacimab for prevention of venous thromboembolism. N Engl J Med. 2021 ; 385 : 609-17.
PubMed
9) Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020 ; 382 : 1599-607.
PubMed
10) Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018 ; 378 : 615-24.
PubMed
11) Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism : results of a randomized trial (SELECT-D). J Clin Oncol. 2018 ; 36 : 2017-23.
 
P.495 掲載の参考文献
1) Ikezoe T. Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies. Int J Hematol. 2021 ; 113 : 34-44.
PubMed
2) Jacomo RH, Melo RA, Souto FR, et al. Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica. 2007 ; 92 : 1431-2.
PubMed
3) Lehmann S, Ravn A, Carlsson L, et al. Continuing high early death rate in acute promyelocytic leukemia : a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia. 2011 ; 25 : 1128-34.
PubMed
4) Park JH, Qiao B, Panageas KS, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood. 2011 ; 118 : 1248-54.
PubMed
5) de la Serna J, Montesinos P, Vellenga E, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood. 2008 ; 111 : 3395-402.
PubMed
6) Breccia M, Avvisati G, Latagliata R, et al. Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features. Leukemia. 2007 ; 21 : 79-83.
PubMed
7) Lavallee VP, Chagraoui J, MacRae T, et al. Transcriptomic landscape of acute promyelocytic leukemia reveals aberrant surface expression of the platelet aggregation agonist Podoplanin. Leukemia. 2018 ; 32 : 1349-57.
PubMed
8) Sanz MA, Fenaux P, Tallman MS, et al. Management of acute promyelocytic leukemia : updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019 ; 133 : 1630-43.
 
9) Umemura Y, Yamakawa K, Ogura H, et al. Efficacy and safety of anticoagulant therapy in three specific populations with sepsis : a meta-analysis of randomized controlled trials. J Thromb Haemost. 2016 ; 14 : 518-30.
PubMed
10) 日本版敗血症診療ガイドライン. https://www.jsicm.org/pdf/jjsicm28Suppl.pdf
 
11) Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation : results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007 ; 5 : 31-41.
PubMed
12) Ikezoe T, Takeuchi A, Isaka M, et al. Recombinant human soluble thrombomodulin safely and effectively rescues acute promyelocytic leukemia patients from disseminated intravascular coagulation. Leuk Res. 2012 ; 36 : 1398-402.
PubMed
13) Kawano N, Kuriyama T, Yoshida S, et al. Clinical features and treatment outcomes of six patients with disseminated intravascular coagulation resulting from acute promyelocytic leukemia and treated with recombinant human soluble thrombomodulin at a single institution. Intern Med. 2013 ; 52 : 55-62.
 
14) Matsushita T, Watanabe J, Honda G, et al. Thrombomodulin alfa treatment in patients with acute promyelocytic leukemia and disseminated intravascular coagulation : A retrospective analysis of an open-label, multicenter, post-marketing surveillance study cohort. Thromb Res. 2014 ; 133 : 772-81.
PubMed
15) Hashimoto S, Koike T, Tatewaki W, et al. Fatal thromboembolism in acute promyelocytic leukemia during all-trans retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage. Leukemia. 1994 ; 8 : 1113-5.
PubMed
16) Yokoyama H, Takahashi N, Katsuoka Y, et al. Evaluation of the safety and efficacy of recombinant soluble thrombomodulin for patients with disseminated intravascular coagulation associated with acute leukemia : multicenter prospective study by the Tohoku Hematology Forum. Int J Hematol. 2017 ; 105 : 606-13.
PubMed
17) Minamiguchi H, Fujita H, Atsuta Y, et al. Japan Adult Leukemia Study Group. Predictors of early death, serious hemorrhage, and differentiation syndrome in Japanese patients with acute promyelocytic leukemia. Ann Hematol. 2020 ; 99 : 2787-800.
 
18) Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997 ; 337 : 1021-8.
PubMed
19) de la Serna J, Montesinos P, Vellenga E, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood. 2008 ; 111 : 3395-402.
PubMed
P.499 掲載の参考文献
1) Khorana AA. Venous thromboembolism and prognosis in cancer. Thromb Res. 2010 ; 125 : 490-3.
PubMed
2) Mukai M, Oka T. Mechanism and management of cancer-associated thrombosis. J Cardiol. 2018 ; 72 : 89-93.
PubMed
3) Falanga A, Marchetti M, Russo L. The mechanisms of cancer-associated thrombosis. Thromb Res. 2015 ; 135 : S8-11.
PubMed
4) Eichinger S. Cancer associated thrombosis : risk factors and outcomes. Thromb Res. 2016 ; 140 : S12-7.
PubMed
5) Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008 ; 111 : 4902-7.
PubMed
6) 窓岩清治. カラー図説 : がん関連血栓症 (CAT) の機序と病態. 日本臨牀. 2020 ; 78 : 1428-35.
Medical*Online
7) Varki A. Trousseau's syndrome : multiple definitions and multiple mechanisms. Blood. 2007 ; 110 : 1723-9.
PubMed
8) 日本循環器学会. 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2017年改訂版) (班長 : 伊藤正明).
 
9) 森山雅人. 凝固・抗凝固療法における臨床検査の活用. 臨床検査. 2021 ; 65 : 748-56.
 
P.502 掲載の参考文献
1) 小林隆夫, 森下英理子, 津田博子, 他. 遺伝性血栓性素因患者の妊娠分娩管理に関する診療の手引き Q&A. 日本産婦人科・新生児血液学会誌. 2021 ; 30 : 5-54.
Medical*Online
2) Kobayashi T, Morishita E, Tsuda H, et al. Clinical guidance for peripartum management of patients with hereditary thrombophilia. J Obstet Gynecol Res. 2021 ; 47 : 3008-33.
 

VII. 支持療法・輸血

P.508 掲載の参考文献
1) World Health A. Availability, safety and quality of blood products. Geneva : World Health Organization ; 2010.
 
2) Leahy MF, Hofmann A, Towler S, et al. Improved outcomes and reduced costs associated with a health-system-wide patient blood management program : a retrospective observational study in four major adult tertiary-care hospitals. Transfusion. 2017 ; 57 : 1347-58.
 
3) 高見昭良, 松下正, 緒方正男, 他. 科学的根拠に基づいた血小板製剤の使用ガイドライン 2019年改訂版. 日本輸血細胞治療学会誌. 2019 ; 65 : 544-61.
Medical*Online
4) 高見昭良, 松下正, 緒方正男, 他. 科学的根拠に基づいた血小板製剤の使用ガイドライン. 日本輸血細胞治療学会誌. 2017 ; 63 : 569-84.
Medical*Online
5) Newland A, Bentley R, Jakubowska A, et al. A systematic literature review on the use of platelet transfusions in patients with thrombocytopenia. Hematology (Amsterdam, Netherlands). 2019 ; 24 : 679-719.
 
6) 松下正, 長谷川雄一, 玉井佳子, 他. 科学的根拠に基づいた新鮮凍結血漿 (FFP) の使用ガイドライン [改訂第2版]. 日本輸血細胞治療学会誌. 2019 ; 65 : 525-37.
Medical*Online
7) 松下正, 長谷川雄一, 玉井佳子, 他. 科学的根拠に基づいた新鮮凍結血漿 (FFP) の使用ガイドライン. 日本輸血細胞治療学会誌. 2017 ; 63 : 561-8.
Medical*Online
8) 宮田茂樹, 板倉敦夫, 上田裕一, 他. 大量出血症例に対する血液製剤の適正な使用のガイドライン. 日本輸血細胞治療学会誌. 2019 ; 65 : 21-92.
Medical*Online
9) 米村雄士, 松本雅則, 稲田英一, 他. 科学的根拠に基づいた赤血球製剤の使用ガイドライン (改訂第2版). 日本輸血細胞治療学会誌. 2018 ; 64 : 688-99.
Medical*Online
10) 米村雄士, 松本雅則, 稲田英一, 他. 科学的根拠に基づいた赤血球製剤の使用ガイドライン. 日本輸血細胞治療学会誌. 2016 ; 62 : 641-50.
Medical*Online
11) Holst LB, Petersen MW, Haase N, et al. Restrictive versus liberal transfusion strategy for red blood cell transfusion : systematic review of randomised trials with meta-analysis and trial sequential analysis. BMJ (Clinical research ed). 2015 ; 350 : h1354.
PubMed
12) Carson JL, Grossman BJ, Kleinman S, et al. Red blood cell transfusion : a clinical practice guideline from the AABB*. Ann Intern Med. 2012 ; 157 : 49-58.
PubMed
13) Hoeks MPA, Kranenburg FJ, Middelburg RA, et al. Impact of red blood cell transfusion strategies in haemato-oncological patients : a systematic review and meta-analysis. Br J Haematol. 2017 ; 178 : 137-51.
PubMed
14) Estcourt LJ, Malouf R, Trivella M, et al. Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support. The Cochrane database of systematic reviews. 2017 ; 1 (1) : CD011305.
 
15) Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med. 2013 ; 368 : 11-21.
PubMed
16) Jairath V, Kahan BC, Gray A, et al. Restrictive versus liberal blood transfusion for acute upper gastrointestinal bleeding (TRIGGER) : a pragmatic, open-label, cluster randomised feasibility trial. Lancet. 2015 ; 386 : 137-44.
PubMed
17) Bergamin FS, Almeida JP, Landoni G, et al. Liberal versus restrictive transfusion strategy in critically Ill oncologic patients : The transfusion requirements in critically Ill oncologic patients randomized controlled trial. Crit Care Med. 2017 ; 45 : 766-73.
 
18) Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N Engl J Med. 1997 ; 337 : 1870-5.
PubMed
P.514 掲載の参考文献
1) van den Akker TA, Grimes ZM, Friedman MT. Transfusion-associated circulatory overload and transfusion-related acute lung injury. Am J Clin Pathol. 2021 ; 156 : 529-39.
PubMed
2) Ferguson ND, Fan E, Camporota L, et al. The Berlin definition of ARDS : an expanded rationale, justification, and supplementary material. Intensive Care Med. 2012 ; 38 : 1573-82.
PubMed
3) Muller MCA, van Stein D, Binnekade JM, et al. Low-risk transfusion-related acute lung injury donor strategies and the impact on the onset of transfusion-related acute lung injury : a meta-analysis. Transfusion. 2015 ; 55 : 164-75.
PubMed
4) Tobian AAR, Sokoll LJ, Tisch DJ, et al. N-terminal pro-brain natriuretic peptide is a useful diagnostic marker for transfusion-associated circulatory overload. Transfusion. 2008 ; 48 : 1143-50.
PubMed
5) Kleinman SH, Triulzi DJ, Murphy EL, et al. The Leukocyte Antibody Prevalence Study-II (LAPS-II) : a retrospective cohort study of transfusion-related acute lung injury in recipients of high-plasma-volume human leukocyte antigen antibody-positive or-negative components. Transfusion. 2011 ; 51 : 2078-91.
PubMed
6) 田崎哲典, 岡崎 仁, 稲田英一, 他. TRALI, TACO鑑別診断のためのガイドライン. 日本輸血細胞治療学会誌. 2015 ; 61 : 474-9.
Medical*Online
7) 日本赤十字社. 日本赤十字社におけるTRALI 及びTACOの評価基準変更のお知らせ. 令和3年3月.
 
P.518 掲載の参考文献
1) Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer : 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011 ; 52 : e56-93.
 
2) Roberts JA, Paul SK, Akova M, et al. DALI : defining antibiotic levels in intensive care unit patients : are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014 ; 58 : 1072-83.
PubMed
3) Egi M, Ogura H, Yatabe T, et al. The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2020 (J-SSCG 2020). Acute Med Surg. 2021 ; 8 : e659.
PubMed
4) Averbuch D, Cordonnier C, Livermore DM, et al. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients : guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011). Haematologica. 2013 ; 98 : 1836-47.
PubMed
5) Kimura S, Oshima K, Sato K, et al. Retrospective evaluation of the area over the neutrophil curve index to predict early infection in hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2010 ; 16 : 1355-61.
PubMed
6) Albasanz-Puig A, Gudiol C, Puerta-Alcalde P, et al. Impact of the inclusion of an aminoglycoside to the initial empirical antibiotic therapy for gram-negative bloodstream infections in hematological neutropenic patients : a propensity-matched cohort study (AMINOLACTAM Study). Antimicrob Agents Chemother. 2021 ; 65 : e0004521.
 
7) Ram R, Halavy Y, Amit O, et al. Extended vs bolus infusion of broad-spectrum beta-lactams for febrile neutropenia : an unblinded, randomized trial. Clin Infect Dis. 2018 ; 67 : 1153-60.
PubMed
8) Aguilar-Guisado M, Espigado I, Martin-Pena A, et al. Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study) : an open-label, randomised, controlled phase 4 trial. Lancet Haematol. 2017 ; 4 : e573-83.
PubMed
9) Kanda Y, Kimura SI, Iino M, et al. D-index-guided early antifungal therapy versus empiric antifungal therapy for persistent febrile neutropenia : a randomized controlled noninferiority trial. J Clin Oncol. 2020 ; 38 : 815-22.
PubMed
10) Paul M, Dickstein Y, Schlesinger A, et al. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia. Cochrane Database Syst Rev. 2013 ; (6) : CD003038.
PubMed
11) Stern A, Carrara E, Bitterman R, et al. Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia resolution in people with cancer. Cochrane Database Syst Rev. 2019 ; 1 : CD012184.
PubMed
12) Tzouvelekis LS, Markogiannakis A, Psichogiou M, et al. Carbapenemases in klebsiella pneumoniae and other enterobacteriaceae : an evolving crisis of global dimensions. Clin Microbiol Rev. 2012 ; 25 : 682-707.
PubMed
P.523 掲載の参考文献
1) FDA Drug Development and Drug Interactions : Table of substrates, inhibitors and inducers (Table 3-2 examples of clinical inhibitors for P450-mediated metabolisms for concomitant use clinical DDI studies and/or drug labeling) (03/06/2020)
 
2) Lindsay J, Teh BW, Micklethwaite K, et al. Azole antifungals and new targeted therapies for hematological malignancy. Curr Opin Infect Dis. 2019 ; 32 : 538-45.
PubMed
3) Bruggemann RJ, Verheggen R, Boerrigter E, et al. Management of drug-drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs. Lancet Haematol. 2022 ; 9 : e58-72.
PubMed
4) 久保田隆廣, 千葉寛, 伊賀立二. CYP2C19, CYP2D6, およびCYP2C9の遺伝子多型と人種差. 薬物動態. 2001 ; 16 (2) : 69-74.
Medical*Online
5) Aiuchi N, Nakagawa J, Sakuraba H, et al. Impact of polymorphisms of pharmacokinetics-related genes and the inflammatory response on the metabolism of voriconazole. Pharmacol Res Perspect. 2022 ; 10 : e00935.
 
6) Abe J, Umetsu R, Uranishi H, et al. Analysis of polypharmacy effects in older patients using Japanese Adverse Drug Event Report database. PLoS One. 2017 ; 12 : e0190102.
PubMed
P.528 掲載の参考文献
1) Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer : American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013 ; 31 : 2500-10.
 
2) Anand ST, Chrischilles EA, Baer RJ, et al. The risk of preterm birth among women with a history of leukemia or lymphoma. J Matern Fetal Neonatal Med. 2021 : 1-9.
 
3) Rossi G, Kicinski M, Suciu S, et al. Fertility status among long-term childhood acute lymphoblastic leukaemia survivors enrolled between 1971 and 1998 in EORTC CLG studies : results of the 58 Late Adverse Effects study. Hum Reprod. 2021 ; 37 : 44-53.
PubMed
4) Diesch-Furlanetto T, Rovo A, Galimard JE, et al. Pregnancy and pregnancy outcomes after hematopoietic stem cell transplantation in childhood : a cross-sectional survey of the EBMT Pediatric Diseases Working Party. Hum Reprod. 2021 ; 36 : 2871-82.
PubMed
5) Cortes JE, Abruzzese E, Chelysheva E, et al. The impact of dasatinib on pregnancy outcomes. Am J Hematol. 2015 ; 90 : 1111-5.
PubMed
6) Birgegard G, Besses C, Griesshammer M, et al. Treatment of essential thrombocythemia in Europe : a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study. Haematologica. 2018 ; 103 : 51-60.
PubMed
7) Anderson C, Engel SM, Mersereau JE, et al. Birth outcomes among adolescent and Young Adult Cancer Survivors. JAMA Oncol. 2017 ; 3 : 1078-84.
 
8) Reulen RC, Bright CJ, Winter DL, et al. Pregnancy and labor complications in female survivors of childhood cancer : The British Childhood Cancer Survivor Study. J Natl Cancer Inst. 2017 ; 109 (11).
PubMed
9) Socie G, Salooja N, Cohen A, et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood. 2003 ; 101 : 3373-85.
PubMed
10) Loren AW, Chow E, Jacobsohn DA, et al. Pregnancy after hematopoietic cell transplantation : a report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant. 2011 ; 17 : 157-66.
 

VIII. 造血幹細胞移植

P.534 掲載の参考文献
1) Hematopoietic Cell Transplantation, NCCN Clinical Practice Guidelines in Oncology, Version 1. 2022
 
2) 造血細胞移植ガイドラインGVHD (第4版). 日本造血細胞移植学会 ; 2018.
 
3) Zeiser R, von Bubnoff N, Butler J, et al. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med. 2020 ; 382 : 1800-10.
PubMed
4) Zeiser R, Socie G, Schroeder MA, et al. Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301) : a randomised, multicentre, double-blind, phase 3 trial. Lancet Haematol. 2022 ; 9 : e14-25.
PubMed
5) Pidala J, Hamadani M, Dawson P, et al. Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD : the BMT CTN 1501 trial. Blood. 2020 ; 135 : 97-107.
PubMed
6) Holtan SG, Hoeschen AL, Cao Q, et al. Facilitating resolution of life-threatening acute GVHD with human chorionic gonadotropin and epidermal growth factor. Blood Adv. 2020 ; 4 : 1284-95.
PubMed
7) Kekre N, Kim HT, Hofer J, et al. Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. Bone Marrow Transplant. 2021 ; 56 : 1006-12.
PubMed
8) Gergoudis SC, DeFilipp Z, Ozbek U, et al. Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin. Blood Adv. 2020 ; 4 : 6098-105.
 
9) Mehta RS, Bassett R, Rondon G, et al. Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD. Bone Marrow Transplant. 2021 ; 56 : 1316-24.
PubMed
P.539 掲載の参考文献
1) Flowers ME, Martin PJ. How we treat chronic graft-versus-host disease. Blood. 2015 ; 125 : 606-15.
PubMed
2) MacDonald KP, Hill GR, Blazar BR. Chronic graft-versus-host disease : biological insights from preclinical and clinical studies. Blood. 2017 ; 129 : 13-21.
PubMed
3) Martin PJ, Lee SJ, Przepiorka D, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease : VI. The 2014 Clinical Trial Design Working Group Report. Biol Blood Marrow Transplant. 2015 ; 21 : 1343-59.
 
4) Miklos D, Cutler CS, Arora M, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017 ; 130 : 2243-50.
PubMed
5) Dubovsky JA, Flynn R, Du J, et al. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest. 2014 ; 124 : 4867-76.
PubMed
6) Miklos D, Zaid MA, Cooney JP, et al. Ibrutinib vs placebo in combination with corticosteroids in patients with new-onset chronic graft-versus-host disease (CGVHD) : Results from the randomized, double-blind phase 3 iNTEGRATE study. EHA meeting abstract. 2021 : S235.
 
7) Zeiser R, Polverelli N, Ram R, et al. Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. N Engl J Med. 2021 ; 385 : 228-38.
PubMed
8) Spoerl S, Mathew NR, Bscheider M, et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood. 2014 ; 123 : 3832-42.
PubMed
9) Jagasia M, Lazaryan A, Bachier CR, et al. ROCK2 inhibition with belumosudil (KD025) for the treatment of chronic graft-versus-host disease. J Clin Oncol. 2021 ; 39 : 1888-98.
PubMed
10) Cutler C, Lee SJ, Arai S, et al. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy : the ROCKstar study. Blood. 2021 ; 138 : 2278-89.
 
11) Flynn R, Paz K, Du J, et al. Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood. 2016 ; 127 : 2144-54.
PubMed
12) Inamoto Y, White J, Ito R, et al. Comparison of characteristics and outcomes of late acute and NIH chronic GVHD between Japanese and white patients. Blood Adv. 2019 ; 3 : 2764-77.
PubMed
13) Doki N, Toyosaki M, Shiratori S, et al. An open-label, single-arm, multicenter study of ibrutinib in Japanese patients with steroid-dependent/refractory chronic graft-versus-host disease. Transplant Cell Ther. 2021 ; 27 : 867.e1-e9.
 
P.543 掲載の参考文献
1) Panoskaltsis-Mortari A, Griese M, Madtes DK, et al. An official American Thoracic Society research statement : noninfectious lung injury after hematopoietic stem cell transplantation : idiopathic pneumonia syndrome. Am J Respir Crit Care Med. 2011 ; 183 : 1262-79.
PubMed
2) Fukuda T, Hackman RC, Guthrie KA, et al. Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. Blood. 2003 ; 102 : 2777-85.
PubMed
3) Zhu K-E, Hu J-Y, Zhang T, et al. Incidence, risks, and outcome of idiopathic pneumonia syndrome early after allogeneic hematopoietic stem cell transplantation. Eur J Haematol. 2008 ; 81 : 461-6.
PubMed
4) Seo S, Yu J, Jenkins IC, et al. Diagnostic and prognostic plasma biomarkers for idiopathic pneumonia syndrome after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2018 ; 24 : 678-86.
PubMed
5) Wenger DS, Triplette M, Crothers K, et al. Incidence, risk factors, and outcomes of idiopathic pneumonia syndrome after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2020 ; 26 : 413-20.
PubMed
6) Parimon T, Madtes DK, Au DH, et al. Pretransplant lung function, respiratory failure, and mortality after stem cell transplantation. Am J Respir Crit Care Med. 2005 ; 172 : 384-90.
PubMed
7) Yanik GA, Horowitz MM, Weisdorf DJ, et al. Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor : enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation : blood and marrow transplant clinical trials network protocol. Biol Blood Marrow Transplant. 2014 ; 20 : 858-64.
PubMed
8) Seo S, Renaud C, Kuypers JM, et al. Idiopathic pneumonia syndrome after hematopoietic cell transplantation : evidence of occult infectious etiologies. Blood. 2015 ; 125 : 3789-97.
PubMed
9) Thompson J, Yin Z, D'Souza A, et al. Etanercept and Corticosteroid therapy for the treatment of late-onset idiopathic pneumonia syndrome. Biol Blood Marrow Transplant. 2017 ; 23 : 1955-60.
 
10) Tizon R, Frey N, Heitjan DF, et al. High-dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCT. Bone Marrow Transplant. 2012 ; 47 : 1332-7.
PubMed
11) Cao M, Liu H, Dong Y, et al. Mesenchymal stem cells alleviate idiopathic pneumonia syndrome by modulating T cell function through CCR2-CCL2 axis. Stem Cell Res Ther. 2021 ; 12 : 378.
 
12) Tomomasa D, Isoda T, Mitsuiki N, et al. Successful ruxolitinib administration for a patient with steroid-refractory idiopathic pneumonia syndrome following hematopoietic stem cell transplantation : A case report and literature review. Clin Case Rep. 2021 ; 9 : e05242.
PubMed
P.548 掲載の参考文献
1) Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014 ; 371 : 2488-98.
PubMed
2) Xie M, Lu C, Wang J, McLellan MD, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014 ; 20 : 1472-8.
PubMed
3) Genovese G, Kahler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014 ; 371 : 2477-87.
PubMed
4) Frick M, Chan W, Arends CM, et al. Role of Donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2019 ; 37 : 375-85.
PubMed
5) Gibson CJ, Kim H, Zhao L, et al. Donor clonal hematopoiesis and recipient outcomes after transplantation. J Clin Oncol. 2022 ; 40 : 189-201.
PubMed
6) Bao EL, Nandakumar SK, Liao X, et al. Inherited myeloproliferative neoplasm risk affects haematopoietic stem cells. Nature. 2020 ; 586 : 769-75.
PubMed
7) Guru Murthy GS, Atallah E. Relapse and disease-free survival in patients with myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation using older matched sibling donors vs younger matched unrelated donors. JAMA Oncol. 2022.
 
8) Koya J, Kataoka K, Sato T, et al. DNMT3A R882 mutants interact with polycomb proteins to block haematopoietic stem and leukaemic cell differentiation. Nature communications. 2016 ; 7 : 10924.
PubMed
9) Meisel M, Hinterleitner R, Pacis A, et al. Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature. 2018 ; 557 : 580-4.
 
P.553 掲載の参考文献
1) Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015 ; 372 : 311-9.
 
2) Blazar BR, Carreno BM, Panoskaltsis-Mortari A, et al. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol. 2003 ; 171 : 1272-7.
PubMed
3) Soiffer RJ. Checkpoint inhibition to prevent or treat relapse in allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2019 ; 54 : 798-802.
 
4) Merryman RW, Kim HT, Zinzani PL, et al. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood. 2017 ; 129 : 1380-8.
PubMed
5) Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation : extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol. 2018 ; 36 : 1428-39.
 
6) Haverkos BM, Abbott D, Hamadani M, et al. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant : high response rate but frequent GVHD. Blood. 2017 ; 130 : 221-8.
PubMed
7) Herbaux C, Gauthier J, Brice P, et al. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood. 2017 ; 129 : 2471-8.
PubMed
8) Minson A, Douglas G, Bilmon I, et al. Low dose PD-1 inhibition in relapsed refractory Hodgkin lymphoma after allogeneic stem cell transplant with concomitant active GVHD. Br J Haematol. 2019 ; 184 : 840-4.
PubMed
9) Ijaz A, Khan AY, Malik SU, et al. Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation. Biol Blood Marrow Transplant. 2019 ; 25 : 94-9.
 
10) Ito A, Kim SW, Matsuoka KI, et al. Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma : a multicenter retrospective study. Int J Hematol. 2020 ; 112 : 674-89.
PubMed
11) Merryman RW, Castagna L, Giordano L, et al. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia. 2021 ; 35 : 2672-83.
PubMed
12) Davids MS, Kim HT, Costello C, et al. A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. Blood. 2020 ; 135 : 2182-91.
 
13) Merryman RW, Redd RA, Nishihori T, et al. Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. Blood Adv. 2021 ; 5 : 1648-59.
PubMed
14) Herbaux C, Merryman R, Devine S, et al. Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma : taming a necessary evil. Blood. 2018 ; 132 : 9-16.
PubMed
15) Schoch LK, Cooke KR, Wagner-Johnston ND, et al. Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood Adv. 2018 ; 2 : 2226-9.
PubMed
16) Paul S, Zahurak M, Luznik L, et al. Non-myeloablative allogeneic transplantation with post-transplant cyclophosphamide after immune checkpoint inhibition for classic Hodgkin lymphoma : a retrospective cohort study. Biol Blood Marrow Transplant. 2020 ; 26 : 1679-88.
PubMed
17) Ikegawa S, Meguri Y, Kondo T, et al. PTCy ameliorates GVHD by restoring regulatory and effector T-cell homeostasis in recipients with PD-1 blockade. Blood Adv. 2019 ; 3 : 4081-94.
PubMed
18) Nieto JC, Roldan E, Jimenez I, et al. Posttransplant cyclophosphamide after allogeneic hematopoietic cell transplantation mitigates the immune activation induced by previous nivolumab therapy. Leukemia. 2020 ; 34 : 3420-5.
PubMed
P.558 掲載の参考文献
1) Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes : a randomised, open-label, phase III study. Lancet Oncol. 2009 ; 10 : 223-32.
PubMed
2) de Lima M, Giralt S, Thall PF, et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome : a dose and schedule finding study. Cancer. 2010 ; 116 : 5420-31.
PubMed
3) Schroeder T, Rautenberg C, Haas R, et al. Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation. Int J Hematol. 2018 ; 107 : 138-50.
PubMed
4) Shah B, et al. NCCN Guidelines Version 1.2022-Acute Lymphoblastic Leukemia ; Ph+ALL (AYA/Adult) Treatment Induction and Consolidation Therapy (ALL-3). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). 2022.
 
5) Burchert A, Bug G, Fritz LV, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN). J Clin Oncol. 2020 ; 38 : 2993-3002.
PubMed
6) Xuan L, Wang Y, Huang F, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation : an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 2020 ; 21 : 1201-12.
PubMed
7) Pollyea DA, et al. NCCN Guidelines Version 1.2022-Acute Myeloid Leukemia (Age > 18 years) ; maintenance therapy (AML-10). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). 2022.
 
8) Oran B, de Lima M, Garcia-Manero G, et al. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Adv. 2020 ; 4 : 5580-8.
PubMed
9) Gao L, Zhang Y, Wang S, et al. Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD-negative AML after HSCT : an open-label, multicenter, randomized controlled trial. J Clin Oncol. 2020 ; 38 : 4249-59.
PubMed
10) Bewersdorf JP, Allen C, Mirza AS, et al. Hypomethylating agents and FLT3 inhibitors as maintenance treatment for acute myeloid leukemia and myelodysplastic syndrome following allogeneic hematopoietic stem cell transplant-a systematic review and meta-analysis. Transplant Cell Ther. 2021 ; 27 : 997.e1-997.e11.
 
11) 名島悠峰. 高リスクMDSに対する同種造血幹細胞移植後アザシチジン維持療法の用量探索試験 [KSGCT1501]. 第82回日本血液学会学術集会. 2020 ; OS-95-2.
 
12) Ali N, Tomlinson B, Metheny L, et al. Conditioning regimen intensity and low-dose azacitidine maintenance after allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Leuk Lymphoma. 2020 : 1-11.
 
13) Maples KT, Sabo RT, McCarty JM, et al. Maintenance azacitidine after myeloablative allogeneic hematopoietic cell transplantation for myeloid malignancies. Leuk Lymphoma. 2018 ; 59 : 2836-41.
PubMed
14) Wei AH, Dohner H, Pocock C, et al. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med. 2020 ; 383 : 2526-37.
PubMed
15) de Lima M, Oran B, Champlin RE, et al. CC-486 maintenance after stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndromes. Biol Blood Marrow Transplant. 2018 ; 24 : 2017-24.
 
P.564 掲載の参考文献
1) Kusumoto S, Tanaka Y, Suzuki R, et al. Monitoring of hepatitis B virus (HBV) DNA and risk of HBV reactivation in B-Cell lymphoma : a prospective observational study. Clin Infect Dis. 2015 ; 61 : 719-29.
 
2) Takahata M, Hashino S, Onozawa M, et al. Hepatitis B virus (HBV) reverse seroconversion (RS) can be prevented even in non-responders to hepatitis B vaccine after allogeneic stem cell transplantation : long-term analysis of intervention in RS with vaccine for patients with previous HBV infection. Transpl Infect Dis. 2014 ; 16 : 797-801.
PubMed
3) Seto WK, Chan TS, Hwang YY, et al. Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation : A prospective study. Hepatology. 2017 ; 65 : 1451-61.
PubMed
4) 肝炎診療ガイドライン作成委員会, 編. B型肝炎治療ガイドライン (第4版). 2022.6.
 
5) 日本造血細胞移植ガイドライン. ウイルス感染症の予防と治療. 肝炎. 2018. https://www.jstct.or.jp/uploads/files/guideline/01_03_06_hepatitis.pdf.
 
6) Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients : a global perspective. Biol Blood Marrow Transplant. 2009 ; 15 : 1143-238.
PubMed
7) Cordonnier C, Einarsdottir S, Cesaro S, et al. Vaccination of haemopoietic stem cell transplant recipients : guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL7). Lancet Infect Dis. 2019 ; 19 : e200-12.
 
8) Onozawa M, Hashino S, Darmanin S, et al. HB vaccination in the prevention of viral reactivation in allogeneic hematopoietic stem cell transplantation recipients with previous HBV infection. Biol Blood Marrow Transplant. 2008 ; 14 : 1226-30.
PubMed
9) Nishikawa K, Kimura K, Kanda Y, et al. A prospective trial of vaccine to prevent hepatitis B virus reactivation after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2020 ; 55 : 1388-98.
PubMed

書評

最近チェックした商品履歴

Loading...